Étude du rôle du récepteur ERa-36 dans la signalisation non génomique des oestrogènes by Omarjee, Soleilmane
Study of the role of estrogen receptor variant, ERα36, in
non genomic signaling and breast cancer
Soleilmane Omarjee
To cite this version:
Soleilmane Omarjee. Study of the role of estrogen receptor variant, ERα36, in non ge-
nomic signaling and breast cancer. Cancer. Universite´ de Lyon, 2016. English. <NNT :
2016LYSE1041>. <tel-01379002>
HAL Id: tel-01379002
https://tel.archives-ouvertes.fr/tel-01379002
Submitted on 11 Oct 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Année Universitaire 2015-2016 
Numéro D’Ordre : 2016LYSE1041 
 
 
 
 
THESE DE L’UNIVERSITE DE LYON 
 
Délivrée par  
L’UNIVERSITE CLAUDE BERNARD LYON 1 
ECOLE DOCTORALE EDBMIC 
DIPLOME DE DOCTORAT 
 
 
Soutenue publiquement le 7 avril 2016 
 
 
 
OMARJEE Soleilmane 
 
 
 
 
 
 
ETUDE DU ROLE DU RECEPTEUR ERα-36 
DANS LA SIGNALISATION NON GENOMIQUE 
DES OESTROGENES 
 
 
 
Directrice de thèse: Muriel Le Romancer 
 
 
 
 
 
 
 
 
 
 
 
 
JURY 
M. Germain GILLET, Professeur Université, Lyon 1. 
M. Jason CARROLL, Principal Investigator, Cancer Research UK. 
M. Filipo ACCONCIA, Associate Professor, Universita Degli Studi Roma Tre. 
Mme. Cecile ROCHETTE-EGLY, Directrice de Recherche, INSERM. 
Mme. Muriel LE ROMANCER, Directrice de Recherche, INSERM. 
 2 
UNIVERSITE CLAUDE BERNARD - LYON 1 
 
 
Président de l’Université 
Vice-président du Conseil d’Administration 
Vice-président  du Conseil des Etudes et de la Vie Universitaire  
Vice-président du Conseil Scientifique 
Directeur Général des Services 
M. François-Noël GILLY 
M. le Professeur Hamda BEN HADID 
M. le Professeur Philippe LALLE 
M. le Professeur Germain GILLET 
M. Alain HELLEU 
 
 
COMPOSANTES SANTE 
 
Faculté de Médecine Lyon Est – Claude Bernard 
Faculté de Médecine et de Maïeutique Lyon Sud – Charles Mérieux 
Faculté d’Odontologie  
Institut des Sciences Pharmaceutiques et Biologiques 
Institut des Sciences et Techniques de la Réadaptation 
Département de formation et Centre de Recherche en Biologie 
Humaine 
Directeur : M. le Professeur J. ETIENNE 
Directeur : Mme la Professeure C. BURILLON 
Directeur : M. le Professeur D. BOURGEOIS 
Directeur : Mme la Professeure C. VINCIGUERRA 
Directeur : M. le Professeur Y. MATILLON 
Directeur : Mme. la Professeure A-M. SCHOTT 
 
COMPOSANTES ET DEPARTEMENTS DE SCIENCES ET TECHNOLOGIE 
Faculté des Sciences et Technologies 
Département Biologie 
Département Chimie Biochimie 
Département GEP 
Département Informatique 
Département Mathématiques 
Département Mécanique 
Département Physique 
UFR Sciences et Techniques des Activités Physiques et Sportives 
Observatoire des Sciences de l’Univers de Lyon 
Polytech Lyon 
Ecole Supérieure de Chimie Physique Electronique 
Institut Universitaire de Technologie de Lyon 1 
Ecole Supérieure du Professorat et de l’Education 
Institut de Science Financière et d'Assurances 
Directeur : M. F. DE MARCHI 
Directeur : M. le Professeur F. FLEURY 
Directeur : Mme Caroline FELIX 
Directeur : M. Hassan HAMMOURI 
Directeur : M. le Professeur S. AKKOUCHE 
Directeur : M. le Professeur Georges TOMANOV 
Directeur : M. le Professeur H. BEN HADID 
Directeur : M. Jean-Claude PLENET  
Directeur : M. Y.VANPOULLE   
Directeur : M. B. GUIDERDONI  
Directeur : M. P. FOURNIER 
Directeur : M. G. PIGNAULT 
Directeur : M. le Professeur C. VITON 
Directeur : M. le Professeur A. MOUGNIOTTE 
Directeur : M. N. LEBOISNE 
 
 
 
 
 
 3 
 
I wish to thank Dr. Acconcia and Dr. Rochette-Egly for their acceptance to be 
on my board of reviewers and to have taken the time to go through my 
manuscript. I wish to thank Pr. Gillet for his acceptance to preside my PhD 
jury. I would like to express my gratitude to Dr. Carroll for having made it to 
my thesis and to honor me as an examiner of my thesis work. 
 
I wish to thank our director, Pr. Alain Puisieux for his welcome into the Cancer 
research Centre of Lyon and the exchanges we had the opportunity to have 
on the numerous council meetings. 
 
I whish to thank Dr. Laura Corbo for her warm welcome into her team during 
my master’s internship. Thank you for your encouragements and, needless to 
say, all your extraordinary scientific advice that appeared in milliseconds. 
These guided me all throughout my thesis and I wish to thank you for putting 
up with me every time I disturbed you in your office to ask for scientific advice. 
 
To Dr. Muriel Le Romancer, I still remember how eager I was to come and 
join your team to work on ERα-36. The first thing that really impressed me 
was your truly dynamic nature, as well as your human and almost motherly 
way of directing your team. Thank you for your patience and I am so grateful 
for everything you brought me and the trust you put in me. Thanks for all the 
great times we have spent together and the times to come. And yes, the 
paper is finished and sent!! 
 
I wish to acknowledge the help of Dr. Vanacker and Dr. Dutertre who 
accepted to be on my PhD follow up comitee and all the advice you gave me. 
 
I have a very special thought for Dr. Isabelle Treilleux, our pathologist, for all 
her help during my thesis. Thanks for your involvement in every single ones of 
our project and your enthusiasm for our research. I also wish to thank former 
pathology technician Sophie Leon, and the current pathology girls, Amelie 
Colombe and Laetitia Odeyer 
 
Thanks to all our collaborators for their precious help in the project, Elisabetta 
Marangoni, Natacha Rochel, Annick Dejaegere, Yassmine Chebaro. 
 
I wish to thank Dr. Olivier Tredan for his participation in our work. I am very 
grateful to Dr Loay Kassem who carried out all our clinical analyses in a 
record time, as well as our collaborators at the statistics department, namely 
Emilie Lavergne and Sylvie Chabaud for their investment in our work. 
 
I wish to thank Dr. Coralie Poulard for all the training she gave me during my 
M2 and her extremely useful advice. Thank you for everything you have 
taught me and for all your help with our projects even though you are no 
longer here. I wish you loads of success during you post-doc and we are 
definitely hoping to see you back real soon. In the same line, I wish to thank 
Dr. Juliette Rambaud, our former postdoc, for all her help, advice and for her 
immensely kind nature. We miss you both. 
ACKNOWLEDGEMENTS 
 4 
I have a special thought for Dr. Clement Chapat who helped me out on 
numerous occasions. Thanks for all your advice and we hope to see you back 
soon. 
 
I wish to thank all team members of the new Le Romancer Team 
 
Farida Nasri for all your solutions and buffers, as well as your constant good 
humor and your delicious pastries. Thanks for all the plasmids you prepared 
for me. I also wish to thank Cecile Languilaire, our lab technician, for all her 
technical help and hygiene and security advice. 
 
I wish to thank Julien Jacquemetton alias ‘Jack’, our engineer, for all his 
precious help to finish the experiments for our project during the last rush 
hour. Thank you for all your microscopy skills and all your informatics advice. 
 
I wish to thank my two previous trainees, Leon Guichard and Allison Voisin for 
their help on my project, as well as all our other team members. My thoughts 
go to Rana Ramouz, our lab technician/esthetician, we had loads of fun 
imitating your Iranian accent when you got here, thank you for always being 
present, I wish you all the best in your future career and loads of success in 
your personal life as well, you deserve it. I also wish to thank Ali Choucair, our 
PhD fellow from Lebanon with whom I shared a very special bond, thanks for 
all the invitations to taste some Lebanese specialities, and I wish him all the 
best with his wife and kid, and many other kids to come. I wish to thank Lucie 
Malbeteau for always being present to ease out our stress, don’t worry the 
cells will grow and I’m confident you will do a great thesis. I wish to thank 
Hanine Lattouf, our other Lebanese student, for all the fun times we have had 
together, whether it be pinky and the brain out to do some vector digestion or 
some protein production, I wish you the best of luck with your LKB1 project 
and if there’s one piece of advice I have to give you, it’s definitely to lay down 
the timer and come grab a drink. Thanks to our new members, Henri Philippe, 
and Dr.Chang with his two fellows Samuele and Romain. 
 
From the other side of the facilities, I would like to thank Caterina Donini, 
Evelyne Grisard and Aurelie Bellanger for all the good moments we spent 
together. My gratitude also goes towards Hubert Lincet and Pascale Cohen 
for their advice and suggestions on our various meetings. 
 
I have a very special thought for my two friends and lab mates, Adrien 
Nougarede and Flora Clement. Adrien I wish to thank you for all the great 
times we have spent together, be it major scientific exchanges, our discrete 
collaborations or our personal exchanges. Thanks for always being present to 
advice me and right after submitting this manuscript we are definitely going 
back to hit the gym bench. Thank you for all the free guitar lessons and your 
general good humour. To Flora, who incidentally is currently chilling out on the 
beaches of Noumea, I wish to convey my heartfelt gratitude for all the good 
times we have spent together in this lab and for all the relaxation sessions 
when things were sour or when my boss is squeezing the experiments out of 
me. Thank your for always being here to listen and all the pastry lessons. I 
 5 
hope all three of us will make the most out of the time we have left to spend 
together. 
 
I wish to thank Dr. Veronique Maguer Satta and her team for her excellent 
advice and our fruitful collaborations. I have a thought for her team members 
whith whom we have a good time; Boris, Stephanie, Anais, Elodie and 
Florence. I also wish to thank Dr. Ruth Rimokh for her useful advice and 
support, as well as her team, Stephane, Rudy, Mathieu, Ivan, Philippe, 
Jonathan and Margaux. 
 
I have a special thought for my former M2 collegues and friends, Baptiste, 
Loic, Thomas, Rodrigo. Thanks for all the great times we have spent together 
and the ones to come. 
 
I wish to thank the English and Biology department of the Lyon 1 University 
with which I have been able to teach and learn so much from. I am thinking of 
Dr. Dominique Baas and Dr. Dominique Leguellec. Thank you for all the trust 
you invested in me and for giving me the passion to teach. 
 
Many people in my personal life helped me make it to here, 
 
I wish to thank my friend Julien and his family, Didier and Lucette, for all their 
help and kindness since my first years in France. I hope to see you guys very 
soon. 
 
I wish to express my sincerest acknowledgements to my partner, Manon. 
Thank you for all your support, understanding and encouragements, the last 
months haven’t been quite easy but we’ll make that up as soon as this 
manuscript is away. Thank you for all you do for me. I also wish to thank her 
parents, Christophe for his advice and excellent culinary skills, and Scarlett for 
all the holidays and support. 
 
I wish to express my heartfelt gratitude to my family, who were always here 
when I needed their support. I wish to thank my mum for all she has done and 
her continuous support daily skype calls lately just to make sure I’m alright. I 
also wish to express my gratitude to my auntie Zeera, without whom I 
definitely wouldn’t have made it till here. Thank you for your ongoing support 
through all these years and I will see you soon in Cambridge. I also wish to 
thank my uncle Jim and his family from Birmingham for all the good times we 
spent together. 
I have a very special thought for my brother Ommar, whose arrival here 
completely changed the way I felt about living here alone, thanks for all your 
help and all the cooking you’ve been doing lately. Last but not least, I cannot 
help but remember my father, whose absence is felt every passing day, and 
to whom I wish to dedicate this thesis. 
 
Finally I wish to acknowledge the financial support of the Rhone Alpes Region 
and the Ligue Contre le Cancer for my PhD grants. 
 
S.O 
 6 
PUBLICATIONS & COMMUNICATIONS 
 
Publications: 
 
The molecular mechanisms underlying the ERα-36-mediated signaling in breast 
cancer. Soleilmane Omarjee, Julien Jacquemetton, Coralie Poulard, Natacha Rochel, Annick 
Dejaegere , Yassmine Chebaro, Elisabetta Marangoni ,Isabelle Treilleux, Laura Corbo, Muriel Le 
Romancer 
(Submitted to Nature Communications) 
 
Analysis of HER2 genomic binding in breast cancer cells identifies a global role in 
direct gene regulation Aisling M Redmond, Soleilmane Omarjee, Muriel Le Romancer, Jason S 
Carroll (In Prep for Submission to Oncogene) 
 
Identification and characterization of PRMT1 as a target for the treatment of breast 
cancer. (Authors include Soleilmane Omarjee and Muriel Le Romancer) (In Prep for 
Submission to Cancer Discovery) 
 
 
 
 
 
Communications: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
 
List of Tables and Figures …………………………………………………... 
 
Page 12 
INTRODUCTION ……………………………………………………… Page 14 
  
Chapter 1 – Breast Cancer ………………………………………………... Page 15 
1. Prevalence …………………………………………………………………. Page 15 
2. The Mammary Gland ……………………………………………………... Page 17 
    A. Anatomy of the mammary gland ……………………………………... Page 17 
        I. The Epithelial Compartment ………………………………………... Page 17 
        II. The Mesenchymal Compartment ………………………………….. Page 18 
    B. Development of the Mammary Gland ……………………………….. Page 18 
3. Breast Cancer ……………………………………………………………... Page 18 
    A. Histological Criteria ……………………………………………………. Page 19 
    B. Anatomo-pathological Criteria ………………………………………... Page 19 
        I. TNM Tumor Classification …………………………………………... Page 20 
        II. The Scarff, Bloom and Richardson Histoprognostic Grade …….. Page 22 
    C. Molecular Criteria ……………………………………………………… Page 23 
        I. Hormonal receptors ………………………………………………….. Page 24 
           a. Estrogen receptor …………………………………………………. Page 24 
           b. Progesterone receptor ……………………………………………. Page 24 
        II. HER2 receptors ……………………………………………………… Page 25 
        III. Ki67 antigen ………………………………………………………… Page 25 
    D. Transcriptome Analysis ………………………………………………. Page 26 
4. Origins of Breast Cancer ………………………………………………… Page 27 
    A. Genetic Factors ……………………………………………………….. Page 27 
    B. Environmental Factors and Lifestyle ………………………………… Page 27 
        I. Ionizing Radiation ……………………………………………………. Page 27 
        II. Obesity, Breast Density and Size …………………………………. Page 27 
        III. Physical Activity …………………………………………………….. Page 28 
        IV. Smoking and Alcohol ………………………………………………. Page 28 
    C. Reproduction and Hormonal Changes ……………………………… Page 28 
    D. Breast Cancer Stem Cells ……………………………………………. Page 29 
Chapter 2 – Estrogen Receptors ………………………………………… Page 30 
Table of Contents 
 8 
1. Estrogens…………………………………………………………………… Page 30 
    A. Synthesis and metabolism…………………………………………….. Page 30 
    B. The Menstrual Cycle…………………………………………………… Page 31 
2. The Estrogen Receptor…………………………………………………… Page 34 
    A. Structure of Estrogen Receptors……………………………………… Page 34 
        I. Genomic Structure…………………………………………………… Page 34 
        II. Protein Structure…………………………………………………….. Page 35 
    B. Isoforms of Estrogen Receptors……………………………………… Page 36 
    C. Action of Estrogen Receptors………………………………………… Page 37 
        I. Inactive, ligand unbounded ERα…………………………………… Page 38 
        II. The Genomic Pathway of ERα…………………………………….. Page 39 
            a. The classical pathway……………………………………………. Page 39 
            b. The non-classical pathway………………………………………. Page 41 
            c. The ligand-independent pathway……………………………….. Page 41 
            d. Estrogen receptors on the genome…………………………….. Page 42 
    D. ERα non-genomic pathway…………………………………………… Page 42 
        I. The nature of the receptor…………………………………………… Page 42 
            a. Conventional ERα………………………………………………… Page 42 
            b. GPR30……………………………………………………………… Page 43 
            c. ERα splice variants……………………………………………….. Page 43 
        II. Protein Complexes…………………………………………………... Page 43 
            a. The ERα/Src/PI3K complex……………………………………… Page 43 
            b. P130Cas…….………………………………………………………. Page 44 
            c. MNAR………………………………………………………………. Page 44 
        III. Effects of the non-genomic pathway……………………………… Page 44 
            a. The MAPK Pathway………………………………………………. Page 44 
            b. The PI3K/Akt Pathway…………………………………………… Page 44 
    E. Post-Translational Modifications of ERα…………………………….. Page 45 
        I. PTM Regulating the genomic pathway…………………………….. Page 46 
            a. Phosphorylation…………………………………………………… Page 46 
            b. Acetylation…………………………………………………………. Page46 
            c. Ubiquitination………………………………………………………. Page 46 
            d. Sumoylation……………………………………………………….. Page 46 
            e. Methylation………………………………………………………… Page 46 
        II. PTM regulating the non-genomic pathway………………………... Page 48 
        III. PTM deregulated in breast cancer………………………………… Page 48 
 9 
            a. Serine 118…………………………………………………………. Page 48 
            b. Serine 167…………………………………………………………. Page 48 
            c. Arginine 260……………………………………………………….. Page 49 
            d. Lysine 303…………………………………………………………. Page 49 
            e. Serine 305…………………………………………………………. Page 49 
Chapter 3 – ERα-36 ………………………………………………………… Page 50 
1. Chromosomal Disposition and Generation……………………………… Page 50 
2. Regulation of Expression…………………………………………………. Page 51 
    A. Promoter Organization………………………………………………… Page 51 
    B. Transregulatory Elements…………………………………………….. Page 52 
         I. ERα…………………………………………………………………… Page 52 
         II. WT1………………………………………………………………….. Page 52 
         III. EGFR……………………………………………………………….. Page 52 
         IV. HER2………………………………………………………………… Page 52 
         V. Bone Morphogenetic Protein 2…………………………………… Page 52 
    C. Action of Molecules……………………………………………………. Page 52 
3. Cellular Localization………………………………………………………. Page 53 
    A. Potential Myristoylation of ERα-36……………………………………. Page 54 
    B. Interaction with GP96………………………………………………….. Page 54 
4. Ligand Binding Properties………………………………………………… Page 54 
5. Signaling Pathways of ERα-36…………………………………………… Page 55 
    A. The Src Pathway……………………………………………………….. Page 56 
    B. The PI3K/Akt Pathway…………………………………………………. Page 56 
    C. The EGFR Pathway……………………………………………………. Page 56 
    D. The PKC Pathway……………………………………………………… Page 56 
    E. The ERK Pathway……………………………………………………… Page 57 
    F. Involvement of Synuclein Gamma……………………………………. Page 57 
    G. Cyclin D1………………………………………………………………… Page 57 
    H. C-MYC Induction……………………………………………………….. Page 57 
     I. JNK Pathway……………………………………………………………. Page 58 
    J. Biphasic Ligand Effects………………………………………………… Page 58 
6. Physiological Consequences…………………………………………….. Page 58 
    A. Proliferation……………………………………………………………… Page 58 
    B. Stemness………………………………………………………………... Page 58 
    C. Neuroprotective Effect…………………………………………………. Page 59 
    D. Apoptosis………………………………………………………………... Page 59 
 10 
    E. Migration and Invasiveness…………………………………………… Page 59 
    F. Anti-inflammatory action……………………………………………….. Page 59 
7. Involvement in Cancer…………………………………………………….. Page 60 
    A. Breast Cancer…………………………………………………………… Page 60 
    B. Gastric Cancer………………………………………………………….. Page 60 
    C. Lung Adenocarcinoma…………………………………………………. Page 61 
    D. Renal Cell Carcinoma………………………………………………….. Page 61 
    E. Colorectal Cancer………………………………………………………. Page 61 
Chapter 4 – Breast Cancer Therapies and Resistance Mechanisms Page 62 
1. Breast Cancer Treatments………………………………………………... Page 62 
    A. Surgery…………………………………………………………………... Page 62 
    B. Radiotherapy……………………………………………………………. Page 62 
    C. Chemotherapy………………………………………………………….. Page 62 
    D. Targeted Therapies……………………………………………………. Page 63 
         I. Hormonotherapy…………………………………………………….. Page 63 
            a. Anti-Estrogens……………………………………………………. Page 63 
            b. Anti-Aromatases………………………………………………….. Page 63 
         II. mTOR Pathway Inhibitors…………………………………………. Page 64 
         III. Humanized Monoclonal Antibodies……………………………… Page 66 
            a. HER2……………………………………………………………….. Page 66 
            b. VEGF……………………………………………………………… Page 67 
2. Tumor Resistance to Treatment………………………………………… Page 67 
    A. Hormonotherapy Resistance………………………………………… Page 67 
         I. Growth Factor Signaling…………………………………………… Page 67 
         II. ERα…………………………………………………………………. Page 68 
            a. Loss of Expression……………………………………………… Page 68 
            b. Mutations on ERα……………………………………………….. Page 68 
            c. Co-Regulators…………………………………………………… Page 69 
         III. Other isoforms………………………………………………………. Page 69 
            a. ERB………………………………………………………………… Page 69 
            b. ERα-36…………………………………………………………….. Page 69 
         IV. Pharmokinetics…………………………………………………….. Page 69 
    B. Resistance to mTOR Inhibitors………………………………………. Page 70 
    C. Trastuzumab Resistance……………………………………………… Page 70 
Chapter 5 – The MAPK Signaling Pathway ……………………………. Page 71 
1. Generalities………………………………………………………………… Page 71 
 11 
2. The ERK Pathway…………………………………………………………. Page 72 
    A. Molecular Actors of the Ras/MAPK pathway………………………... Page 73 
         I. Tyrosine Kinase Receptors…………………………………………. Page 73 
         II. Ras and regulators………………………………………………….. Page 73  
             a. The Ras Superfamily…………………………………………….. Page 73 
             b. Structure and Function of Ras………………………………….. Page 74 
             c. Ras activation…………………………………………………….. Page 74 
         III. The Raf MAPKKK………………………………………………….. Page 75 
         IV. The Mek-1 and Mek-2 MAPKK…………………………………… Page 76 
          V. The ERK-1 and ERK-2 MAPK……………………………………. Page 76 
             a. Activation and Targets…………………………………………… Page 76 
             b. Distinct effects of ERK1 and ERK2…………………………….. Page 77 
    B. Negative regulation of ERK……………………………………………. Page 77 
3. Interactions in the MAPK Pathway………………………………………. Page 78 
    A. D-Domains………………………………………………………………. Page 78 
    B. DEF Domains…………………………………………………………… Page 79 
    C. CD Domains…………………………………………………………….. Page 79 
4. Involvement in Breast Cancer……………………………………………. Page 79 
    A. Involvement in tamoxifen resistance…………………………………. Page 79 
    B. Involvement in chemotherapy resistance……………………………. Page 80 
  
RESULTS ……………………………………………………………………... Page 81 
1. ERα-36 and the non-genomic pathway…………………………………. Page 82 
2. ERα-36 expression in breast tumors……………………………………. Page 92 
  
CONCLUSION AND PERSPECTIVES ……………………………………. Page 101 
  
REFERENCES………………………………………………………………... Page 105 
 
 
 
 
 
 
 
 
 
 
 
 12 
 
Figure 1 Incidence and mortality of breast cancer throughout Europe………………. Page 15 
Figure 2 Estimated incidence and mortality related to breast cancer in France……. Page 16 
Figure 3 Anatomy of the mammary gland in sagittal section…………………………. Page 17 
Figure 4 Schematic representation of a mammary gland cross section…………….. Page 17 
Figure 5 Adenocarcinomas……………………………………………………………….. Page 19 
Figure 6 Representation of tumor cells in a histology section………………………… Page 22 
Figure 7 Model of ER and PR cross-regulation for DNA binding…………………….. Page 24 
Figure 8 Brief overview of the HER2 Signaling Pathway…………………………….. Page 25 
Figure 9 Normal and tumoral mammary differentiation and resulting metastasis….. Page 29 
Figure 10 Biosynthesis of the major steroid hormones…………………………………. Page 31 
Figure 11 The menstrual cycle…………………………………………………………….. Page 32 
Figure 12 Physiological effects of estrogens…………………………………………….. Page 33 
Figure 13 Genomic and protein arrangement of Estrogen Receptors………………… Page 34 
Figure 14 Protein structures of some nuclear steroid receptors……………………….. Page 35 
Figure 15 Structure of the DNA Binding domain of ER…………………………………. Page 35 
Figure 16 Isoforms of ER…………………………………………………………………… Page 37 
Figure 17 ER Signaling Pathways………………………………………………………… Page 38 
Figure 18 Post-Translational Modifications of ERα……………………………………… Page 45 
Figure 19 Chromosomal disposition of ERα-36………………………………………….. Page 50 
Figure 20 Map of the 5’ sequence flanking ERα-36 transcription start site…………… Page 51 
Figure 21 Overview of the mTOR signaling pathway…………………………………… Page 65 
Figure 22 Classification of the MAPK signaling pathways……………………………… Page 71 
Figure 23 Simplified overview of the ERK pathway……………………………………... Page 72 
Figure 24 The Ras-GTP/GDP cycle ……………………………………………………… Page 74 
Figure 25 Simplified overview of the Proximity Ligation Assay Reaction……………... Page 82  
Figure 26 Tamoxifen binding sites on ERα-36…………………………………………… Page 84 
Figure 27 Tamoxifen mediated the formation of the ERα-36/Src and PI3K Complex.. Page 85 
Figure 28 Tamoxifen induces ERK2/ERα-36 interaction and ERK phosphorylation… Page 85 
Figure 29 Growth of HBCc-12A cells under vehicle, estrogen or tamoxifen treatment Page 86 
Figure 30 ERα-36 interacts specifically with ERK2 and not with ERK1……………….. Page 87 
   
Table 1 Complete description of the TNM classification……………………………… Page 20 
Table 2 Tumor Stages arising from the TNM classification………………………….. Page 22 
Table 3 & 4 Grading scale for the SBR Classification……………………………………... Page 23 
Table 5 Modified residues of ERα and their functions………………………………… Page 46 
Table 6 Clinico-Pathological Characteristics of the 160 patient cohort …………….. Page 94 
Table 7 Correlation between ERα-36 expression and clinico-pathological features Page 95 
Table 8 Death, relapse and metastatic events associated with ERα-36 expression Page 96 
 
 
 
 
List of Figures and Tables 
 13 
 
Breast cancer is a major cause of mortality in women. It is associated, in sporadic 
cases, with deregulation of signaling pathways within breast cells, which are  
essential for the maintenance of normal physiological functions. It this aspect, it 
becomes essential to define the role played by these actors. Breast cancer is mainly 
a hormone-dependent cancer, and the various actors involved in estrogen signaling 
can cause the deregulations observed in cancer cells. 
 
Estrogen action mechanisms are quite complex. There exist a classical pathway 
where the hormone binds to its receptor and regulates gene transcription, and in 
parallel, a non-genomic pathway where estrogens induce more rapid effects in the 
cytoplasm, leading to the activation of signal transduction cascades. 
 
ERα-36 is a new variant of the ERα, with a main cytoplasmic/membrane localization, 
which suggested its involvement in estrogen non-genomic pathway. Indeed ERα-36 
has been shown to initiate non-genomic signaling under stimulation with estrogen, 
but also with clinical ERα antagonists such as tamoxifen or ICI 182,780. ERα-36 
might therefore represent a new player in breast cancer and hormone therapy 
resistance. 
 
My PhD project was, first, to dissect the molecular mechanisms associated with ERα-
36 non genomic signaling, and then, to evaluate ERα-36 expression in cohorts of 
breast tumors to evaluate if its expression is correlated with clinical factors and 
whether it can constitute a new prognosis/predictive factor in breast cancer therapy. 
 
My manuscript will present bibliographical data on 5 main axes, (i). Breast Cancer, 
(ii). The estrogen receptor, (iii). ERα-36, (iv). Breast cancer therapies and resistance 
mechanisms and finally, (v). The MAPK Signaling pathway. Results will then be 
presented and discussed. Finally I will give some conclusions and perspectives on 
my work. 
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1. Prevalence 
Breast cancer is the most common breast pathology in women worldwide with 
about 1.7 million new cases diagnosed in 2012. It represent the second most 
common cancer overall. This means about 12% of all new cancer cases and 
25% of all cancers in women (Figure 1). 
 
In France, around 33% of all new cancer cases identify as breast cancers 
(Figure 2). It remains a major health problem. In 2012, there has been reported 
an estimate of 118 incidences breast cancers per 100,000 with a mortality rate of 
23.7 per 100,000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 1: Incidence and mortality of breast cancer throughout Europe.  
(Source iarc.fr) 
Chapter 1: Breast Cancer 
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Figure 2: Estimated incidence and mortality related to  
breast cancer in France (Source iarc.fr) 
 
 
Incidence of breast cancer in France has almost doubled between 1980 and 
2005, while inversely breast cancer related mortality has undergone around a 
13% decrease. This inverse tendency is mainly linked to major progresses being 
made in terms of early stage diagnosis and efficient treatments. 
 
Detection of breast cancers is mainly carried out by mammography and is 
recommended every two years for women between 50 and 74 years of age. 
Magnetic Resonance Imaging (MRI) can also be used but on a much smaller 
scale due to costs and result interpretation. Estimates say that a tumor can be 
detected as early as two years before a woman feels any abnormal growth. Of a 
rarer occurrence (less than 15% of breast cancers), breast cancer can also 
appear in men and has mainly genetic origins. 
 
 
 
 
 
2. The Mammary Gland 
 
A. Anatomy of the mammary gland 
The mammary gland is characterized by its main exocrine function for milk 
production for new-borns. It is made up of an epithelial and a mesenchymal 
(stromal) compartment (Figure 3). 
 
 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Anatomy of the mammary gland in sagittal section 
 
 
I. The Epithelial Compartment 
The epithelial compartment consists of a network of lobules arranged in 
acini joined together by galactophorous canals. The lobules have a main 
role in milk production during breastfeeding while the canals transport the 
milk to the nipple (Figure 3). Lobules and canals are made up of two 
distinct cell types, luminal cells and myoepithelial cells (Figure 4). Luminal 
cells, as their name suggests, border the lumen of canals and lobules. 
Myoepithelial cells surround the luminal cells and are in direct contact with 
the basal membrane. (Hennighausen et al, 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of a mammary gland cross section 
 
Besides these cells, other cell types have been described such as stem 
and progenitor cells. These cells are mostly located in a basal position. 
The fate control of these bipotent cells towards either a luminal or a 
myoepithelial lineage depend on the microenvironment and transcription 
factors such as GATA-3 (Asselin-Labat et al., 2007). 
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II. The Mesenchymal Compartment 
The breast stroma is composed of many cells types such as adipocytes, 
fibroblasts, nerve cells, as well as blood vessels and a lymphatic network 
draining in the axillary ganglions (Hennighausen and Robinson, 2005). 
This plays an important role in breast cancer where tumor cells can invade 
the lymphatic system and proliferate in ganglions representing the first step 
in metastasis. Also this represents a breast cancer prognostic factor 
(Weigelt et al., 2005). 
 
B. Development of the mammary gland 
Mammary gland development onsets during embryogenesis. This 
development is impeded and resumes in women on the onset of puberty with 
the development of lobules. Total breast development, however, occurs only 
by the time of the first birth giving. 
 
The development of the mammary gland rests on numerous hormonal 
factors such as estrogen and progesterone. Estrogens mainly participate in 
mammary gland development at puberty by stimulating growth of 
galactophoric canals during the menstrual cycle. They also play a very 
important role during pregnancy. In the pregnant woman, estrogens and 
progesterone concentrations stimulate the proliferation of breast acini, which 
can triple their numbers. 
 
Other factors such as EGF (Epidermal Growth Factor) and Prolactin can also 
influence breast development. In fact, in response to a decrease in estrogens 
and progesterone after birth, prolactin secreted by the pituitary gland induces 
the production of milk by breast acini. (McCave et al., 2010; Parmar and 
Cunha, 2004; Rudland et al., 1995) 
 
3. Breast Cancer 
Breast tumors account for a wide variety of cancers with distinct biological and 
morphological characteristics with varying types of progression and response to 
treatment (Rakha and Ellis, 2011). Breast cancer discovery arises from clinical 
symptoms such as pain and a detectable mass. Then follows a series of 
examinations (mammography, biopsy), which establishes the diagnostic. The 
histological examination allows the identification of an infiltrant breast cancer. 
Clinical treatment is proposed based on various prognostic and predictive factors 
and will help physicians decide whether to orient the treatment towards 
chemotherapy, radiotherapy or hormonotherapy. These prognostic factors are 
linked to the time of diagnosis, the histological grade of the tumor, to the 
pathology report and its molecular characteristics. 
 
A. Histological Criteria 
The most frequent cancers develop from the epithelial cells in the mammary 
gland and are known as adenocarcinomas. Histologically they can be either 
in-situ adenocarcinomas, which are generally associated with a good 
prognosis or infiltrant adenocarcinomas, which have a less favorable 
outcome. Infiltrant adenocarcinomas occur when tumor cells have passed 
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the basal membrane to invade the mesenchymal compartment thereby 
having a chance to infiltrate surrounding blood vessels and lymphatic canals. 
Adenocarcinomas represent about 95% of all breast cancers and can arise 
from either from mammary ducts, thereby being named ductal 
adenocarcinomas, or from mammary lobules, thereby being lobular 
adenocarcinomas (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Adenocarcinomas. A: Ductal adenocarcinoma. B: Lobular 
adenocarcinoma. (Source American Cancer Society) 
 
 
There are other types of breast cancer, on a rarer scale, with particular 
histological particularities notably, medullar carcinomas, tubular, papillary, 
Paget’s nipple disease, each one with their own prognostic values. 
 
 
B. Anatomopathological Criteria 
Upon confirmation of the cancer diagnostic, therapy is applied in accordance 
with the disease stage and prognostic factors (Elston et al., 1999).  Clinically, 
the disease stage is determined by tumor size, whether the tumor has 
infiltrative properties, ganglionnar involvement, and the presence of 
metastases. The tumor grade gives an insight into its agressivity and takes 
into account the differentiation of tumor cells and proliferation rate. 
 
I. TNM Tumor Classification 
The TNM classification has been proposed by the International Union 
Against Cancer and the American Joint Committee on Cancer. The TNM 
classification is based on Tumor size (T), the presence of lymph node 
involvement (N) and the presence of metastases (M) (Table 1). Tumors 
are therefore divided into 5 distinct stages (Table 2). 
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Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis 
(Paget) 
Paget disease of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS 
and/or LCIS) in the underlying breast parenchyma. 
T1 Tumor ≤ 20 mm in greatest dimension 
T1mi Tumor ≤ 1 mm in greatest dimension 
T1a Tumor > 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumor > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumor > 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumor > 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumor > 50 mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) 
T4a Extension to chest wall, not including only pectoralis muscle adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d’orange) of the skin, which do not meet the criteria for inflammatory carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional lymph nodes (N) 
Clinical 
NX Regional lymph nodes cannot be assessed (eg, previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral level I, II axillary lymph node(s) 
N2 
Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted or in clinically 
detected* ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node 
metastasis 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures 
N2b Metastases only in clinically detected* ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases 
N3 
Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s), with or without level I, II axillary 
node involvement, or in clinically detected * ipsilateral internal mammary lymph node(s) and in the 
presence of clinically evident level I, II axillary lymph node metastasis; or metastasis in ipsilateral 
supraclavicular lymph node(s), with or without axillary or internal mammary lymph node involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s) 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
Pathologic (pN) 
pNX Regional lymph nodes cannot be assessed (for example, previously removed, or not removed for pathologic study) 
pN0 
No regional lymph node metastasis identified histologically. Note: Isolated tumor cell clusters (ITCs) are 
defined as small clusters of cells ≤ 0.2 mm, or single tumor cells, or a cluster of < 200 cells in a single 
histologic cross-section; ITCs may be detected by routine histology or by immunohistochemical (IHC) 
methods; nodes containing only ITCs are excluded from the total positive node count for purposes of N 
classification but should be included in the total number of nodes evaluated 
pN0(i-) No regional lymph node metastases histologically, negative IHC 
pN0(i+) Malignant cells in regional lymph node(s) ≤ 0.2 mm (detected by hematoxylin-eosin [H&E] stain or IHC, including ITC) 
pN0(mol-) No regional lymph node metastases histologically, negative molecular findings (reverse transcriptase polymerase chain reaction [RT-PCR]) 
pN0(mol+) Positive molecular findings (RT-PCR) but no regional lymph node metastases detected by histology or IHC 
pN1 Micrometastases; or metastases in 1-3 axillary lymph nodes and/or in internal mammary nodes, with metastases detected by sentinel lymph node biopsy but not clinically detected† 
pN1mi Micrometastases (> 0.2 mm and/or > 200 cells, but none > 2.0 mm) 
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm) 
pN1b Metastases in internal mammary nodes, with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected† 
pN1c Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes, with micrometastases or 
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macrometastases detected by sentinel lymph node biopsy but not clinically detected† 
pN2 Metastases in 4-9 axillary lymph nodes or in clinically detected‡ internal mammary lymph nodes in the absence of axillary lymph node metastases 
pN2a Metastases in 4-9 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm) 
pN2b Metastases in clinically detected‡ internal mammary lymph nodes in the absence of axillary lymph node metastases 
pN3 
Metastases in ≥ 10 axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically 
detected‡ ipsilateral internal mammary lymph nodes in the presence of ≥ 1 positive level I, II axillary 
lymph nodes; or in > 3 axillary lymph nodes and in internal mammary lymph nodes, with micrometastases 
or macrometastases detected by sentinel lymph node biopsy but not clinically detected†; or in ipsilateral 
supraclavicular lymph nodes 
pN3a Metastases in ≥ 10 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes 
pN3b 
Metastases in clinically detected‡ ipsilateral internal mammary lymph nodes in the presence of ≥ 1 
positive axillary lymph nodes; or in > 3 axillary lymph nodes and in internal mammary lymph nodes, with 
micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected† 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
Distant metastasis (M) 
M0 No clinical or radiographic evidence of distant metastasis 
cM0(i+) 
No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically 
detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no 
larger than 0.2 mm in a patient without symptoms or signs of metastases 
M1 Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven > 0.2 mm 
 
Table 1: Complete description of the TNM classification. Letter T symbolizes the 
initial tumor and is graded from T0 to T4. Letter N takes into account lymph node 
involvement with grading from N0 to N3. This can be split into two categories 
depending on how lymph node involvement is detected. cN stands for a clinical 
detection, while pN stands for a pathological exam detection. The letter M 
symbolizes the presence of metastases and is scored M0-M1. (Source Medscape) 
 
 
 
 
 
 
 
 
 
Table 2: Tumor Stages arising from the TNM 
classification. Different scores from T, N and M 
values allows to establish a stage I-IV (Source 
Medscape) 
The higher the TNM grade, the worse is the 
prognosis for the patient. At stage IV, 5-year 
survival is dramatically reduced (less than 20%). 
 
 
 
 
 
 
 
 
 
 
 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
  T1 N1mi M0 
IIA T0 N1 M0 
  T1 N1 M0 
  T2 N0 M0 
IIB T2 N1 M0 
  T3 N0 M0 
IIIA T0 N2 M0 
  T1 N2 M0 
  T2 N2 M0 
  T3 N1 M0 
  T3 N2 M0 
IIIB T4 N0 M0 
  T4 N1 M0 
  T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
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II. The Scarff, Bloom and Richardson histoprognostic grade (SBR) 
The SBR classification evaluates agressivity of infiltrating tumors (Tables 
3&4). Tumors are generally considered to be of good prognosis when the 
cells show good differentiation i.e., morphology and characteristics similar 
to normal cells with epithelial phenotypes and little proliferation. 
Oppositely, less differentiated tumor cells have a bad prognosis (Figure 
6). These have lost all epithelial characteristics and proliferate quite 
rapidly. 
 
 
 
 
 
 
 
 
 
 
Figure 6: Representation of tumor cells in a histology section 
(Source e-cancer.com) 
 
 
 
Tubule Formation (% of Carcinoma Composed of Tubular Structures) Score 
  > 75% 1 
  10-75% 2 
  less than 10% 3 
Nuclear Pleomorphism (Change in Cells) Score 
  Small, uniform cells 1 
  Moderate increase in size and variation 2 2 
  Marked variation 3 
Mitosis Count (Cell Division) Score 
  Up to 7 1 
  8 to 14 2 
  15 or more 3 
 
Grade Description Score 
Grade 1 
(lowest) 
Well-differentiated breast cells; 
cells generally appear normal 
and are not growing rapidly; 
cancer arranged in small tubules. 
3,4,5 
Grade 2 Moderately differentiated breast cells; 
have characteristics between  
Grade 1 and Grade 3 tumors. 
6,7 
Grade 3 
(highest) 
Poorly differentiated breast cells; 
Cells do not appear normal and tend to  
grow and spread more aggressively. 
8,9 
Tables 3 & 4: Grading scale for the SBR Classification. (Source Imaginis.com) 
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After microscopic analysis of the tumor, the pathologist evaluates the 
morphological characteristics and grades them from 1-3.  The sum of the 
scores for the 3 above criteria allows the obtention of a global score 
ranging from I-III corresponding to the SBR Grade. 
 
The tumor SBR grade thus obtained constitutes a prognostic marker. In 
fact, high SBR graded tumors are associated with a bad prognosis. It is 
also considered as a predictive marker for response to hormonotherapy 
and chemotherapy. 
 
 
C. Molecular Criteria 
Besides the numerous pathological characteristics listed above, there have 
been several molecular markers that have been developed to optimize 
patient treatment. Hence, clinical biomarkers with a clear prognostic/ 
predictive value are used. These markers represent an important basic for 
therapeutic decision and takes into consideration the sensibility or resistance 
of the tumor towards treatment. 
 
Therefore, clinicians analyze tumors for well-described molecular markers 
such as Estrogen Receptor α (ERα), Progesterone Receptor (PR), the genic 
amplification of the HER2 gene and recently the proliferative antigen Ki-67. 
The presence or absence of these markers will determine the therapeutic 
strategy to be adopted. 
 
I. Hormonal Receptors 
a. Estrogen Receptor  
 The estrogen receptor α has been identified in 1966 (Toft and 
Gorski, 1966) which has then led to the use of anti-estrogenic 
molecules in the treatment of breast cancer. In normal mammary 
tissue, less than 10% of cells express the estrogen receptor ERα 
(Clarke et al 1997), but however, almost 70% of breast cancers are 
ERα-positive. These tumors depend on estrogen for growth, thus 
giving rise to the name of hormone-dependent breast cancers. It 
represents the most important biomarker in breast cancer as it is 
the major target of endocrine therapies and also represents a 
strong prognostic and predictive marker of hormonotherapy. 
 
b. Progesterone Receptor 
Progesterone receptor is a major biomarker in breast cancer since 
its expression strongly correlates with ERα. PR is considered as a 
functional marker of ERα since ERα induces PR expression. There 
are different PR isoforms namely PR-A and PR-B and some studies 
show that the PR-A/PR-B ratio can condition the response to 
endocrine therapy for ER+/PR+ patients(Hopp et al., 2004). 
   
  Recently a breakthrough study has revealed that PR does not actually 
have the attributed passive role of ERα activity report (Figure 7). 
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Instead, PR activity has been shown to change ER binding sites to 
DNA, directly modulating ER function (Baird and Carroll, 2016). When 
ER-positive, PR-positive tumors are compared with ER-positive, PR-
negative tumors, the ER DNA binding sites are distinct, with different 
genes being switched on and off as a result (Mohammed et al., 2015). 
 
 
Figure 7: Model of ERα and PR cross-regulation for DNA binding A: Old 
model. B: New model(Baird and Carroll, 2016) 
 
 
 
II. HER2 Receptors 
Growth and differentiation of normal and breast cancer cells are partly 
regulated by human epidermal growth factors. HER is one of the 
receptors which can bind epidermal growth factors (EGF) and hence 
activate their transmembrane kinase activity to promote downstream 
cellular signaling leading to cell growth, migration or adhesion (Holbro 
et al., 2003). HER exists as many monomers (HER-1, 2, 3 and 4). 
HER2 principal function occurs as a result of its heterodimerization 
with HER-1, 2 or 3 (Figure 8) . 
 
The first amplification of the HER2 gene was described in 1987 in 
breast cancer. This results in a major overexpression of the 
corresponding protein. This genetic alteration is found in 15% of 
breast cancers and these correlate with a decrease disease free 
survival (Pegram and Slamon, 2000). 
 
In breast tumors, HER2 status is monitored by Fluorescent In Situ 
Hybridization (FISH) on chromosome region 17q12 (Bertucci et al., 
2004), or by IHC. An increase in HER2 protein results in a more active 
downstream signaling pathway. Nowadays, there are blocking agents 
that target the HER2 receptor and blocks its signaling in breast 
tumors. 
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Figure 8: Brief overview of the HER2 Signaling Pathway. 
Following ligand binding, the receptor heterodimerizes, undergoes 
autophosphorylation and activates downstream cellular kinases. 
 
 
III. Ki67 antigen 
Ki67 is a nuclear protein universally expressed in proliferating cells 
and absent from quiescent cells, making it a proliferation marker. 
Through there is not much known about Ki67, it is mainly expressed at 
a peak during mitosis (Lopez et al., 1991) Recent studies describe 
Ki67 as a prognostic marker where in ERα-positive, tumors, a low 
expression of Ki67 is more beneficial in terms of endocrine treatment 
(Delpech et al., 2012; Reyal et al., 2013).Cutbacks of this method is 
the lack of standardization in IHC reading and the positivity threshold 
is not clearly defined. 
 
D. Transcriptome Analysis 
 
Despite all the previous morphological and molecular characterizations, 
breast cancers remain quite different. This is mainly due to variations in the 
transcriptional program of these cells.  
 
Using recent techniques such as high-throughput genomic and 
transcriptional analyzes, DNA chips, CGH arrays, the heterogeneity of breast 
cancer has been discovered.. These techniques have allowed to define 
different sub-types of breast cancer based on transcriptional programs with 
more and more precise genetic aberrations being identified (Perou et al., 
2000; Sørlie et al., 2001). 
x The luminal A subtype expresses ERα and regroups low SBR grade 
tumors with a favorable evolution 
x The luminal B subtype also expresses ERα, but regroups less 
differentiated tumors which proliferate more (SBR II or III).Some studies 
also propose a luminal C subtype which can be identified by its 
expression of the mesenchymal marker Vimentin 
x The basal subtype which does not express hormone receptors (ERα, PR) 
and does not present HER2 amplification. These tumors are of high SBR 
grade and are of bad prognostic. They are often associated with triple 
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negative breast tumors. These tumors highly express cell cycle 
regulators and frequently present with P53 mutations. They can also be 
identified based on their expression of basal epithelial cell markers such 
as Cytokeratin 14 and Cytokeratin 5/6. 
x The HER2+ subtype, which is characterized by an over-expression of 
HER2. 
x The normal subtype is not widely known. These tumors do not express 
epithelial genes but rather express adipose tissue genes. Some speak of 
sample contamination by adipose tissue due to low tumor cellularity. 
 
Basal and luminal cancers are quite different by the expression of 
approximately 5000 genes. The HER2+ and basal subtypes are the most well 
characterized (Gruver et al., 2011). 
 
More recently, three more subtypes of tumors have been identified: 
x The apocrine subtype which is characterized by the expression of the 
androgen receptor (AR). This subtype of tumors do not express the 
hormone receptors and is characterized by the expression of AR (Farmer 
et al., 2005). 
x The claudin-low subtype, which forms part of basal tumors but is 
characterized by an expression of mesenchymal markers. These cells 
have been shown to have a high Epithelial to Mesenchymal transition 
(EMT) capacity which is a key process in tumor progression (Prat et al., 
2010). 
x The interferon-rich subtype forms part of basal tumors. It is characterized 
by a high expression of interferon regulated genes and lymphocyte 
infiltration (Teschendorff et al., 2007). 
 
This molecular classification based on DNA chips is not robust enough to be 
used in clinical diagnostic for the moment and identification of novel 
prognostic markers is an ongoing thing. 
 
4. Origins of breast cancer 
Several epidemiological studies carried out worldwide have ascertained that 
several factors can influence breast cancer apparition, notably genetic 
susceptibility, environmental factors, lifestyle. These however are neither 
necessary nor sufficient to initiate the pathology. There is the notion of risk of 
breast cancer which means that the probability of developing the disease is 
higher than average. 5-10% of breast cancers have a genetic origin and 90% are 
sporadic. The latters are not hereditary and their origin is not well defined and 
multifactorial. 
 
A. Genetic factors 
Family history, in a general manner, is associated with an increase in the 
risk of breast cancer. Various mutations have been found to be associated 
with breast cancer. In cancers with genetic origins, the most commonly 
mutated genes are BRCA1 (BReast CAncer 1) and BRCA2 (BReast Cancer 
2). The two corresponding proteins have a major role to play in DNA 
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damage repair. Having a mutation on either of those two genes greatly 
increases the risk of breast cancer. The breast cancer risk associated with 
these mutations is more than 87% in women and around 6% in men 
(Wolpert et al., 2000).  
There are several other genetic predisposition factors to breast cancer and 
they affect in great majority genes involved in DNA repair: TP53, ATM, 
PTEN and others.  
 
B. Environmental factors and lifestyle 
I. Ionizing Radiation 
Ionizing radiation is widely known to be detrimental to DNA and its 
constituents. The breast is a particularly sensitive organ to ionizing 
radiation and exposure of mammary tissue to an equivalent dose of 1Gy 
can triple the risk of breast cancer (Key et al., 2001). 
 
II. Obesity, Breast Density and Size 
Obesity doubles the risk of breast cancer in post-menopausal women. 
This is probably due to the fact that adipose tissue is a key storage and 
metabolism site for steroid hormones, thereby leading to an increase in 
circulating estrogens (Key et al., 2001). 
 
Around 30% of breast cancers are associated with high breast density 
since the breast is very rich in glandular tissue. Furthermore studies have 
shown that typical mammography has a particular flaw in detecting 
tumoral anomalies in women with dense breast due to the fact that the 
mammography exam does not distinguish between normal breast tissue 
and tumor tissue thus delaying early detection and finding the disease at 
a much later stage of development (Rhodes et al., 2005). 
 
III. Physical Activity 
Some studies demonstrate that a moderate physical activity (30-60mins 4 
times a week) can significantly decrease the risk of breast cancer by 
35%, particularly in post-menopausal women(Glade, 1999). This could be 
linked to a decrease in estrogen production (Friedenreich, 2001). 
 
IV. Smoking and Alcohol 
Tobacco smoke has been proven to be a carrier of multiple cancer 
causing risk of breast cancer due to a decrease in circulating estrogens 
and tobacco’s anti-estrogenic action. Other studies found an increased 
risk of breast cancer associated with smoking agents. Different 
conclusions have been drawn between smoking and cancer. Some 
studies have found that smoker women have a reduced. (Charafe-
Jauffret et al. 2007) 
Alcohol consumption has been found to be linked with breast cancer. In 
fact moderate alcohol has been found to increase the risk of breast 
cancer in women by 7% (Hamajima et al., 2002). This could be explained 
by the fact that alcohol increases the circulating amounts of hormones 
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and particularly an increase in IGF (Insulin-like Growth Factor) which 
increases breast cancer risk (Yu et al., 2003). 
 
C.  Reproduction and hormonal changes 
Breast cancers are mainly hormone dependent cancers and are therefore 
influenced by hormonal imbalances in the body. Physiologically, breast 
cancer risk is increased with premature hormonal exposition (first menses 
before 12) and prolonged exposition in case of tardive menopause (Glade, 
1999). The use of the contraceptive pill before the age of 20 could therefore 
also be a risk factor. 
 
Women giving birth before the age of 30 find their risk factor decreased by 
25% and this effect increases proportionally with the number of births given 
(Layde et al., 1989). The mechanisms for this protective effect are not well 
understood. Breast-feeding, on the same line seems to have a protective 
effect from breast cancer onset. Women who have breast-fed for at least 25 
months have a 33% risk decrease in breast cancer compared to women 
who did not (Layde et al., 1989). Breastfeeding causes internal hormonal 
changes, particularly a decrease in estrogen and an increase in prolactin. 
This could reduce the cumulative exposition of women to estrogens and 
therefore repress the apparition and development of breast cancer. 
 
D. Breast Cancer Stem Cells 
An increasing number of arguments allow to hypothesize that breast cancer 
arises from mammary stem cells or their immediate descendants, 
progenitors. These cancer stem cells could undergo either symmetrical or 
asymmetric division, which engages a self-renewal or a differentiation 
process. The heterogeneity of breast tumors could be explained by the 
types of descendants given by the altered stem cell (Figure 9). For instance 
luminal breast tumors could arise from progenitors already engaged in that 
particular lineage in a more or less complete manner. The same statement 
could stand true for basal or myoepithelial differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Normal and tumoral mammary differentiation  
and resulting metastasis (Weigelt et al., 2005) 
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Estrogen receptors belong to the nuclear receptor superfamily binding steroid 
hormones. These receptors function mainly after their activation by the ligands 
estrogens. 
 
1. Estrogens 
Estrogens are synthetized in both sexes but are mainly produced in non 
menopausal women. They act on sexual traits and participate in controlling the 
menstrual cycle. 
 
A. Synthesis and metabolism 
Estrogens, like most steroid hormones, are derived from cholesterol, with a 4 
cycle carbon skeleton. The main estrogens are Estradiol (E2) which is the 
principal form secreted by women and is obtained after testosterone 
processing, Estriol (E3) produced by the placenta during pregnancy and 
esterone (E1) produced after menopause by androgen processing. 
 
In non pregnant women, estrogens are mainly synthetized by the ovaries, 
while during pregnancy, a large amount is synthetized by the placenta. 
Androgens are secreted by the ovaries in thecal cells then diffuse to the 
granulosa where they will be processed into estrogen by aromatization and 
demethylation (Figure 10). 
 
After menopause, ovarian function ceases and estrogen synthesis is relayed 
by aromatization of androgens in various tissues such as adrenal glands, 
adipocytes, breast tissue, bones and the liver. 
In men, estrogens are synthetized in the testicles and in the adrenal cortex. 
In the testicles, synthesis arises in leydig cells and resulting androgens are 
processed into estrogens in sertoli cells (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Estrogen Receptors 
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Figure 10: Biosynthesis of the major steroid hormones. Synthesis arises in 
gonads, leading to the formation of progesterone then androgens. Androgens are then 
aromatized into esterone and testosterone into estradiol (Source: gfmer.com) 
 
 
Following synthesis, estrogens undergo endocrine secretion into the 
bloodstream where they are bound to carrier proteins such as albumin or 
Gonadal Steroid Binding Globulin. 
 
 
B. The Menstrual Cycle 
Estrogen production is under control of the hypothalamus-pituitary axis. 
Gonadotropin Releasing Hormone (GnRH) secreted by the hypothalamus 
acts on the anterior pituitary gland and promote secretion of Follicle 
Stimulating Hormone (FSH) and Luteinizing Hormone (LH) 
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Figure 11: The menstrual cycle. The cycle is under strict hormonal control by 
pituitary hormones, estrogen and progesterone. The follicular phase begins on the 
day of menses and last 14 days and its end is marked by ovulation. Then begins 
the luteal phase. 
 
 
 
During the first days oh the cycle, FSH and LH secretion cause the 
maturation of ovarian follicles which in turn secrete estrogens which is 
responsible for the thickening of the uterine lining so as to be prepared for an 
eventual fertilization. During the follicular phase, estrogen concentrations 
increase induces the secretion of LH by a positive feedback loop. This 
causes rupture of the ovarian follicle and ovulation takes place. The ruptures 
follicle, now known as corpus luteum secretes progesterone. If the egg is not 
fertilized, the corpus luteum is evacuated leading to a drastic progesterone 
decrease, which results in the shedding of the uterine lining. Another cycle 
can then take place (Figure 11). 
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In addition to their effects on the ovaries, estrogens have a number of 
additional functions in the body. Their effects have been mainly described on 
the cardiovascular system, skeletal functions, liver, central nervous system 
and growth regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Physiological effects of estrogens (Gruber et al 2002) 
 
In addition to their functions in reproduction, they have several roles in the 
development and the maintenance of the female reproductive organs and in 
the development of feminine traits (Carpenter and Korach, 2006). 
Furthermore they are deeply involved in the development of breast and 
endometrial cancer. 
 
Estrogens play a natural role in the regulation of blood cholesterol levels by 
the liver by modulating lipoprotein receptors (Paganini-Hill et al., 1996). In 
the skeletal system, estrogens help maintain bone density which explains 
that post menopausal women are more susceptible to develop osteoporosis 
and are more prone to fractures. In vascular system, estrogens have an anti-
apoptotic role in endothelial cell thereby maintaining endothelial integrity 
(Spyridopoulos et al., 1997). Estrogens have also been described as being a 
pro-angiogenic factor. In the nervous system, estrogens can play a role in 
synaptic remodeling and memory (Woolley et al., 1997). Furthermore, 
studies have shown that estrogens can mediate a neuroprotective effect 
against cell death. 
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2. The Estrogen Receptor 
Estrogen receptor was first identified in 1962 and cloned in 1986 (Green et al.; 
Greene et al., 1986). 10 years later, another isoform Estrogen Receptor β (ERβ) 
was identified (Kuiper et al., 1998), this giving the name ERα to the first one 
identified. These receptors are transcription factors, members of the steroid 
nuclear receptor superfamily. Our laboratory and this manuscript will concentrate 
mainly on ERα and it’s splice variant ERα-36. 
 
A. Structure of Estrogen Receptors 
I. Genomic Structure 
The ERα gene, named ESR1 is localized in chromosome 6q25.1 in 
humans (Menasce et al., 1993). Previously the ESR1 gene was supposed 
to contain 8 coding exons, until in 2005, when a ninth exon was discovered 
downstream exon 8 (Wang et al., 2005). The coding exons 1-8 are highly 
conserved in between different species, except for exon 9, which is found 
only in humans and chimpanzees. The variable 5’ extremity of the ESR1 
gene and the existence of multiple promoters in this region may account 
for the differential expression of ERα in different tissues and during 
development (Kos et al., 2001). 
 
The ERβ gene, named ESR2 is localized on chromosome 14q23.2 and is 
composed of 8 coding exons (Enmark et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Genomic and protein arrangement of Estrogen Receptors 
(all intronic sequences between exons are not to scale) A: Structure of 
ESR1 and corresponding ERα protein. B: Structure of ESR2 and 
corresponding ERβ protein. Numbers below the proteins represent amino 
acid numbers from the N-terminus. 
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II. Protein Structure 
The nuclear receptor superfamily represents a great diversity of receptors 
and despite that, all these receptors have a relative homology in their 
organization and function. For most of these factors, the common fact is 
that they are capable of DNA binding in response to their ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Protein structures of some nuclear steroid receptors (Wahli 
and Martinez, 1991) 
 
In accordance to the structure of the nuclear receptor superfamily, ERα is 
composed of 6 functional domains named A – F (Kumar et al., 1987).  
x The A/B domain is composed of the transcription transactivation domain 
AF1 (activation function 1), and is responsible for ligand independent 
transcription. 
x The C domain, also called the DNA Binding Domain allows for the 
recognition of estrogen response elements (ERE) on DNA, generally 
located on the promoters of target genes. It is made up of two zinc-
finger structure. A P-Box present in the first zinc finger structure is 
important for recognition of the ERE while a D-Box in the second zinc 
finger structure is responsible for receptor dimerization 
(Ponglikitmongkol et al., 1988). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  Figure 15: Structure of the DNA Binding domain of ER 
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x The D Domain serves as a Hinge between domains C and E and is 
responsible for providing flexibility to the DBD for adopting different 
conformations. This region also carries three Nuclear Localization 
Sequences, permitting nuclear import of the receptor 
x The E domain carries the Ligand Binding Domain (LBD) and has a main 
function in the dimerization of ER. It also carries the AF2 (activator 
function 2) transcription transactivation domain, which is ligand 
dependent. After ligand binding, helix 12 of ER will close on the ligand 
binding pocket and this will lead to a stabilization of the dimeric form of 
the receptor, dissociation from co-repressors and the creation of new 
interaction sites for interactions with co-activators. Helix 12 also plays a 
crucial role in the conformation of the receptor when bound to different 
ligands and will be responsible for the agonist or antagonist actions of 
the receptor (Ruff et al., 2000). 
x The F-Domain, located on the C-Terminal part of the protein is still not 
fully characterized. It could have a role in modulating ERα activity by 
modulating protein-protein interactions with co-activators such as SRC1 
(Steroid Receptor Co-activator 1) (Koide et al., 2007). 
 
 
At the functional level, ERα activity is associated with cell proliferation. 
Also, ERα KO mice present with infertility, uterine atrophy and impaired 
mammary development. Furthermore these mice are obese and there is 
no feedback loop on the hypothalamic-pituitary axis in regard to LH 
secretion (Emmen and Korach, 2003). 
 
 
 
B. Isoforms of Estrogen Receptors 
Besides the described ERα and ERβ, many variants arising from either 
alternative splicing or alternative promoters have been characterized. The 
most described variants of ERα are ERα46 and ERα46, named thus due to 
their respective protein sizes (46kDa and 36 kDa respectively) (Figure 16A). 
 
Isoform ERα46 is transcribed from an alternative promoter in Exon 2 and 
was identified in 1996. It has been demonstrated to inhibit the transcriptional 
activity of ERα via the recruitment of co-repressors (Flouriot et al., 2000; 
Penot et al., 2005). 
 
Isoform ERα-36 will be described in detail in the next chapter. 
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Figure 16: Isoforms of ER. A: ERα-36 and ERα46 are variants of ERα. 
B: ERβ2/cx and ERβ5 are isoforms of ERβ (Le Romancer et al., 2011). 
  
 
Other splice variants have also been described for ERβ (Figure 16B) in breast 
cancer (Davies et al., 2004). Their exact roles have not been described but 
they are suspected to be involved in resistance to hormonotherapy (Skliris et 
al., 2006). 
 
 
 
C. Action of Estrogen Receptors 
Estrogen receptor is the main mediator of estrogen action by regulating the 
expression of estrogen dependent genes involved in proliferation, development 
and differentiation of the mammary gland. 
 
Briefly, after ligand binding, the receptor will dimerize and translocate into the 
nucleus to bind directly onto ERE or indirectly via binding to transcription factors, 
this is the classical genomic pathway (Figure 17A,B). Otherwise there is a ligand 
independent pathway, which relies on the phosphorylation of ER by Growth 
Factor Receptor activation, this is non non-classical genomic pathway (Figure 
17C). Finally there is the non-genomic pathway, which involves a cytoplasmic 
fraction of ERα and the recruitment of cytoplasmic kinases to initiate a 
downstream signaling pathway (Figure 17D) 
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Figure 17: ER Signaling Pathways. ER designates either ERα or ERβ. A,B: 
Classical Genomic Pathway, C: Non classical genomic pathway, D: Non-
genomic signaling pathway (Le Romancer et al., 2011) 
 
 
I. Inactive, ligand-unbounded ERα 
Steroid receptors have been found to interact with Hsp90 (Heat shock 
protein) as well as other chaperones, which participate in maintaining the 
inactive state of these receptors (Sanchez et al., 1987). In eukaryotes, Hsp 
90 plays a major role in the folding, localization and degradation of various 
proteins (Becker and Craig, 1994). Hsp90 is a dimer made up of three 
distinct domains, an ATP binding N-Terminal Domain, a central domain 
involved in protein recruitment and binding specificity and a C-terminal 
domain responsible for dimerization (Prodromou et al., 2000). 
 
Besides Hsp90, many other chaperones have been described as steroid 
receptor couples such as Hsp40, Hsp70, which are also involved in 
maintaining the inactive state (Picard, 2006). Hsp90 will bind to the LBD of 
ERα and the C-terminal ends dimerize after ATP fixation which folds over 
ERα(Cintron and Toft, 2006; Johnson et al., 1994). 
 
Alongside these Hsp’s, other proteins called immunophilins can form part of 
the complex to maintain ERα in its inactive state. Several of these 
immunophilins have been described such as FKBP52 (p59), FKBP51, 
Cyclophilin 40 (Ratajczak and Carrello, 1996; Renoir et al., 1990). 
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In the absence of ligand, this complex around Hsp90 sequesters the receptor 
but also allows ERα to acquire a structure having maximal affinity to its 
ligand. 
 
Upon ligand binding, ATP hydrolysis allows the opening of the clamp around 
ER and ligand fixation. 
 
 
II. The genomic pathway of ERα 
 
a. The Classical Pathway 
Hormone binding to the receptor brings a conformational change, which 
dissociates it from the complex of chaperone proteins. The receptor 
dimerizes and translocates in the nucleus(Sabbah et al., 1996). The 
receptor dimer can then bind to estrogen response elements (ERE), 
located in the promoter of target genes. The minimal conserved 
sequence between ERE is a 13bp palindromic sequence divides by 3 
random nucleotides (n) 5’- GGTCAnnnTGACC-3’ (Walker et al., 1984). 
However a limited number od ERα regulated genes process this 
sequence and in most cases, the receptor dimer will bind on imperfect 
ERE or half-palindromic sequences (Ramsey and Klinge, 2001). 
Depending on the cell type, the type of ERE used and the ligand, the 
receptor can have either positive or negative trans-activation on target 
genes. 
 
 
Transcriptional Activation 
Once bound to an ERE, ERα can mediate gene transcription through its 
AF1 or AF2 transactivation domains and it can also recruit several co-
activators. Three major co-activator complexes have been identified for 
ERα transcriptional activity and play a key role in transcription activation 
(Rosenfeld et al., 2006). 
 
The p160/SRC family of co-activators 
SRC-1, SRC-2 and SRC-3 are three members of this family and contain 
LxxLL motifs that allow binding to ERα hydrophobic pocket on the AF2 
domain (Leers et al., 1998). Furthermore they contain two transcription 
activation domains AD-1 and AD-2. AD-1 is involved in the recruitment of 
CBP/p300 and AD-2 in the recruitment of PRMT1 and CARM1 which are 
involved in histone methylation and chromatin decompaction (Chen et al., 
1999). SRC’s N-terminal ends also have the capacity to recruit several 
co-activators including Fli-I which is involved in recruiting the SWI/SWF 
complex. 
 
CBP/p300 complex 
CBP/p300 contains an ERα binding site via a consensus LxxLL motif and 
its role in ERα activation has been well documented. 
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The SWI/SNF complex 
This complex is recruited to ERα target genes in the case of estrogenic 
signaling by BAF’s (BRG1 associated factors), for instance BAF57 in the 
recruitment of ERα.  
The Mediator Complex 
This large co-activator complex is made up of more than 26 protein sub-
units and is also called the TRAP/SMCC/DRIP complex. It has a role in 
maintaining ERα dependent transcription after the CBP/p300 complex 
(Kim et al., 2006). 
 
Other proteins have been describes to act as ER genomic regulators. For 
instance, GREB1 has been identified as an ER co-factor that will serve to 
stabilize the binding of ER to other cofactors and mediate ER 
transcriptional activity. 
 
In all, these complexes bring forward enzymatic activities that will allow 
histone modification and chromatin opening to facilitate transcription of 
target genes. 
 
 
 
Transcriptional Repression 
 
Apart from binding co-activators, the AF2 domain of ERα can also recruit 
various co-repressors. Two main proteins, RIP140 and SHP have co-
repressor activities and act in a SRC antagonist manner. 
 
RIP140 
The RIP140 protein, identified as a co-repressor of ERα, includes 9 
LxxLL repeats and can therefore be easily recruited onto steroid 
receptors (Cavaillès et al., 1995). RIP140 has the ability to recruit various 
transcriptional co-repressors such as  HDACs I and II . RIP140 also has 
the capacity to recruit CtBP proteins, which act as negative transcriptional 
regulators. Other studies however have described RIP140 to act as a 
positive ER transcriptional regulator and to serve as a co-
activator(Nautiyal et al., 2013). 
 
SHP 
SHP is a nuclear orphan receptor and can interact with ERα through a 
LxxLL motif. It can repress ERα activity by direct interaction with its AF2 
domain (Johansson et al., 2000). 
 
Upon binding to antagonists like Tamoxifen, a different conformation of 
the receptor is induced which leads to ERE binding but with the induction 
of binding to co-repressors like N-Cor, SMRT which participate in the 
recruitment of HDAC for chromatin compaction and transcriptional 
repression (Shang et al., 2000). 
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b. The Non-Classical Pathway 
ER is also capable of inducing the transcription of genes devoid of ERE 
by indirect DNA binding through interactions with other transcription 
factors. ER can thus modulate the activity of transcription factors such as 
AP1, SP1 or NF-kB. 
 
 
AP-1 
This is a transcription factor complex, which includes JUN, and FOS, 
which binds to AP-1 sites in gene promoters. Estrogen activated ERα 
can bind to the AP-1 complex through the p160 coactivator family 
(Webb et al., 1999). 
 
Regulated genes through ERα and AP-1 interplay include c-fos, 
Cyclin D1 and IGF, all involved in cell proliferation and motility. In 
some cells types, this AP-1 interplay with ERα could account for the 
differential effects of anti-estrogens such as tamoxifen and fulvestrant 
(DeNardo et al., 2005). 
 
SP-1 
SP-1 was identified as forming part of an ERα/SP-1/DNA complex in 
the study of Cathepsin D, an estrogen-regulated gene. In this context, 
the SP-1/ERα complex has been found responsible for mediating 
transcription of c-myc, Cyclin D1 and Bcl-2 proteins, thus having a 
role in cell proliferation and apoptotic resistance (O’Lone et al., 2004). 
 
NF-kB 
ERα has been reported to modulate NF-kB transcriptional activity by 
acting as a transcriptional repressor. This pathway has been 
evidenced for in the maintenance of bone homeostasis to inhibit the 
NF-kB induced IL-6 upregulation. ERα is thought to function by 
blocking NF-kB’s ability to bind DNA (Kalaitzidis and Gilmore, 2005). 
 
 
c. The Ligand Independent Pathway 
 
The activity of ER can be modulated, in the absence of ligand, by 
extracellular signals. EGF and IGF have been reported to activate ER by 
phosphorylation thus inducing the transcription of downstream target 
genes (Le Romancer et al., 2011). The AF-1 ligand independent 
transactivation domain of ER carries this out. The main described 
phosphorylation site on ERα is Serine 118 (Bunone et al., 1996). This 
phosphorylated ER had been found to bind DNA and locate on the 
promoters of several target genes. 
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d. ER on the genome 
 
While most studies focus on the proximal ERE in the promoters of genes 
for ER binding, genome wide studies revealed that most ER binding sites 
are located at significant distances from TSS. Further investigation 
demonstrated that the Forkhead factor FoxA1 had a crucial role to play in 
ER chromatin binding in the sense that ERE which had a Fox A1 binding 
site in close proximity were much more likely to be bound by ER (Carroll 
et al., 2005) . 
 
Furthermore, ER binding sites throughout the genome can be altered 
during drug resistance mechanisms. For instance, in an endocrine-
resistance setting, ER has been shown to relocate with SRC-1 and the 
chromatin protein HMGB2 and bind a different subset of non-ER related 
regulatory elements (Redmond et al., 2015).  
 
D. ERα non genomic pathway 
Besides the fore-mentioned genomic effects, there are rapid effects mediated by 
estrogens which take place in the minutes following estrogen exposure, meaning 
they are way too fast to be mediated by transcriptional activation (Pietras and 
Szego, 1977). 
 
I. The nature of the receptor 
 
a. Conventional ERα 
Several studies demonstrate the existence of a pool of ERα located at 
the plasma membrane (Chambliss and Shaul, 2002; Clarke, 2000; 
Pappas et al., 1995). It has also been reported in IHC studies (Norfleet et 
al., 1999). However these observations do not provide a mechanism for 
ERα location at the plasma membrane, keeping in mind that ERα does 
not process any membrane insertion signal or peptide, no hydrophobic 
domains nor any glycosylation. The protein shuttles between the 
cytoplasm and the nucleus through nuclear localization and export 
sequences. 
 
In 2004, the palmitoylation of ERα on Cysteine 447 was described and 
was shown to contribute to ERα cytoplasmic localization. A mutation of 
this cysteine residue prevented cytoplasmic ERα localization and 
abrogated the rapid estrogen induced MAPK activation (Acconcia et al., 
2004). Palmitoylation of ERα allows its interaction with Caveolin-1 at the 
plasma membrane in lipid rafts (Acconcia et al., 2005). 
 
Furthermore, protein association seems to be necessary for ERα 
localization near the plasma membrane. The adaptor protein Shc which 
plays a role in IGF-1R signaling and upon auto-phosphorylation of IGF-
1R, Shc is recruited and allows the recruitment of ERα (Ravichandran, 
2001). These describe Shc and IGF1R as key regulators for ERα 
membrane localization (Song et al., 2004). 
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Serine 522 found in the E-Domain of ERα seems to play a role in its 
membrane localization. Mutants of this serine fail to locate to the 
membrane and fail to colocalize with Caveolin-1 (Razandi et al., 2003). 
 
 
b. GPR30 
The G-Protein coupled receptor 30 is a 7TM membrane receptor 
(Carmeci et al., 1997) which has been shown to mediate estrogen 
response in ERα negative cells (Filardo et al., 2000). GPR30 has been 
shown to mediate estrogen dependent MAPK activation, which leads to 
the accumulation of downstream c-fos. GPR30 signaling can also 
activate the PI3K/Akt pathway in a G-Protein independent manner 
suggesting its potential role as an estrogen receptor (Revankar et al., 
2005). The signaling of GPR30 can induce rapid post-translational 
modifications of several transcription factors such as CREB with 
downstream accumulation of FOS and JUN and their respective target 
genes (Prossnitz and Maggiolini, 2009). The role of GPR30 in physiology 
is a bit less clear since mice devoid of GPR30 do not present major 
problems with mammary gland development or reproduction . 
 
 
c. ERα splice variants 
ERα splice variants could also be involved in the cytoplasmic localization. 
ERα46 can be palmitoylated and inhibition of this palmitoylation impairs 
its membrane localization in endothelial cells (Li et al., 2003). 
 
The ERα-36 isoform will be discussed in the next chapter. 
 
II. Protein Complexes 
ERα has no intrinsic kinase activity and cannot on its own transduce 
extracellular signals. Its association with different kinases is therefore 
necessary to initiate rapid membrane signaling. Ligand bound ERα dimers 
can bind to many different proteins for this purpose, mainly the tyrosine 
kinase Src and the regulatory sub-unit of the PI3K, p85. 
 
a. The ERα/Src/PI3K Complex 
The Src and PI3K proteins form part of the core of the non genomic 
signaling complex (Castoria et al., 2001). This association has been 
observed firstly in endothelial cells in the induction of eNOS and the 
activation of the Akt pathway (Simoncini et al., 2000). Then it was 
observed that estrogen induced the rapid and transient formation of a 
ERα/Src/PI3K complex (Castoria et al., 2001). Estrogens thus induce 
the activation of PI3K increasing the intracellular PIP3 concentration. In 
parallel, estrogens mediate Src kinase activity and the activation of the 
Src pathway (Castoria et al., 2001). 
 
Phosphorylation of ERα on tyrosine 537 is essential for its fixation with 
the SH2 domain of Src (Migliaccio et al., 2000). Pharmacological 
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abrogation of this interaction with a peptide abrogated the ERα/Src 
interaction and the downstream signaling including the arrest of Cyclin 
D1 expression (Varricchio et al., 2007).  
 
The interaction domains between ERα and P85 are not clearly 
elucidated. 
 
There seems to be an interplay between the Src and PI3K activities 
mediated through ERα. In fact, inhibition of Src kinase activity 
abrogated the estrogen induced PI3K activation, and the formation of 
the core ERα/Src and PI3K complex (Cabodi et al., 2004). Inversely, the 
use of a PI3K inhibitor abrogates Src activity (Castoria et al., 2001). 
 
b. P130Cas 
This adaptor protein, Crk-associated substrate, is a major Src substrate. 
It is involved in cytoskeleton remodeling during cell migration and 
transformation. It has been shown to be transiently associated with ERα 
upon estrogen stimulation and this association depends on Src kinase 
activity (Cabodi et al., 2004). 
 
c. MNAR 
MNAR (Modulator of Nongemonic Activation of ER) is an adaptor 
protein making up the Src/ERα/PI3K complex. It functions as a scaffold  
which favors the ERα/Src interaction and it is thought to be crucial in the 
recruitment of p85 to the complex (Greger et al., 2007). 
 
III.  Effects of the non genomic pathway 
ERα non-genomic signaling has mainly been linked to two major 
pathways. 
a. The MAPK pathway 
Estrogen stimulation induces the ERα/Src interaction, which rapidly 
leads to Src activation. Src’s tyrosine kinase properties will activate 
downstream RAS. This will in turn lead to the activation of MEK 
which will specifically lead to the activation of ERK1/2. 
Phosphorylated ERK1/2 will migrate to the nucleus where they 
activate the transcription of proliferative genes such as cyclin D1 
(Zassadowski et al., 2012). The activation of the MAPK pathway has 
been described in numerous cells types such as nervous cells, 
endothelial cells and mammary cells (Hammes and Levin, 2007). 
 
b. The PI3K/Akt pathway 
Estrogen rapidly leads to the interaction between ERα and the 
regulatory subunit of the PI3K, p85. This will lead to the activation of 
the catalytic subunit p100 and leads to an increase in intracellular 
PIP3. The kinase Akt is then relocalized to the plasma membrane 
where it is activated and can lead to downstream substrate activation 
(Castoria et al., 2001). 
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The PI3K/Akt pathway is linked to an increase in cell proliferation by 
favoring S-phase entry of cells as well as the induction of Cyclin D1 
(Castoria et al., 2001). 
Akt can also phosphorylate the pro-apoptotic protein BAD which 
leads to its sequestration. BAD phosphorylation also leads to the 
release of anti-apoptotic proteins like Bcl-2 and Bcl-XL. Through this 
mechanism, estrogens protect against apoptotic cell death 
(Fernando and Wimalasena, 2004). 
 
Non-genomic and genomic ERα pathways tend to converge rather than 
being two separate pathways.  There is increasing evidence on the 
convergence between the two pathways, however there are some distinct 
estrogen effects that can be attributed to either one of these pathways. For 
instance, membrane induced expression of ERα cannot revert the ERα KO 
phenotype in mice (Abnormal reproductive system, mammary gland 
atrophy). Estrogen actions in the liver have been attributed to the non-
genomic pathway. 
 
E. Post-translational modifications of ERα 
The discovery of post-translational modifications of proteins has brought 
forward a huge leap in understanding protein function diversity. In this 
perspective, the decrypting of ERα post-translational modifications (Figure 
18) is crucial to understand the global estrogen signaling, be it the genomic 
or the non-genomic signaling (Table 5). 
 
 
Figure 18: Post-Translational Modifications of ERα. Me: Methylation, P: 
Phosphorylation, Ub: Ubiquitination, SUMO: Sumoylation. Modification 
functions are represented in red for inhibitory and in green for activator (Le 
Romancer et al., 2011). 
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I. PTM regulating the genomic pathway 
a. Phosphorylation. 
ERα is subject to numerous phosphorylation along all its length and 
these are mainly involved in the activation of transcriptional activity. 
The serine 118 for instance can be phosphorylated by MAPK, thereby 
regulating ERα genomic pathway in an estrogen-independent manner 
(Bunone et al., 1996). Phosphorylation’s on serines 104, 106, 167 
and 305 are also involved in transcriptional activation (Le Romancer 
et al., 2011). 
 
Other properties of ERα are also affected by phosphorylation such as 
phosphorylation on serine 236 which inhibits receptor dimerization 
(Sheeler et al., 2003). Phosphorylation of threonine 311 by p38 
inhibits ERα nuclear import (He et al., 2010). Furthermore, 
phosphorylation of tyrosine 537 by the Src family of kinases regulates 
estradiol fixation on the receptor . 
 
b. Acetylation 
Histone acetyltransferase p300 has been shown to acetylate ERα. 
When acetylated on lysines 302 and 303, ERα transcriptional activity 
is repressed (Popov et al., 2007). Estrogen dependent acetylation of 
lysines 266 and 268 by p300 however stimulate the binding of ERα to 
DNA and boosts its transcriptional activity (Kim et al., 2006). 
 
c. Ubiquitination 
The proteasome pathway is involved in ERα turnover. The two lysines 
concerned with ubiquitination are lysines 302 and 303, which can also 
be acetylated (Berry et al., 2008).  This turnover is essential to allow 
cells to respond quickly to changing hormonal concentrations. 
 
d. Sumoylation 
Our team showed that ERα can be sumoylated in tis hinge domain by 
the E3 ligases PIAS1 and PIAS 3. This PTM affects lysines 266, 268, 
299, 302 and 303 and allows a boost of ERα transcriptional activity 
(Sentis et al., 2005). Sumoylation of ERα is a dynamic and reversible 
process which can be a way to regulate the dynamics of ERα 
transcriptional complexes. 
 
e. Methylation 
ERα is methylated by the SET7 methyltransferase on lysine 302 
located in the hinge domain. It is necessary for the recruitment of ERα 
to promoter regions and leads to transcriptional activation. This 
process is thought to be very rapid and transient and followed by a 
rapid deactivation by an unidentified demethylase (Subramanian et 
al., 2008). 
 46 
 
 
Table 5: Modified residues of ERα and their functions. ND: Not determined, 
ROS: Reactive Oxygen Species, CK2: Casein Kinase 2, PMA: Phorbol 
Mystistate Acetase (Le Romancer et al., 2011) 
 
 
 
 
 
 
 47 
II. PTM regulating the non-genomic pathway 
 
Our team clearly demonstrated that arginine methylation is a crucial step 
in the activation of the non-genomic pathway by estrogens. Following 
estrogen exposure, ERα is methylated on Arginine 260 by the Protein 
MethylTransferase 1 (PRMT1) (Le Romancer et al., 2008). This 
methylated form of ERα is exclusively cytoplasmic and is an essential 
prerequisite for the formation of the ERα/Src and PI3K complex. The 
methylation of ERα is rapid and transient and our team has identified the 
arginine demethylase JMJD6 to be involved in the negative regulation of 
the methylation process (Poulard et al., 2014, 2015). 
 
Two other modifications are involved in the regulation of the non-genomic 
pathway. Palmitoylation of ERα on cysteine 447 which allows its 
anchorage to the plasma membrane and ERα phosphorylation of 
Tyrosine 537 which favors the interaction between Src and ERα through 
Src’s SH2 domain (Migliaccio et al., 2000). 
 
In the proposed model of ERα non genomic pathways, steroid deprivation 
induces palmtoylation of an ERα pool which localizes to the plasma 
membrane through association with Caveolin-1. Estrogen binding to the 
receptor induces a conformational change which leads to the disruption 
of the Caveolin-1/ERα complex. ERα dimerizes and can be methylated 
by PRMT1 and phosphorylated on tyrosine 537 by Src. This induces the 
recruitment of the Src/PI3K complex to induce downstream Akt signaling 
and downstream signaling cascades and physiological responses (Le 
Romancer et al.). 
 
III. PTM deregulated in breast cancer 
Owing to the different and dynamic roles brought about by protein 
modifications, their implication in breast cancer cannot be neglected. The 
use of  histone deacetylase inhibitors in certain cancers has shown some 
promising results, but these approaches need, for obvious reasons, to be 
more targeted (Mottet and Castronovo, 2010). A few post translational 
modifications of ERα have been found in breast cancer with respect to 
their expression levels. 
a. Serine 118 
High Serine 118 phosphorylation on ERα has been found in low 
grade tumors with a good prognosis (Murphy et al., 2004). 
Furthermore, it has been concluded that this modification is 
associated with a better response to endocrine therapies such as 
tamoxifen and anti-aromatases (Generali et al., 2009). 
b. Serine 167 
In ERα positive tumors, phosphorylation of serine 167 is associated 
with good prognosis and an increase in global survival and disease 
free survival (Jiang et al., 2007). 
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c. Arginine 260 
Our team demonstrated, using a specific antibody recognizing 
methylated R260 in IHC, that cytoplasmic methylated ERα expression 
is increased in 50% of mammary tumors (Le Romancer et al., 2008). 
Our team later demonstrated that tumors expressing high levels of 
methylated ERα had a higher expression of the ERα/Src and 
ERα/PI3K complexes. This also correlated with an increase in 
phosphorylated Akt in these tumors. We found that patients with 
tumors expressing high levels of these complexes had a poorer 
outcome in terms of disease free survival (Poulard et al., 2012). 
 
d. Lysine 303 
A study revealed that 505 of breast tumors have a somatic A908G 
mutation conducting to the lysine being replaced by an arginine. This 
modification is associated with a poor prognosis and induces a 
hypersensibility of cells to estrogen (Herynk et al., 2007). This 
suggests that this lysine has a very important role to play in ERα 
regulation and it is subject to many PTM such as acetylation, 
ubiquitination and simulation. 
 
e. Serine 305 
Phosphorylation of ERα on serine 305 seems to play a role in 
tamoxifen resistance. It is a target site for PKA and induces a 
conformational change allowing the fixation of ERα with SRC-1 
despite the presence of tamoxifen and therefore leads to an agonist 
action of tamoxifen on the receptor (Zwart et al., 2007). 
 
 These new data suggest that ERα PTM can be considered as new predictive 
and prognostic markers in breast cancer. In this objective the decrypting of all 
modified sites and mechanisms hold a huge potential in developing targeted 
therapies in breast tumorigenesis. 
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Several reports indicated that three predominant bands of 36, 46 and 66kDa had 
been identified in western blots probed with hERα antibodies targeting the ligand-
binding domain. In 2005, Z.Y Wang identified a full-length clone from a normal 
endometrium cDNA library (Genbank BX640939) encoding a 310aa ORF. This cDNA 
sequence matched 100% the DNA sequences of exons 2-6 of hERα genomic 
sequence (Wang et al., 2005). 
 
1. Chromosomal disposition and generation 
The human ESR1 gene has been discussed in chapter 2. ERα-36 transcription is 
initiated from a previously unidentified promoter in the first intron of the ESR1 
gene. Transcription starts with a novel small exon located in the first intron of 
ERα, named exon 1’. This non-coding exon 1’ is spliced directly onto exon 2 of 
ESR1 and continues from exon 2 to exon 6. 
 
While studying the 3’ end of ERα-36 cDNA, Z.Y Wang found that the C-Terminal 
27 amino acids and the 4293bp 3’ untranslated region matched a continuous 
region 64,241bp downstream of the ESR1 gene. This previously undescribed 
exon in has thus been designated Exon 9, to reflect the additional exon beyond 
the previously described 8 ESR1 exons (Wang et al., 2005). 
 
The hERα-36 protein is initiated from a favorable Kozak sequence located in the 
ESR1 exon 2, which is the same used to generate ERα46. The resulting hERα-
36 protein differs from ERα by lacking both AF1 and AF2 transcription 
transactivation domains. ERα-36 retains the DNA binding, dimerization and 
partial ligand binding domains. Alternative splicing onto exon 9 confers it with a 
unique 27aa C-Terminal Domain that replace the last 138 amino acids encoded 
by exons 7 and 8 of the ESR1 gene (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Chromosomal disposition of ERα-36. A: Chromosomal location of the ESR1 locus 
(red). B: Genomic disposition of the different exons of the ESR1 gene. AUG in exon 1 is used to 
initiate ERα while the AUG in Exon 2 is used to initiate both ERα46 and ERα-36. The lower panel 
shows a representation of the resulting ERα-36 protein compared to ERα. 
Chapter 3: ERα-36 
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2. Regulation of expression 
Like all other genomic elements, the ERα-36 gene is subject to regulation by its 
promoter and several other transcription factors and co-factors. 
 
A. Promoter Organization 
The molecular region corresponding to the promoter of ERα-36 has been 
identified and cloned in 2009. Sequence analysis revealed that the 5’ flanking 
region contains a high G/C content, a non-canonical TATA box, but lacks the 
CCAAT box. A number of SP1 and AP1 sites were also identified in the 5’ 
flanking region of ERα-36. The promoter region of ERα-36 also contains 
putative binding sites for the following transcription factors: AhR (Aryl 
Hydrocarbon Receptor), Erg-1 (ETS-related gene 1), NF-kB (Nuclear Factor 
Kappa B), WT1 (Wilms’ tumor suppressor), PU.1, GATA-1, Elk-1 and GR 
(Glucocorticoid Receptor) (Figure 20). The region is devoid of a consensus 
palindromic ERE site but however contains an imperfect half site located at -
369 to -365, relative to the transcription initiation site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Map of the 5’ sequence flanking ERα-36 transcription  
start site. +1 designates ERα-36 TSS. 
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B. Transregulatory Elements 
 
I. ERα 
Using the promoter region of ERα-36 in ERα negative HEK293 cells, it 
was shown that ERα can negatively regulate the transcription of ERα-36. 
This has been shown to me mediated through the imperfect ERE found in 
this region (Kang et al., 2011a). 
 
II. WT1  
Through silencing and luciferase approaches, a study has identified the 
Wilms’ tumor suppressor to be a negative regulator of ERα-36 
transcription. WT1 exists as four different isoforms and all four had the 
ability to negatively impact ERα-36 transcription. ERα-36 promoter 
analysis revealed the existence of two putative WT1 binding sites in this 
region, one located upstream and the other located downstream of the 
TATA box. Interestingly, WT1 has been shown to upregulate ERα 
transcription, consistent with the idea that it functions to oppositely 
regulate the promoter activities of ERα and ERα-36 (Kang et al., 2011a) 
 
III. EGFR 
EGFR signaling has been shown to positively regulate ERα-36 
expression (Rao et al., 2011). Through luciferase assays and using 
specific EGFR inhibitors, it was concluded that EGFR signaling had a 
three-fold increase effect on ERα-36 promoter activity. Further assays 
using truncated promoters of ERα-36 showed that EGFR acted via an 
AP1 binding site in the ERα-36 promoter region(Yin et al., 2014). 
 
IV. HER2 
Using similar luciferase approaches in combination with the HER2 
inhibitor Lapatinib, a study has shown that HER2 signaling can positively 
regulate ERα-36 promoter activity through the action of an AP1 binding 
site located upstream of the ERα-36 transcription initiation site (Kang et 
al., 2011b; Rao et al., 2011; Yin et al., 2014). 
 
V. BMP2 
Bone Morphogenetic Protein 2 has been described to upregulate ERα-36 
expression in ERα-positive MCF7 and ERα-negative MDA-MB-231 cells 
through activation of the Smad pathway and this study supposed direct 
interactions between members of the Gab Family and ER’s (Wang et al., 
2012a). 
 
 
C. Action of molecules 
Besides the involvement of signaling pathways and transcription factors, 
some molecules have been reported to have an effect on ERα-36. 
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I. Tamoxifen 
Through a positive regulatory loop involving EGFR, chronic exposition of 
MCF7 cells to tamoxifen has been reported to increase intracellular levels 
of ERα-36. This goes together with the fact that MCF7 cells rendered 
resistant to tamoxifen express higher levels of ERα-36 (Zhang et al., 
2011a). 
 
II. Broussoflavonol B 
Broussoflavonol B (5, 7, 3’, 4’-tetrahydroxy-3-methoxy-6,8-
diprenylflavone) is a flavonoid purified from the bark of the paper 
mulberry tree. It has been shown to process a strong inhibitory effect on 
the proliferation of MCF7 and SKBR3 cells. Furthermore, Broussoflavonol 
B has successfully inhibited the growth of breast cancer stem cells and 
induced the differentiation of breast cancer stem-like cells (Guo et al., 
2013a). A study revealed that the effects of this molecule had to do with 
its ability to strongly downregulate ERα-36 expression. Alongside 
downregulating ERα-36, Broussoflavonol B can also lead to the 
downregulation of HER2. It is supposed that this molecule acts on ERα-
36 through the abolition of the positive feedback loop between ERα-36 
and HER2(Guo et al., 2013b; Yin et al., 2014). 
 
III. Icaritin 
Icaritin is a flavonoid isolated from the Chinese herb Herba Epimedii. It 
has been shown, like other flavonoids, to exert estrogen antagonist-like 
action. A brief report suggested that Icaritin might act as a SERM for 
ERα-36, thereby downregulating its expression levels. A phase I clinical 
trial is currently evaluating the use of Icaritin as an ERα-36 modulator in 
advanced breast cancer patients (Source: ClinicalTrials.gov). 
 
3. Cellular Localization 
 
ERα has been described to localize mainly in the nucleus when detected by IHC. 
This is mainly due to the presence of three NLS in its hinge domain. However, 
cell fractionation experiments revealed that unlike ERα, ERα-36 mainly localizes 
outside the nucleus. In fact, 50% of ERα-36 localizes at the plasma membrane, 
40% in the cytoplasm and 10% of ERα-36 localizes in the nucleus. This result 
has been confirmed by IF and IHC using antibodies directed specifically at ERα-
36 in numerous other studies (Rao et al., 2011; Weidle et al.). Further data show 
that the membrane fraction of ERα-36 colocalized perfectly with lipid rafts and 
Caveolin-1. The mechanism by which ERα-36 localizes to the plasma membrane 
is not clear. It has no N-Terminal Signal Peptide and retains the three NLS 
present in ERα.  
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A. Potential Myristoylation of ERα-36 
Three potential myristoylation sites have been identified in ERα-36, which 
are conserved in ERα, residues 25-30 (GVWSCE), 76-81 (GMMKGG) 
and 171-176 (ELLTNL). This finding raised the possibility of myristoyl 
residues participating in the localization of ERα-36 to the plasma 
membrane (Wang et al., 2005).  
Of note, these three putative myristoylation sites are localized proximal to 
the N-Terminus of the protein, a localization that favors myristoylation. 
These sites are located far away in ERα but when it comes to ERα-36 
and ERα46, they are well positioned to confer these two proteins the 
ability to locate to the plasma membrane (Wang et al., 2005). 
 
B. Interaction with GP96 
GP96 is an endoplasmic reticulum resident member of the cytosolic Heat 
Shock Protein 90 (HSP90) family. Interestingly, GP96 has been shown to 
translocate to the plasma membrane in certain tumor cells. It has been 
shown that ERα-36 can bind to GP96 at the plasma membrane. 
Invalidation of GP96 leads to a delocalization of ERα-36 from the plasma 
membrane and a loss in its stability though proteasomal degradation (Hou 
et al., 2015).  
 
4. Ligand Binding Properties 
 
Alternative splicing of ESR1 exon 6 directly onto exon 9 in ERα-36 depletes it 
of exons 7 and 8. These exons in the structure of ERα are responsible for the 
formation of part of the ligand binding pocket and the AF2 domain and 
consequently, the classical C-Terminal Domain of ERα. When the structure of 
ERα-36 is analyzed, it does not process a complete ligand-binding domain. 
Indeed, of the 12 helixes requires to form the ligand binding pocket in ERα 
(helixes 1-12), it has been observed that ERα-36 lacks helixes 9-12. This 
modification leads to a more open ligand-binding pocket, which is believed to 
confer ERα-36 the ability of binding a broader spectrum of ligands other than 
classical ERα ligands. 
 
Various studies have depicted the role of E2 binding to ERα-36 to activate 
extra nuclear estrogen signaling. Most of these studies have been carries out 
in ERα positive MCF7, T47D and H3396 cell lines. In fact, overexpression or 
silencing of ERα-36 in these cell lines consequently affected the non genomic 
signaling mediated by E2 (Deng et al., 2014a; Wang et al., 2014; Zhang et al., 
2012c). Other studies have revealed that E2 can also mediate non-genomic 
signaling through ERα-36. (Shi et al., 2010). 
 
Tamoxifen is a widely used Selective Estrogen Receptor Modulator (SERM) 
to treat ERα positive breast cancers. It functions by occupying the LBD, 
thereby preventing fixation of estrogen and hence abolishes estrogen action. 
However, tamoxifen has been shown to have agonist actions on ERα in non-
breast tissues, in the bone, liver or uterine cells for instance (Lin et al., 2010). 
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Studies have demonstrated that tamoxifen acts as an agonist through ERα-36 
to activate estrogen non genomic signaling in breast cells (Shi et al., 2010). 
Fulvestrant (ICI 182, 780) forms part of a family of molecules known as 
Selective Estrogen Receptor Downregulators (SERD). In contrast to SERM, 
they function by binding to ERα, which in turn leads to an accelerated 
degradation of the receptor by the proteasome pathway. SERD have 
effectively been used to treat ERα positive metastatic breast cancer. 
In 2006, Z.Y Wang demonstrated that Fulvestrant could have an agonist 
action through ERα-36 to mediate rapid activation of the estrogen non-
genomic signaling in breast cells. This controversial data can be explained by 
the fact that Helix12 of the LBD of ERα is important for fulvestrant-mediated 
degradation of the receptor, which is absent from the structure of ERα-36. 
Besides, the open conformation of the LBD in ERα-36 could explain the 
differential action between ERα and ERα-36. 
Using the endometrial ERα and AR negative Hec1A cell line, Shi et al 
demonstrate that testosterone can bind to ERα-36 to mediate non-genomic 
signaling in a similar manner as estrogen. The authors suggest that this might 
be an explanation for the elevated risk of endometrial cancer in women with 
higher plasma levels of testosterone (Lin et al., 2009) . 
The orphan G-Protein coupled receptor GPR30 has been a matter of great 
controversy in the estrogen receptor field for decades. Indeed there have 
been reports of GPR30 mediating rapid estrogen signaling via activation of 
the MAPK/AKT pathways(Filardo et al., 2000). Thus GPR30 has long been 
considered as a novel type of extranuclear ER (Filardo et al., 2007). Studies 
have used G1, a selective GPR30 agonist, to demonstrate that it can 
specifically bind to ERα-36 to mediate non-genomic signaling. Furthermore 
the authors demonstrate that GPR30 mediates its actions via upregulation of 
ERα-36 but G1 still functioned as a normal ERα-36 ligand in cells knocked 
down for GPR30 expression (Kang et al., 2010).  
Z.Y Wang used ERα-36 overexpressing HEK293 cells to demonstrate that 
taken altogether, Estrone (E1), Estriol (E3) and Estetrol (E4), could activate 
the non-genomic pathway through ERα-36 (Liu et al., 2015; Su et al., 2014) . 
  
Taken altogether, these observations help to conclude on the broader and 
more diverse ligand bonding spectrum of ERα-36 to mediate downstream 
cellular signaling pathways. 
 
 
 
5. Signaling Pathways of ERα-36 
 
The main cytoplasmic and membrane localization of ERα-36 led to believe that it 
could be involved in rapid extranuclear non-genomic signaling. Indeed, since its 
identification in 2005, ERα-36 has been shown to be involved in various rapid 
cytoplasmic non-genomic events. 
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A. The Src pathway 
The Src pathway has been the first to be studied when it comes to ERα-36 
signaling. Besides ERα-36’s ability to physically associate with Src in an 
estrogen dependent manner (Gu et al., 2014), ERα-36 has been reported on 
several accounts to induce Src phosphorylation on Tyrosine 416, indicating 
its activation(Wang et al., 2013; Zhang et al., 2011a). Furthermore, other 
ERα-36 ligands, such as Tamoxifen and Fulvestrant (ICI182,780) have been 
reported to induce Src Y416 phosphorylation. In line with these findings, 
ERα-36 activity has been shown to reduce Src phosphorylation on Tyrosine 
527 which represents an inactivation of Src. Src activation through ERα-36 
has been demonstrated in both ERα positive MCF7 cells, and also ERα 
negative MDA-MB-231 and SKBR3 cells (Zhang et al., 2012b). 
 
B. The PI3K/Akt pathway 
In response to E2 or tamoxifen stimulation, ERα-36 has been reported to 
activate the PI3K/Akt pathway in endometrial cells. In fact, ligand treatment 
induces a rapid and transient increase in the phosphorylation of AKT. 
Furthermore, pretreatment of cells with a PI3K inhibitor (LY294002) 
abrogated ligand induced Akt activation confirming the involvement of PI3K 
in ERα-36 mediated PI3K signaling(Deng et al., 2014b; Fu et al., 2014; Lin 
et al., 2009). 
 
C. The EGFR Pathway 
ERα-36 has been described to interact with the EGFR pathway by inducing 
the phosphorylation of EGFR on Tyr 845 after estrogen or tamoxifen 
treatment. ERα-36 acts on EGFR by activating Src, which in turn leads to 
the phosphorylation and activation of EGFR. Furthermore, there appears to 
be a positive feedback loop between EGFR and ERα-36. Indeed, when 
ERα-36 is silenced, there is a significant decrease in EGFR protein without 
any change in EGFR mRNA levels. This has led to the conclusion that ERα-
36 stabilizes EGFR through prevention of its degradation (Zhang et al., 
2011a). In addition to the above, activated EGFR has been shown to 
upregulate ERα-36 promoter activity, thereby increasing ERα-36 
transcription (Su et al., 2014). 
 
D. The PKC Pathway 
ERα-36 has been shown to activate Protein Kinase C (PKC) upon treatment 
with E2 and more particularly BSA-conjugated E2 demonstrating that the 
membrane fraction of ERα-36 is involved in this activation (Chaudhri et al., 
2012; Tong et al., 2010). These results have been reproduced in MCF7, 
HCC38 breast cell lines but also in Ishikawa endometrial cells. Use of a PKC 
inhibitor in both cases completely abrogated ERα-36 mediated rapid ERK 
1/2 phosphorylation. Data also suggested that the estrogen induced 
activation of PKC through ERα-36 will stabilize k-Raps through the inhibition 
of its proteasomal degradation (Koo et al., 2015). 
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E. The ERK Pathway 
The MAPK pathway has been the most extensively studied in ERα-36 
signaling. It has first been described in endometrial Ishakawa cells. Both 
estrogen and tamoxifen have been shown to activate the phosphorylation of 
ERK in a rapid and transient manner(Rao et al., 2011). Further studies 
confirmed these data in ERα-36 transfected MCF7 cells and in ERα 
negative MDA-MB-231 and MDA-MB-436 cells(Rao et al., 2011; Shi et al., 
2010).  
 
In terms of ligands, E2-BSA has been shown to induce ERK phosphorylation 
through ERα-36, and this activation was blocked when cells were pretreated 
with an ERα-36 specific antibody. Furthermore, ICI 128,780 has also been 
describes to induce ERK phosphorylation through ERα-36(Rao et al., 2011). 
 
Further studies demonstrated that upon ERK activation by ERα-36, ERK 
could regulate the promoter activity of the transcription factor Elk-1. In line 
with these observations, use of a MEK Inhibitor U1026 abrogated ligand 
induced ERα-36 dependent ERK phosphorylation. 
 
F. Involvement of Synuclein Gamma 
Synuclein gamma has been identifies as a breast cancer specific gene, 
which participates in the HSP90-based multi chaperone complex for steroid 
receptors. It has been shown that Synuclein gamma significantly enhanced 
ERK1/2 activation by ERα-36 in MCF7 cells. It functions by acting as a 
chaperone for ERα-36 trough direct physical interaction. It binds to ERα-36 
in the presence of E2 and potentiates its non genomic signaling activity (Shi 
et al., 2010). 
 
G. Cyclin D1 
The main described genomic downstream effect of ERα-36 signaling to be 
described is an increase in CyclinD1 transcription (Tong et al., 2010) which 
is involved in cell proliferation. Several reports show that estrogen and anti-
estrogens (Tamoxifen, ICI182,780) activation of ERα-36 will result in 
increased cellular levels of CyclinD1 mainly through the activation of Src and 
EGFR (Wang et al., 2014; Zhang et al., 2012b). 
 
It is of interest to note that the Cyclin D1 promoter contains consensus 
gamma interferon activation sites (GAS) for the activation of transcription 
through STAT5. In an attempt to evaluate whether estrogen/anti-estrogen 
mediated Cyclin D1 transcription involved STAT5, X.T Zhang demonstrated 
that following ERΑ-36 ligand treatment and through the activities of Src and 
EGFR, CyclinD1 transcription requires STAT5 binding to its promoter 
(Zhang et al., 2012c). 
 
H. C-Myc Induction 
In parallel to cyclin D1 induction, there has been a report  of ERα-36 for it’s 
ability to induce transcription of the oncogene C-Myc. This induction is 
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dependent on the ERα-36 mediated ERK activation. MDA-MB-436 cells 
knocked for ERα-36 lost E2 dependent c-Myc activation (Guo et al., 2013b; 
Lin et al., 2010). 
 
I. Jun Pathway 
ERα-36 has been reported to have a positive regulatory effect on the Jun 
pathway. Indeed a knockdown of ERα-36 consequently reduced the Jun 
pathway and sensitized cells to paclitaxel treatment(Gu et al., 2014; Zhang 
et al., 2012a). 
 
J. Biphasic Ligand Effects 
ERα-36 signaling has been shown to be dependent ligand concentration. In 
fact ERα-36 has been shown to activate Src in a ligand concentration 
dependent manner. When used at relatively low concentrations (1nM), ERα-
36 mediated Src activation by Y416 phosphorylation (Wang et al., 2014; 
Zhang et al., 2012c). On the other hand, when used at relatively higher 
concentrations, various ERα-36 ligands including E2, Tamoxifen and ICI 
182,780, did not induce Src Y416 phosphorylation, but rather led to Src 
phosphorylation on Y526, which leads to its deactivation (Zhang et al., 
2012b). This has also been shown to impact on ERα-36 mediated Cyclin D1 
transcription, which comforts with the finding that ERα-36 can effect its 
signaling in a biphasic manner. 
 
 
6. Physiological Consequences 
In response to the vast array of signaling pathways described for ERα-36, there 
have been reports of the physiological responses of these pathways in cell lines 
and in vivo. 
 
A. Proliferation 
ERα-36 has been shown to be involved in the proliferation of MCF7 cells 
under E2 or Tamoxifen treatment. Furthermore, it participates in a ligand 
dependent manner to promote anchorage independent growth of MCF7 and 
T47D cells. More recently, ERα negative HCC38 cells have shown an 
increased cell proliferation and DNA synthesis through ERα-36 (Chaudhri et 
al., 2012). 
 
B. Stemness 
Aldehyde Dehydrogenase enzyme expression is a well-characterized 
hallmark of cancer stem cells. Interestingly, there has been report of a 
relatively high expression of ERα-36, suggesting that ERα-36 expression is 
associated with stem cell like properties (Deng et al., 2014a). 
Further reports indicate that a knockdown of ERα-36 leads to reduced 
CD44+/CD24- cells in breast cell tumorspheres. Accordingly, E2, tamoxifen 
and ICI182,780 treatment of spheres dramatically increases the 
CD44+/CD24- cell population in spheres (Deng et al., 2014a). ERα-36 has 
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thus been described as one of the components, which participates in the 
maintenance of breast cancer stem cells in ERα positive tumors. 
In line with these observations, another study confirmed that ERα-36 
expression positively enriched the ALDH+ subpopulation in ERα negative 
SKBR3 cells, suggesting that ERα-36 could also have a role in the 
maintenance and proliferation of ALDH+ breast cancer cells (Kang et al., 
2011b). 
 
C. Neuroprotective effect 
Estrogen receptor ERα has been described to have neuroprotective effects. 
A recent study carried out in SH-SY5Y and IMR-32 human neuroblastoma 
cell lines have demonstrates that E2 and the GPR30 agonist G1 confer a 
protective effect against H2O2 stress through ERα-36 (Han et al., 2015; Zou 
et al., 2015). Knockdown of ERα-36 in these cells resulted in a loss of the 
protective effect mediated by either ligand. The neuroprotective effects 
mediated by ERα-36 seem to be effected through the simultaneous 
activation of the MAPK and the AKT pathways. 
 
D. Apoptosis 
ERα-36 has been reported to have an anti apoptotic effect in HCC38 cells. 
Indeed, E2 and E2-BSA treated cells had a significantly higher resistance to 
taxol induced apoptosis. HCC38 cells knocked down for the expression of 
ERα-36 completely lost the ERα-36 mediated anti-apoptotic property 
(Chaudhri et al., 2014). 
 
E. Migration & Invasiveness 
ERα-36 has been identified as a positive regulator of migration and 
invasiveness through scratch assays performed in ERα negative HCC38 
cells. Use of a blocking antibody abrogated this E2 dependent effect proving 
that the membrane signaling meaning from ERα 36 is responsible for the 
migratory phenotype. Furthermore ERα-36 has been found to upregulate 
EMT factors like Snail, while it’s activity down regulated epithelial markers 
like E-Cadherin (Zhang et al., 2012a). These findings suggest that ERα-36 
has a crucial role to play in invasive and metastatic tumor phenotypes 
(Chaudhri et al., 2012) 
 
F. Anti-inflammatory action 
A study carried out on Peripheral Mononuclear Cells from healthy patients 
showed that ERα-36 was the only ER to be expressed in these cells. 
Furthermore, when these cells are primed for inflammation by LPS 
treatment, parallel treatment with E2 dramatically decreased the secretion of 
pro-inflammatory cytokines IL6 and TNFα. ERα-36, under E2 activation was 
found to inhibit transcription of these pro-inflammatory cytokines by direct 
binding to the p65 subunit of the well known transcription factor NFkB 
(Ohshiro et al., 2012). Further studies show that these cells still maintain the 
expression of ERα-36 after their differentiation to macrophages suggestion 
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that ERα-36 might have an inflammatory role in normal human tissues 
(Pelekanou et al., 2016) 
 
 
 
7. Involvement in Cancer 
 
A. Breast Cancer 
Numerous studies have analyzed the expression of ERα-36 in breast tumor 
samples (Wang and Yin, 2015).  
Most of the studies point towards a negative role of ERα-36 since its 
expression has been associated with poorer DFS. Furthermore, ERα-36 
expression constitutes an independent marker of tamoxifen resistance. 
Indeed, women with high ERα-36 expression had much less benefit from 
tamoxifen treatment than women who expressed low levels of ERα-36.(Shi 
et al., 2009). Otherwise, ERα-36 expression has been found to be positively 
correlated to HER2 expression (Gu et al., 2014) which makes sense, 
knowing that there exists a positive feedback loop between both actors. 
 
Further analyses revealed that ERα-36 was more likely to be expressed in a 
particular subtype of tumors. Indeed its expression was found mostly in 
apocrine and adenoid cystic carcinomas of the breast (Vranic et al., 2011). 
The two types of breast tumors are characteristically negative for ERα 
expression. 
 
Using quantification of ERα-36 mRNA on 74 breast cancer samples and 
their normal matched tissues, one study reported that ERα-36 was down 
regulated in breast tumors when compared to normal tissues. Furthermore, 
the authors correlated low ERα-36 expression with local progression, lymph 
node metastasis and advanced cancer stage (Zheng et al., 2010).  
 
 
B. Gastric Cancer 
ERα has been found to be a marker of poor prognosis among patients with 
gastric cancer. There have been two independent clinical studies regarding 
the expression of ERα-36 in gastric cancer.  
A first study on 45 patients who underwent curative resection of gastric 
cancer showed that ERα-36 mRNA was significantly higher in normal gastric 
tissues then in the matched cancerous tissues. Among these patients, 
tumors expressing high levels of ERα-36 mRNA had less lymph node 
metastasis and tumors of smaller sizes. Other studies provided similar 
results(Wang et al., 2012b).  
A second study of ERα-36 expression by IHC and western blotting in a 
cohort of 117 gastric adenocarcinomas showed that ERα-36 expression 
positively correlated with age, male gender and serosal invasion. IHC also 
confirmed the membrane expression of ERα-36. Furthermore western 
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blotting revealed that ERα-36 expression positively correlated with 
expression of CyclinD1(Deng et al., 2010) . 
 
C. Lung Adenocarcinoma 
ERα-36 expression has been evaluated by IHC on a cohort of 126 tumor 
resections. The study revealed a high tendency of ERα-36 to associate with 
adenocarcinoma rather than squamous cell carcinoma. In 92% of cases, 
high ERα-36 expression was associated with lymph node metastasis (Zhang 
et al., 2014). In adenocarcinoma patients, high ERα-36 expression was 
associated with poorer prognosis in terms of Disease Free Survival (DFS) 
and Overall Survival (OS). No such difference has been observed in patients 
with squamous cell carcinoma. Multivariate analysis show that ERα-36 is an 
independent prognostic marker for DFS (Zhang et al., 2014). 
 
D. Renal Cell Carcinoma 
ERα-36 expression has been studied by IHC in 125 cases of renal cancer. 
Pericarcinous and benign renal tumors showed a faint staining for ERα-36. 
Its expression seemed to be limited to the cytoplasm and plasma membrane 
of cancer cells. ERα-36 expression positively correlated with tumor size, 
clinical stage and necrosis. More necrosis was observed when ERα-36 had 
a membranous expression. Patients with high ERα-36 staining had a poor 
clinical outcome in terms of DFS and OS. Furthermore patients with 
membrane ERα-36 expression had a worse prognosis. Multivariate analysis 
on this cohort showed that ERα-36 is an independent predictor of shorter 
DFS and ERα-36 membrane expression is a significant predictor of shorter 
DFS and OS (Wang et al., 2015). 
 
E. Colorectal Cancer 
35 malignant colorectal tumors and their normal matched tissues were 
analyzed for ERα-36 expression by RT-PCR. The authors found that ERα-
36 expression was correlated to that of ERα46 and that is was down 
regulated in 71% of colorectal cancers while compared to the normal 
tissues. ERα-36 expression was inversely correlated to lymph node 
metastasis (Jiang et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
Various approaches are used to treat breast cancer which is a complex and diverse 
disease. The major approach to treating breast cancer remains surgical removal of 
tumor tissue coupled or not with radiotherapy. Besides these, there are systemic 
treatments such as chemotherapy or targeted treatments like hormonotherapy and 
other molecular targeted approaches. These treatments significantly impact on 
breast cancer remission and survival. 
 
1. Breast Cancer Treatments 
A. Surgery 
Breast cancer surgery is a local treatment to control the tumor. When the 
latter is too voluminous, a neo-adjuvant therapy is administered to shrink 
tumor volume before surgery. Two types of breast surgeries are currently 
practiced: tumorectomy whereby only the tumor and some surrounding 
breast tissue, and mastectomy where the whole breast tissue is removed. In 
both cases, sentinel lymph node is analyzed to evaluate if cancer cells have 
migrated through the lymphatic system. Following breast surgery, a systemic 
treatment can be proposed to decrease the risk of tumor reappearance or 
metastasis. 
 
B. Radiotherapy 
Radiotherapy generally follows breast cancer surgery. It helps in preventing 
local relapse. Radiotherapy can also be applied to axillary lymph nodes if 
they are present with tumor cells. In some cases, curietherapy can also be 
given to the patient where radioactive sources are implanted in the tumor 
core or around the tumor to target it directly. 
 
C. Chemotherapy 
Most commonly administered through intravenous way, chemotherapy is a 
way of destroying proliferating cells. They can be used alone or more 
frequently in combinations. However these treatments are not specifically 
targeted to tumor cells. Paclitaxel which forms part of the taxane family of 
molecules inhibit microtubule depolymerization thereby leading to a mitotic 
catastrophe. Cyclophosphamide which is an alkylating agent. In functions 
by alkylating DNA thus inhibiting replication. Doxorubicin, of the family of 
anthracyclins, which intercross with DNA and are Topoisemerase I inhibitors. 
They also function through inhibition of DNA replication. Fluoro-uracil, an 
anti-metabolite which gets incorporated into RNA molecules and leads to 
transcription failure and cell death. Methotrexate which inhibits dihydrofolate 
reductase, thereby inhibiting folic acid synthesis and blocks mitotic cells in 
the S-phase. 
 
 
 
 
 
Chapter 4: Breast Cancer Therapy and Resistance 
Mechanisms 
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D. Targeted Therapies 
 
I. Hormonotherapy 
a. Anti-Estrogens 
These can be classified into two main categories: 
- Selective Estrogen Receptor Modulators (SERM) which include 
tamoxifen and its analogs (raloxifen, toremifen and arzoxifen). These 
can act as antagonists or agonists depending on the tissular context. 
- Selective Estrogen Receptor Downregulators (SERD) or pure anti-
estrogens which are devoid of any agonist activity and induce ERα 
degradation 
 
About 80% of breast tumors express ERα and are defined as being 
hormone-dependant. Despite their early discovery in 1963, anti-
estrogens have not been used to clinically treat breast cancer until 
the 1970 (Lerner and Jordan, 1990), where tamoxifen was 
discovered. It became the standard treatment for targeted hormone-
therapy (Lerner and Jordan, 1990). It reduced breast cancer relapse 
by 50% and reduces breast cancer related death by almost 35% 
annually. 
 
Tamoxifen binds to ERα and induces a conformational change in the 
receptor structure which renders it only partially active, and thereby 
reduces its ability to induce gene expression (Jordan, 1994). 
Furthermore, tamoxifen bound ERα will recruit co-repressor 
complexes and histone deacetylases, which leads to transcriptional 
arrest.  
 
However tamoxifen, while exhibiting antagonist estrogen effects in 
breast tissue, has been reported to have an agonist effect in the 
endometrium, increasing the risk of cervical cancer. 
 
Pure anti-estrogens have been discovered in 1987 and the molecule 
ICI 182,780 is the most active one of them (Wakeling et al., 1991). It 
binds to ERα and prevents its nuclear import and directs it to the 
endoplasmic reticulum where ERα is ubiquitinated and undergoes 
proteosomal degradation (Wakeling, 1991). This molecule, also called 
Fulvestrant or Faslodex has been used to treat metastatic hormone-
dependent breast cancer where the use of tamoxifen has failed. 
 
b. Anti-Aromatases 
More recently, other endocrine therapies have been used, targeting 
the physiological synthesis of estrogens. Estrogen production relies 
mainly on the aromatization of endogenous androgens. Anti-
aromatases such as Anastrozole or Letrozole target the enzyme 
responsible for this aromatization and reduce estrogen production in 
peripheral and adipose tissue (Simpson and Dowsett, 2002). These 
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molecules have been used successfully in post-menopausal women 
and have a high anti-proliferative activity. Anti-aromatases are also 
used in anti-estrogen resistant breast tumors. Side effects include 
skeletal disorders such as osteoporosis . 
 
II. mTOR Pathway inhibitors 
The mammalian target of rapamycin (mTOR) signaling pathway 
integrates both intracellular and extracellular signals and serves as a 
central regulator of cell metabolism, growth, proliferation and survival. 
Numerous cellular stimuli can lead to mTOR pathway activation such as 
tyrosine kinase receptors which constitute the canonical activation 
pathway but also other stimuli such as genotoxic stress, inflammation and 
hypoxia (Laplante and Sabatini, 2009). 
 
The mTOR protein is a 289-kDa serine-threonine kinase that belongs to 
the phospho-inositide 3-kinase (PI3K)-related kinase family. mTOR 
nucleates at least two distinct multi-protein complexes, mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2) (Zoncu et al., 2011). 
 
mTORC1 is sensitive to rapamycin and is responsible for the majority of 
rapamycin-induced processes. It consists of mTOR, raptor, proline-rich 
Akt substrate 40 kDa, and LST8. It appears that all of these components 
are needed for mTORC1 activity. mTORC1 is regulated by numerous 
signaling pathways, including the PI3K/Akt pathway, which is activated by 
growth factors and known to be dysregulated in many cancers, resulting 
in the activation of Akt. This regulates mTORC1 by (1) phosphorylating 
the tuberous sclerosis complex 2, preventing it from forming a 
heterodimer with tuberous sclerosis complex 1, and (2) phosphorylating 
PRAS40, causing it to disassociate from mTOR. Both of these 
phosphorylations prevent the activity of the negative regulators of 
mTORC1 and increase downstream signaling by mTORC1. mTORC1 
activation results in the downstream phosphorylation of two main 
effectors: eukaryotic translation initiation factor 4E-binding protein 1 
(4EBP1) and ribosomal protein S6 kinase 1 (S6K1). Phosphorylation of 
4EBP1 prevents it from binding to and inactivating eukaryotic translation 
initiation factor 4E (eIF4E). eIF4E is then capable of increasing cell 
proliferation, survival, and angiogenesis through increased messenger 
RNA (mRNA) translation of cyclin D1, Bcl-2, and vascular endothelial 
growth factor. S6K1 is also phosphorylated by mTORC1, resulting in the 
phosphorylation of several proteins, including ribosomal protein S6 and 
insulin receptor substrate-1. Phosphorylation of S6 ribosomal protein 
allows for the translation of mRNAs encoding for proteins and elongation 
factors, while phosphorylation of IRS-1 prevents insulin-induced signaling 
to Akt via the PI3K pathway, providing negative feedback to mTOR 
activation (Laplante and Sabatini, 2009). 
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The second mTOR complex, mTORC2, contains mTOR, LST8, and 
several unique proteins, including rictor (rapamycin-insensitive 
companion of mTOR). Rapamycin and its analogues do not bind directly 
to mTORC2, and mTORC2 functioning is not impaired with short-term 
rapamycin treatment. Although less is known about this complex than 
mTORC1, two major functions have been attributed to mTORC2: 
regulation and organization of the actin cytoskeleton and Akt regulation 
through phosphorylation of its carboxyl terminal. Phosphorylation of Akt 
by mTORC2, along with phosphorylation through the PI3K pathway, is 
required for full Akt activation (Zoncu et al., 2011). 
 
The different interactions in this signaling pathway give rise to a complex 
network in the regulation of cell growth. Deregulation of this pathway has 
been linked to breast cancer progression and is also linked to resistance 
to endocrine therapies. 
 
Three generations of inhibitors have been developed to target the mTOR 
pathway (Figure 21). 
 
Figure 21: Overview of the mTOR signaling pathway. A: Physiological consequences 
of mTOR pathway activation with key protein actors. Ba: Interplay between the mTORC1 
and 2 and main downstream effectors S6K1 and eiF4E. Bb: Mode of action of rapamycin 
and other rapalogues (first generation mTOR inhibitors). Bc: Mode of action of second 
generation inhibitors which suppress mTOR catalytic activity. Bd: Third generation mTOR 
inhibitors which suppress both mTOR activity and PI3K/Akt pathway (Zoncu et al., 2011). 
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The first generation of inhibitors of the mTOR pathway has focused on 
the use of rapamycin, along with three rapamycin analogues: 
temsirolimus, everolimus, and deforolimus. In vitro, Rapamycin and its 
analogues bind to their intracellular receptor, FKBP12, and this complex 
binds to mTORC1 at the FKBP12-rapamycin binding domain (FRB 
domain) that is adjacent to the kinase domain. This leads to a decrease 
in phosphorylation of the mTORC1 effectors 4EBP1 and S6K1 and a 
decrease in cell growth. Failure to inhibit mTORC2 is related to the fact 
that the FRB domain in this complex of mTOR is not accessible to the 
rapamycin-FKBP12 complex (Zoncu et al., 2011). 
 
The second generation of inhibitors corresponds to Small-molecule 
inhibitors of mTOR kinase, which inhibit the kinase-dependent function of 
both mTORC1 and mTORC2. These agents have demonstrated the 
ability to block mTORC1 and mTORC2 effectors namely, S6K1 and Akt, 
respectively. Agents currently being evaluated include OSI-027 and 
XL765 compounds (Zoncu et al., 2011). 
 
The third generation of inhibitors, commonly named dual-inhibitors, 
have the property of inhibiting both the mTORC1/2 complexes, as well as 
PI3K, thus preventing any feedback from the PI3K pathway. Such an 
inhibitor under development is the BEZ235 actually in Phase I and II trials 
and has demonstrated anticancer properties in a variety of cell lines. 
 
III. Humanized monoclonal antibodies 
a. HER2 
After demonstration of HER2 amplification and overexpression in 
some breast cancers, a monoclonal antibody has been generated for 
the treatment of breast tumors. This antibody, trastuzumab or 
Herceptin, targets the extracellular domain of HER2 (Baselga et al., 
1998). In fact, the antibody binding to the extracellular part of the 
receptor will inhibit receptor dimerization(Arnould et al., 2006), leads 
to its internalization and degradation, and will attract immune cells on 
the tumor site leading to ADCC. Herceptin has also been shown to 
inhibit the MAPK and PI3K/Akt pathways leading to cell cycle arrest. 
Other molecules targeting the ATP binding sites in the intracellular 
domains of HER2 have been developed, such as Lapatinib, which 
has proven to be efficient at targeting both HER2 and EGFR signaling 
(Rusnak et al., 2001). 
 
b. VEGF 
Vascular Endothelial Growth Factor (VEGF) is the main actor of 
angiogenesis in physiology and during tumoral neoangiogenesis 
which is essential for tumor progression and metastasis (Presta et al., 
1997). Bevacizumab (commercially known as Avastin) is a 
monoclonal antibody targeted to bind VEGF and prevent the fixation 
of the latter to its receptor, thereby inhibiting its action. Clinically, 
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treatment with bevacizumab alone does not provide efficient results, 
but its efficiency increases when used in combination with 
chemotherapy. Patients with metastatic breast cancer benefited from 
this combination in terms of survival(Gerber and Ferrara, 2005). 
 
2. Tumor resistance to treatment 
Irrespective of the therapy, resistance of breast cancers to treatment occur and 
most of the mechanisms are poorly understood. Following are some mechanistic 
insights on the resistance to treatment of some breast cancers. 
 
A. Hormonotherapy resistance 
Endocrine therapies block the proliferative effects mediated by estrogens. 
The most common described resistance to endocrine therapy is with the 
case of tamoxifen, which is never administered for more than 5 years to 
patients. Furthermore, not all ERα positive breast tumors respond to 
tamoxifen, and this forms part of what is called ‘de-novo’ resistance. 
Regarding the tumors responding to tamoxifen at the start of therapy, some 
of them acquire a resistance to treatment, this is called ‘acquired resistance’. 
 
I. Growth Factor Signaling 
The overexpression of HER2 and growth factors has been well 
characterized with respect to resistance to endocrine therapies. In cells 
overexpressing HER2, tamoxifen has been shown to have agonist 
effects on ERα. Independantly of estrogens, tamoxifen can lead to the 
activation of the HER2/EGFR signaling leading to MAPK/Akt activation. 
These kinases are able to phosphorylate ERα and leads to expression 
of estrogen dependant genes (Shou et al., 2004). In fact, the 
ERα/Tamoxifen complex recruits co-activators such as SRC-3. The 
proliferative effects mediated by the EGFR/ERα/Tamoxifen loop is 
significantly repressed by EGFR inhibitors (Shou et al., 2004). 
 
The involvement of IGF-1R signaling in tamoxifen resistance has also 
been shown. In fact an increase of IGF-1R activity has been reported in 
tamoxifen resistant cells and acts upstream of the estrogen-mediated 
EGFR activation(Zhang et al., 2011b). 
 
Recent studies from our lab have shown that the PI3K/Akt pathway is 
constitutively activated in anastrozole- or letrozole- resistant cells. This 
constitutive activation has also been demonstrated in anti-aromatase 
resistant breast tumors. These studies suggest that patients with anti-
aromatase resistance could be treated in combination with inhibitors of 
the Akt/mTOR pathway (Vilquin et al., 2013). 
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II. ERα 
a. Loss of expression 
ERα positive tumor cells depend on its expression for proliferation 
and invasiveness. One of the leading mechanisms in resistance to 
endocrine therapies is the loss of expression of ERα, meaning that 
tumors cells have bypassed the ERα pathway dependence to other 
pathways. For 17% of patients, a loss in ERα expression could be 
responsible for tamoxifen resistance (Kuukasjärvi et al., 1996).  
 
Chromatin modifications with histone deacetylation and DNA 
methylation could be an explanation for the loss of ERα in breast 
cancer cells. Some studies demonstrate that DNA 
methyltransferase deacetylase 1 can physically interact with HDAC 
and that co-treatment with DNMT1 inhibitors coupled with HDAC 
inhibitors could re-induce ERα expression in ERα negative cells 
(Mottet and Castronovo, 2010). 
 
Growth factor signaling could also be involved in the decreased 
levels of ERα. Of note, EGFR, HER2 and IGF1R expression are 
more elevated in ERα negative tumors than in positive ones. This 
suggests that growth factor signaling can contribute to 
transcriptional repression of ERα and lead to treatment resistance . 
 
The involvement of CUE domain containing protein 2 (CUEDC2) 
which contains an ubiquitin binding motif can modulate ERα stability 
through the proteasome pathway. There exists a very strong inverse 
correlation between CUEDC2 and ERα expression, which is also 
correlated with tamoxifen resistance, probably due to a loss in ERα 
expression by degradation through the proteasome pathway. 
  
b. Mutations on ERα 
Mutations on ERα can be linked to hormone resistance, however 
these events are relatively rare and cannot account on their own 
endocrine therapy resistance mechanisms. Lysine 303 mutation into 
arginine has been found in invasive tumors and has been linked to 
estrogen hypersensibility, tamoxifen resistance and anti-aromatase 
resistance (Fuqua et al., 2000). Estrogen hypersensitivity occurs 
due to an increase in co-activator binding in the presence of low 
estrogen levels. This lysine 303 is a post-translational modification 
hotspot on ERα (Le Romancer et al., 2011) and prevention of PTM 
could lead to this ERα hypensensitivity.  
 
c. Co-regulators 
SRC-3 is a ERα coregulator overexpressed in 50% of breast 
tumors. High SRC-3 expression is accociated with a DFS decrease 
in tamoxifen treated patients (Shou et al., 2004). This could be due 
to interplay between SRC-3 and HER2. Furthermore, in anti-
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aromatase resistant cells, the ERα/SRC-3 complex is constitutively 
recruited onto ERα target gene promoters to promote their 
expression. This suggests that an increase in co-activator function 
can contribute to the agonist effect of endocrine therapies and 
hence, resistance. 
 
III. Other isoforms 
a. ERβ 
Discrete studies have suggested a role for ERβ in hormonotherapy 
resistance. It is suggested that tamoxifen binding to ERβ can 
activate AP-1 regulated genes (Paech et al., 1997). Another study 
demonstrated that ERβ mRNA was increased in patients presenting 
with tamoxifen resistance (Speirs et al., 1999). More study is 
however needed to elucidate the role of ERβ in endocrine therapy 
resistance. 
 
b. ERα-36 
Estrogen receptor ERα-36 has been extensively shown to mediate 
non-genomic signaling (Chapter 3) and its role in breast cancer 
resistance to endocrine therapies has been evaluated. Tamoxifen 
and fulvestrant have both been shown to activate the MAPK and Akt 
pathway through ERα-36, leading to an anti-estrogen mediated cell 
growth and proliferation. In ERα-36 positive cells, these treatments 
would be likely to act as agonists of ERα-36 (Zhang et al., 2012b). A 
study on a large cohort of breast tumors showed that ERα positive 
patients were less likely to benefit from tamoxifen therapy if they 
expressed ERα-36 (Shi et al., 2009). 
 
IV. Pharmacokinetics 
Tamoxifen is metabolized by the liver into its metabolically active form 
4-hydroxytamoxifen by cytochrome p450. About 8% of Caucasian 
women bear a p450 deficient allele which prevent tamoxifen metabolism 
into its active counterpart (Johnson et al., 2004). This might explain why 
these women do not react as well to tamoxifen and this has to do with 
primary or ‘de-novo’ resistance. 
 
As discussed above, endocrine resistance is a multifactorial mechanism. 
However growth factor signaling seems to play a major role in breast cancer 
resistance to endocrine therapies. 
 
B. Resistance to mTOR inhibitors 
Rapalogues are drugs targeting specifically mTor1. There have been various 
accounts of resistance mechanisms regarding first generation mTOR 
inhibitors. Rapalogues inhibit only the phosphorylation of S6K1 without having 
any effect on 4E-BP1, therefore only partially inhibit protein synthesis (Lee et 
al., 2015). This could be part of the mechanism by which cells acquire 
resistance to rapalogues. 
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Furthermore there are many feedback mechanisms in the mTOR pathway 
and with these feedback loops blocked; a resistance mechanism is set up. 
Rapalogues block the protein degradation of IRS1 involved in IGF1R 
signaling. This can lead to an activation of PI3K which will then activate 
mTorc1. mTorc1 has been shown to inhibit mTorc2 through S6K mediated 
Rictor phosphorylation. Rapalogues, by blocking mTorc1 can induce Akt 
activation through mTorc2. mTorc1 inhibition induces the activation of the 
MAPK pathway through S6K/PI3K. Indeed there has been an association 
between apologue use and MAPK pathway activation in metastatic tumors 
(Lee et al., 2015). 
 
C. Trastuzumab resistance 
Trastuzumab mainly targets HER2 extracellular domain. However, since its 
use, many resistance mechanisms have been identified, which can be either 
primary or secondary. 
 
There is a tumor sub-population expressing a mutated version of HER2 
called p95-HER2. It is truncated in its extracellular N-Terminal domain and 
therefore cannot bind trastuzumab. Furthermore, this truncated form of 
HER2 is constitutively active and has been found in 30% of tumors 
overexpressing HER2 (Scaltriti et al., 2007) . A study had demonstrated that 
patients expressing p95-HER2 are less likely to benefit from trastuzumab 
treatment than patients who express the normal receptor. 
 
Overexpression of tyrosine kinase receptors have a big role to play in 
trastuzumab resistance. For instance, it has been demonstrated that the c-
Met tyrosine kinase receptor can physically interact with HER2 and modulate 
its signaling. Furthermore c-Met depletion renders HER2 expressing cells 
more sensitive to trastuzumab. IGF-1R overexpression renders normally 
sensitive SKBR3 cells resistant to trastuzumab (Nahta et al., 2005). This is 
thought to be due to a crosstalk whereby IGF-1R will phosphorylate HER2 
and lead to downstream PI3K activation. Furthermore high expression of 
IGF-1R in breast tumors is associated with a weaker response to 
trastuzumab. 
 
There are a few intracellular alterations that have been linked to trastuzumab 
resistance. For instance, it has been shown that relapsing HER2 expressing 
tumors have a loss of PTEN expression. Trastuzumab response is also 
significantly decreased in patients having low PTEN expression (Berns et al., 
2007). Other cellular alterations such as on the catalytic subunit of PI3K have 
been shown to be linked to trastuzumab resistance (Kataoka et al., 2010). 
There has been a link between trastuzumab resistance and Src activation in 
breast cancer cells. 
 
 
 
 70 
 
1. Generalities 
The Mitogen Activated Protein Kinase (MAPK) signaling pathways are responsible 
for the transduction of numerous extracellular signals from the plasma membrane 
to the nucleus in order to establish an appropriate cellular response. It is involved 
in the regulation of gene expression and controls several other cytoplasmic 
activities. The MAPK pathways are well conserved throughout evolution in all 
eukaryotes and the most characterized pathways can be clustered into three main 
pathways; the Extracellular signal regulated Kinase (ERK) pathway, the c-Jun N-
Terminal Kinase (JNK) pathway and the p38/MAPK pathway (Figure 22) 
(Schaeffer and Weber, 1999). Each of these pathways responds to various 
external stimuli and exert different biological functions like proliferation, 
differentiation, cell cycle regulation or apoptosis. To add to the complexity of the 
MAPK signaling pathway, these 3 above-named pathways can have common 
effectors such as the Elk-1 transcription factor, which can be a substrate for either 
ERK or JNK (Houliston et al., 2001). In between these pathways, numerous 
interconnections exist that can lead to their activation by direct and canonical 
stimuli such as growth factor signaling, or indirectly by G-Protein coupled 
receptors and hormone receptors such as ERα and PR. The ERK/MAPK pathway 
will be the main focus of this chapter and can be activated by growth factor 
signaling and whose activation has also been reported possible by both ERα and 
ERα-36. This pathway is mainly involved in cell proliferation, differentiation, cell 
survival or apoptosis as well as cell cycle regulation (Malumbres and Barbacid, 
2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Classification of the MAPK signaling pathways. 
Signaling pathways can be classified into three main families, 
ERK, JNK and p38-MAPK. (Adapted from Roberts et al, 2007) 
 
The MAPK signaling pathways share common mechanisms and a conserved 
structure composed of modules of three kinases. These three kinases are 
Chapter 5: The MAPK Signaling Pathway 
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activated through a phosphorylation cascade, in order to relay extracellular signals. 
The first kinase to be activated is a MAPKKK (MAP3K), activated by a small G-
Protein which has been activated itself by cell surface receptors or intracellular 
receptors. The MAPKKK will activate a MAPKK(MAP2K) through phosphorylation, 
which will itself activate and phosphorylate a MAPK. The small G-Protein serves 
as an intermediate to phosphorylate MAPK modules. When the small G-Protein is 
activated, it physically interacts with the MAPKKK by recruiting it to the plasma 
membrane and activating it through phosphorylation. Once the MAPKKK has been 
activated the initiation of the complex signaling pathway can take place. MAPKK 
are very specific of their substrates and will activate only a handful of MAPK. The 
MAPK for their part have numerous substrates localized in the cytoplasm and in 
the nucleus.  
 
2. The ERK Pathway 
The ERK pathway has been the first signaling pathway to be fully characterized 
from plasma membrane to the nucleus. The involved MAPKKK is the Raf protein. 
Downstream Raf lies the MAPKK MEK1/2 which further activates ERK1/2. The 
ERK cascade is initiated by the small G-Protein Ras, which is activated following 
tyrosine kinase receptor activation at the plasma membrane.  Following its 
activation, Ras will recruit Raf to the plasma membrane where it will be 
phosphorylated and activated. At the plasma membrane Raf will recruit the dual 
MAPKK Kinases MEK-1 and MEK-2 and these will lead to the downstream 
activation of ERK 1 and 2 (Chong et al., 2003). Phosphorylated ERK can in turn 
activate cytoplasmic proteins or translocate to the nucleus to regulate target 
genes by activation of transcription factors (Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Simplified overview of the ERK pathway  
(Adapted from diff.org) 
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A. Molecular actors of the Ras/MAPK Pathway 
I. Tyrosine kinase receptors 
Tyrosine kinase receptors are a superfamily of proteins with an intrinsic 
tyrosine kinase ability, i.e. transferring a phosphate group to a tyrosine of a 
substrate protein. They have a common transmembrane domain and differ 
by their extracellular part. TKR’s are activated by ligand induced receptor 
dimerization which induces a conformational change in the receptor 
resulting in an autophosphorylation on tyrosine residues in their kinase 
activation loop. These phosphorylated residues serve as anchoring 
domains for adaptor proteins such as Grb2 and Crk via their SH2 or PTB 
domains. These adaptor proteins recruit downstream signaling proteins 
such as Guanine Exchange Factors (Sos) which leads to the activation of 
the small G-Protein Ras. A well documented example of TKR is EGFR  
and its homologues which are involved in cell division, adhesion and 
proliferation (Hubbard and Miller, 2007). 
 
II. Ras and molecular actors 
a. The Ras superfamily 
The Ras superfamily are a cluster of small G Proteins pocessing a 
GTPase activity. They are very well conserved throughout evolution. The 
Ras superfamily can be divided into 6 distinct sub-groups associated with 
distinct functions (Wennerberg et al., 2005). 
 
The Ras (Rat Sarcoma) group is the most characterized and comprises 
36 members. They are involved in various signaling pathways regulating 
gene expression, cell proliferation, as well as cellular differentiation and 
cell death. Most of the members of the Ras group are oncogenes where 
mutations have been identified in various cancer types (Wennerberg and 
Der, 2004). 
The Rho group (Ras Homologous) is made up of 10 members including 
RhoA, Rac1 and Cdc42. These proteins are mainly involved in the 
regulation of the actin cytoskeleton, cell cycle progression and cell motility 
and polarity. They are also involved in exocytosis and endocytosis 
processes (Etienne-Manneville, 2006). 
The Miro group has been described as a group of the Ras superfamily 
which are mainly located at the outer mitochondrial membrane and are 
involved in maintaining mitochondrial integrity (Zerial and McBride, 2001). 
The Rab group which is involved in intracellular vesicular transport and 
protein trafficking between organelles involved in endocytosis or secretion. 
The Ran group (Ras-like Nuclear) which is involved in nucleo-cytoplasmic 
RNA and protein transport. It is also involved in the regulation of DNA 
replication and spindle fiber assembly (Weis, 2003). 
The Arf group (ADP-Ribosylation factor) is involved in regulating vesicular 
transport (Memon, 2004). 
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b. Structure and Function of Ras 
Members of the Ras group are monomeric small G proteins with an 
intrinsic GTPase activity which oscillate between an inactive GDP bound 
form and an active GTP bound form. They are made up of a G-domain in 
their N-terminal part and a hypervariable domain in their C-Terminal region 
(Colicelli, 2004). The G-Domain carries the catalytic GTPase activity and 
also regulates binding to effectors and activators. The hypervariable 
domain is involved in protein trafficking and membrane anchoring of the 
Ras proteins via post-translational modifications on a CAAX site in their C-
Terminal region. Membrane anchoring occurs upon farnesylation of the 
cysteine which will result in the creation of a hydrophobic region allowing 
membrane association (Mor and Philips, 2006). Ras proteins have been 
found at the plasma membrane but also on endoplasmic reticulum, 
mitochondrial and golgi membranes. 
 
c. Ras Activation 
Ras proteins are involved in various transmembrane receptor signaling 
such as TKR’s, cytokine receptors, integrins or calcium channels. The 
switch from the inactive to the active form of Ras mainly depend on 
activators like Guanine Exchange Factors (GEF) which will switch GDP to 
GTP on Ras, or inhibitors such as GTPase Activating Proteins (GAP) 
which returns Ras to its GDP bound state. 
 
Following TKR stimulation by their ligands and receptor dimerization and 
auto-phosphorylation, the phosphotyrosine sites will serve as anchoring 
sites for adaptor proteins such as Grb2 or Shc through SH2 or 
phosphotyrosine binding domains. Grb2, upon phosphorylation by the 
tyrosine kinase receptors will expose its two SH3 domains and associate 
with the proline rich C-Terminal domain of the protein Sos (son of 
Sevenless), which incidentally is a Ras GEF. Sos will then activate Ras by 
swapping GDP to GTP. GTP bound Ras is then able to recruit various 
effectors through their RBD’s (Ras Binding Domains). Such effectors 
include the Raf kinase, and PI3K. The signaling is terminated through GTP 
hydrolysis with Ras’s intrinsic GTPase activity and trough assistance from 
combined GAP’s (Figure 24) (Sondermann et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: The RasGTP/GDP cycle 
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During the active period of Ras, it will interact with various effectors and 
initiate the canonical Ras/Raf/MEK/ERK pathway(Marshall, 1995). 
 
III. The Raf MAPKKK 
The Raf (Rapidly Accelerated Fibrosarcoma) of serine/threonine kinases 
are highly conserved in their structure and contain three CR1, CR2 and 
CR3 conserved regions corresponding to functional domains. The N-
Terminal CR1 region carries a Ras Binding Domain and a Cystein Rich 
Domain. These two domains within the CR1 region are essential for Ras 
binding and are involved in Raf activation. The CR2 region is rich in serine 
and threonine residues, including the Raf activation site as well as 
inhibitory phosphorylation sites. The CR3 region carries the catalytic 
serine/threonine kinase domain (Wellbrock et al., 2004). There are 
different variants of Raf, some with tissue specific expression. 
 
The Raf kinases represent the entry point of the ERK/MAPK pathway since 
its activation leads directly to the activation of the enzymatic cascade of 
ERK activation. The regulation of Raf kinases is very complex and still not 
completely understood. 
 
The activation of Raf takes place near the plasma membrane in the 
presence of Ras. It rests on several factors such as relocalization to the 
plasma membrane, phosphorylation of activating sites and 
dephosphorylation of deactivating sites, adaptor and scaffold proteins. In 
its inactive form, Raf is phosphorylated on serines 259 and 261, which 
represent binding sites for the 14-3-3 protein. 14-3-3 will maintain Raf in its 
inactive state by masking Raf’s CR2 and CR3 regions as discussed above 
(Dhillon and Kolch, 2002). 
 
The first step in Raf activation is mediated by its binding to active Ras 
which displaces 14-3-3 from Raf. In fact Raf’s RBD domain has a very high 
affinity for Ras-GTP (Kubicek et al., 2002). Upon binding to Ras and 
following 14-3-3’s displacement, the serine phosphatase PP2A will 
dephosphorylate Raf on the inhibitory serines 259 and 261. Raf can only 
be activated if these two serines are dephosphorylated (Kubicek et al., 
2002). The interaction between Ras and Raf therefore exposes Raf’s 
catalytic site which primes the latter for anchoring Mek1/2. 
 
To reach complete activation, Raf needs to be phosphorylated on specific 
residues within the CR3 region. Several mitogens, integrins and Ras itself 
participate in phosphorylating Raf mainly on Serine 338 which will lead to 
its complete activation. Phosphorylation on other residues such as tyrosine 
341, threonine 491 and serine 494. These phosphorylations are effected 
by PAK kinases such as PAK 1 and 3 and some studies report this occurs 
in a PI3K dependant manner (Chiloeches et al., 2001). 
 
Raf’s deactivation occurs through a detachment from Ras-GDP and also 
through phosphorylation on Serine 43 with decreases its affinity for Ras. 
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ERK1 and 2 have been shown to exert a negative feedback loop on Raf by 
mediating the Serine 43 phosphorylation. 
 
IV. The MEK-1 and MEK-2 MAPKK 
There are two isoforms of MEK encoded by two distinct genes, MEK-1 
(45kDa) and MEK-2 (47 kDa). These two proteins present with 80% 
homology and differ in their N- and C-Terminal regions (Zheng and Guan, 
1994). In addition of their catalytic domains, MEK proteins have an ERK 
interacting domain in their C-Terminal region. Their proline rich N-Terminal 
region confers them with the ability to bind Raf (Zheng and Guan, 1994). 
The two MAPKK seem to present with different regulatory mechanisms 
since MEK-1 needs to undergo phosphorylation on some sites for 
activation and those sites are absent from MEK-2. 
 
To undergo activation, MEKs have to be phosphorylated on two serine 
residues, S218 and S222 on MEK-1 and S22 and S226 on MEK-2. The 
phosphorylation is carried out by Raf (Catling et al., 1995). Other proteins 
can directly activate MEK such as the MEKK1-3 (MEK Kinase 1, 2 and 3), 
PKC α and ζ, PI3K and others. Different isoforms of Raf will preferentially 
activate MEk-1 or 2 in cells. MEK-1 and -2 have the property of being dual 
kinases, meaning that they can phosphorylate on Serine/Threonine, as 
well as on Tyrosine residues. MEK-1 and MEK-2 will therefore 
phosphorylate ERK1 on Threonine 183 and Tyrosine 185 and ERK2 on 
Threonine 202 and Tyrosine 204 (Catling et al., 1995; Payne et al., 1991). 
 
 
V. The ERK-1 and ERK-2 MAPK 
a. Activation and Targets 
The ERK1 and ERK2 kinases are the last actors in the MAPK cascade and 
the two proteins present with 90% homology (Cobb et al., 1991). They 
differ mainly in their N-terminal region. They exert their functions on 
cytoplasmic as well as nuclear targets. As stated above, ERK activation 
results from a double phosphorylation by MEK on a TEY motif (Payne et 
al., 1991). Once active, the subcellular localization of these proteins can 
vary according to cell type, tissue or stimulus. In quiescent cells for 
instance, active ERK1 and 2 are mainly cytoplasmic. In other cases, upon 
stimulation active ERK1 and 2 will rapidly translocate to the nucleus. 
Through these processes, active ERK1 and 2 will activate their nuclear or 
cytoplasmic target substrates (Marchetti et al., 2005). 
 
More than 160 substrates have been identified for active ERK1/2.These 
include transcription factors, cytoplasmic proteins, membrane proteins 
which will be phosphorylated on either a serine or a threonine residue 
(Pouysségur et al., 2002). ERK substrates contain a consensus 
phosphorylation site PXS/TP or the minimal sequence S/TP where X is 
generally a leucine (Yoon and Seger, 2006). Phosphorylation of these 
substrates can impact on their stability, DNA binding capacity and 
transcription inhibition or activation. 
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Cytoplasmic targets of ERK include phospholipase A2, P90RSK, MSK1/2 
and the phosphatase MKP3 as well as cytoskeletal proteins such as Tau, 
MAP2 or Paxillin, which plays a major role in cell adhesion. 
 
Nuclear targets of ERK are mainly transcription factors such as Elk-1, c-
Jun, c-Fos, c-Myc but also the MPKP1/2 phosphatases (Marchetti et al., 
2005; Pouysségur et al., 2002). Recently, paxillin was identified to be a key 
mediator of MAPK action in the nucleus. This occurs via a 
Paxillin/ERK/Elk-1 complex which has been shown to be essential for the 
up-regulation of c-Fos and CyclinD1 (Sen et al., 2012).  
 
b. Distinct effects of ERK1 and ERK2 
For a long time, and mainly due to the high degree of homology between 
the two proteins, no distinction was made between the substrates of the 2 
kinases. However more and more studies are starting to depict different 
roles for ERK1 and ERK2. 
 
The first studies suggesting different roles for ERK1 and 2 appeared in 
2008 when microarray based gene expression profiling studies on 
zebrafish embryos demonstrated that ERK1 and 2 regulated distinct gene 
sets (Krens et al., 2008). Later it was shown that ERK2 and not ERK1 was 
responsible for Ras induced EMT in oncogenic processes (Shin et al., 
2010). More studies depicted a distinct role for ERK2 and not ERK 1 in 
processes such as HGF-induced cell motility(Radtke et al., 2013). 
Recently, a study found that only ERK2 alone was responsible for 
inflammatory pain and not ERK1 (O’Brien et al., 2015). 
 
B. Negative Regulation of ERK 
ERK pathway inactivation rests on the action of phosphatases. Three major 
phosphatase families participate in the inhibition of ERK kinases. The serine 
threonine phosphatase PP2A maintains ERK in an inactive state in the 
cytoplasm, the family of Phospho Tyrosine Phosphatase such as PTP-SL, 
HePTP and STEP, and finally the dual specificity phosphatases which are able 
to dephosphorylate on both tyrosine and threonine residues (Marchetti et al., 
2005). The MKPs or DUSP dual phosphatases are the most characterized and 
they exert their function by removing the phosphate groups on threonines and 
tyrosines in the TXY activation motifs of MAPK. MKP’s share a common 
structure composed on a non-catalytic N-Terminal Domain and a catalytic C-
Terminal part. The non-catalytic domain is less conserved than the catalytic 
one and contains two CH2 (Cdc25 homology 2) domains as well as a 
positively charged amino acid sequence essential for binding with MAPK 
(Farooq and Zhou, 2004). The MKP family can be divided into 3 sub-groups, 
based on sequence homology and subcellular localization (Theodosiou and 
Ashworth, 2002). 
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- Class I MKPs (DUSP1/MKP1, DUSP2/PAC1, DUSP4/MKP2, and DUSP5) 
have a main nuclear localization and exert their phosphatase roles on ERK 
as well as JNK and P38. 
- Class II MKPs (DUSP6/MKP3, DUSP7/MKP-X, DUSP9/MKP4) have a main 
cytoplasmic localization and dephosphorylate ERK1 and 2. 
- Class III MKPs (DUSP8, DUSP10/MKP5) have a main cytoplasmic 
localization and act mainly on p38 and JNK. 
 
Alongside regulating MAPK, these phosphatases are themselves subjected to 
regulation at different levels. At the transcriptional level, MKPs are induced as 
a early genes as targets of MAPK signaling to provide a negative feedback 
mechanism to avoid constitutive activation of the MAPK pathway (Bermudez 
et al., 2010). They can also be regulated through modulation of their mRNA 
stability. For instance HuR and NF90 are known to bind and stabilize DUSP 
mRNA (Kuwano et al., 2008). Another level of control is provided by the 
modulation of protein stability. For instance phosphorylation of DUSP6/MKP3 
on serines 159,174 and 197 by either ERK or CK2a leads to its proteasomal 
degradation. Another means of regulations involves modulation of the catalytic 
activity of MKPs. Some MKP’s like DUSP 1, 2, 6 and 9 need a conformational 
change to be active and this is provided by the binding of these MKP to their 
respective substrate (Bermudez et al., 2010). 
 
 
3. Interactions in the MAPK pathways 
Above, we discussed the specificity of MAPK to their substrate of their regulators. 
This specificity is given by a number of domains, which serve as specific 
recognition sites for the target proteins. Below is a list of some of these described 
domains. 
 
A. D-Domains 
MAPK signaling and specificity is achieved in part through a specialized 
docking motif present in the components of the MAPK cascade. The D-
Domain or D-site consists of a core of basic residues followed by a 
hydrophobic patch (Lys/Arg-Lys/Arg-X2-6-ϕ-X-ϕ), where ϕ is a hydrophobic 
residue such as Leu, Iso or Val, D-domains can be recognized by more than 
one group of MAPK but they have been demonstrated to increase signaling 
specificity and efficiency. D-domains are generally located upstream or 
downstream the phosphor-acceptor site and are present in many MAPK 
regulatory proteins and substrates. D-Domain mediated interactions are very 
stable and are often required for pre-existing complexes between MAPK and 
their substrates. Such motifs have been identified in several MAPK binding 
proteins such as MK5 and RSK.  
 
B. DEF Domains 
The second major MAPK docking sites are called DEF Domains (Docking site 
for ERK, FXFP), also called the F site of the DEF site. They have been 
identified in a number of ERK1/2 substrates. DEF domains are characterized 
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by a Phe-X-Phe-Pro sequence, where one of the Phe residues can also be a 
Tyr. This domain is generally located 6-20 amino acids, C-terminal to the 
phosphoacceptor site. DEF domains are required for efficient binding of 
ERK1/2 and have been showed to be required for ERK1/2 mediated substrate 
phosphorylation.   
 
C. CD Domains 
CD or Common Docking Domains have been identified independently outside 
the catalytic region of ERK, p38 and JNK. These domains are involved in D-
Domain interactions. The CD Domain contains acidic and hydrophobic 
residues, which are necessary for establishing electrostatic and hydrophobic 
interaction with the positively charged and hydrophobic residues of D-
Domains. The CD domain is prolonged by a specific 2 amino-acid patch, 
which is neutral in ERK1/2 (TT motif) and acidic in p38 (ED motif), and this 
results in the formation of a groove for their interacting partners. 
 
4. Involvement in breast cancer 
A. Involvement in endocrine therapy resistance 
Several studies have pointed out the involvement of the MAPK pathway in 
tamoxifen resistance. In fact, an increased activity of ERK has been shown to be 
associated with endocrine resistance and decreased survival in breast cancer 
patients (Kurebayashi, 2005). One mechanism for this is the phosphorylation of 
Serine 118 in ERα which leads to the activation of ligand independent functions of 
the receptor (Le Romancer et al., 2011). Another possible mechanism of 
tamoxifen resistance involving the MAPK pathway is the overexpression of HER2. 
Indeed studies have shown that HER2 overexpression result in an increase in the 
MAPK pathway in breast cancer cell lines and HER2 inhibitors can partially 
restore sensitivity to anti-estrogens (Kurokawa et al., 2000). 
Another suggested mechanism involves the induction of cell cycle arrest following 
the activation of the MAPK pathway. In this situation, strong, sustained ERK 
activity leads to senescence or differentiation. Increased MKP activity arising from 
HER2 overexpression, may reduce this strong signal. The result is weak or 
transient ERK activity, which favors cell proliferation (Boutros et al., 2008). 
Increased p38 activity has also been observed in resistant tumors. It is possible 
that activated p38 may promote resistance to tamoxifen because of its ability to 
phosphorylate the ER and enhance its nuclear functions (Riggins et al., 2007). 
B.  Involvement in chemotherapy resistance 
Triple-negative breast cancers do not express ER, PR, or HER2, and hence, do 
not respond to targeted therapy (Stockmans et al., 2008). Research has shown 
that MAPK expression may be an underlying mechanism contributing to the 
generation of chemoresistance in triple-negative breast cancer. Epidermal growth 
factor receptor, which is a receptor tyrosine kinase upstream from MAPK, has 
been shown to be overexpressed in up to 66% of triple-negative breast cancers 
(Reis-Filho and Tutt, 2008). Increased growth factor activity could lead to 
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increased MAPK activity, which can contribute to an increase in cell growth. In 
addition, microarray data derived from primary tumor samples identified a cluster 
of genes associated with triple-negative breast cancer. Among these are genes 
that activate ERK, PI3K, AKT, p38, and NF-κB (Kang et al., 2008). Since triple-
negative cancers do not respond to current targeted therapies aimed at the 
estrogen receptor and HER2, developing targeted agents aimed at the pathways 
that are activated in triple-negative breast cancer remains an important goal in 
cancer research. 
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Estrogens play a major role in breast cancer. While the main studied pathway of ERα 
activation remained the genomic pathway, our team and other demonstrated the 
relevance of the non-genomic pathway in breast tumors. 
 
Upon my arrival as a PhD student, Muriel Le Romancer’s team was extensively 
studying the role of ERα non-genomic pathway in breast tumorigenesis. In fact our 
team demonstrated that the methylation of ERα on Arginine 260 was an essential 
pre-requisite for estrogen non-genomic signaling and for the recruitment of the non-
genomic actors Src and PI3K. Furthermore, our team demonstrated that estrogen 
non-genomic signaling was deregulated in aggressive breast cancer. 
 
Upon my arrival in the team, we decided to study ERα-36 since it was reported this 
novel cytoplasmic splice variant was able to rapidly initiate MAPK signaling induced 
by estrogen but also by anti-estrogens. 
 
Despite these reports on ERα-36, the mechanisms by which it mediated non-
genomic signaling were not very clear. The first objective of my project was to unveil 
the molecular mechanisms in ERα-36 could mediate non-genomic signaling. 
 
The second objective of my project was to study the expression of ERα-36 in breast 
tumors to evaluate whether its expression could constitute a prognostic/predictive 
marker in breast tumors. Through the pathology department of the Leon Berard 
cancer Hospital, our team has access to two cohorts of human breast tumors. 
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INTRODUCTION TO ARTICLE 1 
 
 Estrogens play a major role in physiology as well as in the development of breast 
cancer. Besides its classical genomic action, the estrogen receptor ERα mediates 
rapid extranuclear signaling at the plasma membrane. Our team has thoroughly 
investigated the estrogen non-genomic pathway. In 2005, reports of a new ERα 
splice variant arose, namely ERα-36, and very quickly, it had been observed that this 
new variant had a main cytoplasmic and membrane localization. Furthermore ERα-
36 mediated estrogen non-genomic signaling through the rapid and transient 
phosphorylation of MAPK. However, the mechanism by which ERα-36 mediated non-
genomic signaling was not properly understood. 
 
We decided to use several approaches to elucidate the non-genomic signaling 
mediated by ERα-36. We coupled in-vitro GST Pulldown assays and in-cellulo 
‘proximity ligation assays’ to monitor and study the kinetics and proteins partners 
involved in ERα-36 non-genomic signaling. 
 
The ‘Proximity Ligation Assay’ technology from OLINK Bioscience, commercialized 
by Sigma Aldrich Ltd, allows to monitor in-situ protein-protein interactions. A pair of 
antibodies recognize and bind to two potentially interacting targets. These antibodies 
are conjugated to a matched pair (labeled +/-) of short single-stranded 
oligonucleotides. If the two respective targets interact, and hence remain in very 
close proximity, the oligonucleotide probes will hybridize and ligate with two 
additional “connector oligos” to form a continuous circular DNA structure. DNA 
polymerase enzymes will amplify these circular molecules through simple, reliable 
rolling-circle amplification. The result is a highly amplified circular DNA molecule that 
can be detected via standard fluorescent methods, and that acts as a qualitative 
marker of interaction between the two proteins (Figure 25).  
 
 
Figure 25: Simplified overview of the Proximity Ligation Assay Reaction 
 
 
This work allowed us to identify key molecular actors involved in ERα-36 signaling 
and has allowed us to propose a model for the estrogen mediated cellular effects 
through ERα-36. 
 
 
1. ERα-36 and the non-genomic pathway 
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2SUMMARY 
Alterations in estrogen-mediated cellular signaling have largely been involved in the pathogenesis of 
breast cancer. Here, we investigate the signaling regulation of one splice variant of the estrogen 
receptor, namely ERĮ-36, associated with a poor prognosis in breast cancers. Coupling in vitro and in 
vivo approaches we determine the precise sequential molecular events of a new estrogen signaling 
network LQ DQ (5Į-negative cell line and in an original patient derived xenograft. After estrogen 
treatment, ERĮ-36 rapidly associates with Src at the plasma membrane, initiating downstream 
cascade, including MEK1/ERK activation and paxillin phosphorylation on S126, which in turn 
triggers higher expression of cyclin D1. Of note, the direct binding of ERĮ-36 to ERK2 prevents its 
dephosphorylation from MKP3 and enhances the downstream signaling. These findings improve our 
understanding of the estrogen signaling regulation and open new avenues for personalized 
therapeutic approaches targeting Src or MEK inhibition in ERĮ-36-positive patients. 
3INTRODUCTION
Estrogen signaling is essential in the initiation and development of human breast cancers. The 
biological actions of eVWURJHQDUHPHGLDWHGWKURXJK(5ĮDQG(5ȕ which function in the nucleus as 
ligand-dependent transcription factors. Both receptors share the common nuclear hormone receptors 
structure composed of functional domains (Nilsson et al., 2001) including (i) the variable N-terminal 
A/B domain containing the transactivation domain AF-1, (ii) the C or DNA-binding domain (DBD),
(iii) the hinge domain (D) and (iv) the E/F domains containing the ligand-binding domain (LBD) and 
the transactivation domain AF-2 (Kong et al., 2003).
The molecular mechanisms underlying estrogen signaling has been extensively studied for ERs. In 
addition to the well-documented effects on transcription (genomic signaling), estrogen can activate 
signal transduction cascades outside of the nucleus (i.e., non-genomic signaling) (Levin, 2009; Levin, 
2015). In this process(5Į interacts directly with various proteins kinases to form protein complexes 
triggering the activation of downstream molecules such as Akt (Castoria et al., 2001; Song et al., 
2005) One such complex is the (5Į6UFPI3K complex and our team demonstrated that methylation 
of the receptor on the arginine residue R260, located in the DBD, is a prerequisite for its estrogen-
induced formation (Le Romancer M. et al., 2008). Recently, we showed that the (5Į6UF3,.
complex is activated in aggressive breast tumors and could constitute a new potential target for 
therapy (Poulard et al., 2012). $SSUR[LPDWLYHO\RIEUHDVW FDQFHUV H[SUHVV(5ĮDQGHQGRFULQH
therapies have led to significant improvements in patient survival. In contrast WR(5Į-positive breast 
cancers, triple-negative breast cancers, ZKLFK DUH QHJDWLYH IRU (5Į IRU WKH SURJHVWHURQH UHFHSWRU
(PR) and for the human epidermal growth factor receptor 2 (HER2), are highly aggressive and 
treatment options are, so far, restricted to cytotoxic agents (Foulkes et al., 2010).
Owing to the alternative mRNA splicing of the ESR1 gene, several isoforms are known to exist in 
cells. At least three ERD variants have been reported (Le Romancer M. et al., 2011) including ERĮ-
36 (Wang et al., 2005). The transcription of ERĮ-36 is initiated by a previously unidentified promoter 
4located in the first intron of the ESR1 gene. Compared to ERĮ, ERĮ-36 retains DNA-binding, 
dimerization, and partial LBD, but lacks both AF-1 and AF-2 domains. Furthermore, the last 138 
amino-acids, encoded by the final exon 7 and 8 are replaced by an extra unique 27 amino-acid 
sequence at C-terminus domain (CTD). ERĮ-36 is mainly located at the level of the plasma 
membrane and within the cytoplasm, mediating non-genomic estrogen signaling by the activation of 
the ERK pathway (for review, (Rao et al., 2011). Indeed, ERĮ-36 was shown to activate ERK1/2 
through the protein kinase C delta signaling pathway, leading to elevated expression of cyclin 
D1/cdk4, which modulates the cell cycle progression (Tong et al., 2010). Moreover, ERĮ-36-
mediated MAPK/ERK signaling pathway contributes to the potential invasion and metastasis of 
cancer cells (Chaudhri et al., 2012). Interestingly, ERĮ-36 has been reported to be expressed LQ(5Į-
QHJDWLYHEUHDVWFDQFHUFHOOOLQHVDQG(5Į-negative tumor samples (Gu et al., 2014; Lee et al., 2008; 
Shi et al., 2009; Wang et al., 2006). Intriguingly, ERĮ-36 can stimulate ERK activation in cells 
treated with the anti-estrogen tamoxifen (Wang et al., 2006; Zhang et al., 2012b), and is also involved 
in the development of tamoxifen resistance in ERĮ-positive breast cancer cell lines (Yin et al., 2014; 
Zhang et al., 2011). ,QGHHGDUHWURVSHFWLYHVWXG\RIFDVHVRIEUHDVWFDQFHUVUHYHDOHGWKDW(5Į-
positive patients, expressing high levels of ERĮ-36 are less likely to benefit to tamoxifen treatment 
(Shi et al., 2009). In ERĮ-negative breast cancer cell lines, ERĮ-36 induces paclitaxel resistance 
through c-jun N-terminal kinases, a component of the ERK family (Zhang et al., 2012a).
However, the exact mechanisms underlying ERĮ-36-mediated ERK activation were not explored.
The aim of the present study was to unravel these molecular mechanisms, and we identified a new 
estrogen signaling network LQ (5Į-negative cell lines, involving ERĮ-36/Src/ERK and PXN
(paxillin), which regulates cell proliferation via cyclin D1 expression. This signaling was also shown 
to occur in patient-derived xenograft (PDX) models of breast cancer treated with estrogen, 
comforting our findings as to the importance of the activation of this signaling pathway in breast 
cancers.
5RESULTS
ERĮ-36 contains a nuclear export signal and retains estrogen ligands binding sites
Although ERĮ-36 contains a nuclear localization signal, it is not expressed in the nucleus, and the 
protein has primarily been reported in the cytoplasm and at the plasma membrane (see Rao et al, 
2011). Since ERĮ-36 GLIIHUV IURP (5Į E\ LWV XQLTXH &-terminal 27 amino-acid sequence, this 
sequence was submitted to the NetNES 1.1 prediction server which is a web interface designed to 
predict the presence of putative nuclear export signal (NES) sequences. A putative leucine-rich NES 
was identified in the CTD of ERĮ-36 (Figure S1A), which was very homologous to known NES 
sequences (Figure S1B). To confirm that this NES sequence was responsible for the absence of ERĮ-
36 from the nucleus, we either deleted the 27 amino-acids (ERĮ-36'C) or replaced two conserved 
hydrophobic residues, namely valine (V288) and Leucine (L295) by alanine (A) (5Į-
36V288A/L295A) (Figure 1A). The different constructs were transfected into MCF-7 cells and 
analyzed by fluorescence microscopy. As expected, the wild type ERĮ-36 was localized in the 
cytoplasm and at the level of the plasma membrane (Figure 1B, panels d-f), whereas, the 'C and the 
V288A/L295A NES mutants were mainly present in the nucleus (panels g-l). Hence, our results have 
uncovered the presence of a functional NES, inducing the exportation of ERD-36 from the nucleus.
Since ERĮ-36 lacks a part of the LBD, we verified, in silico and in cellulo, whether this isoform was 
able to transduce estrogen binding-dependent signal. For this purpose, we built homology models of 
(5Į-36 with E2 based on the available crystal structures of ERD LBD complexes. The initial model 
indicated that two residues, namely glutamic acid (E180) and arginine (R221) (corresponding to 
E353/R394 in ERĮ), could anchor the ligand in an open pocket in (5Į-36 (Figure 1C). The 
remaining accessibility of a ligand pocket is in agreement with previous studies indicating high 
affinity binding of E2 to ERD-36 (Kang et al., 2010). However, it must be noted that the 
modifications and truncation of the C-terminal helices in (5Į-36 ZLWK UHVSHFW WR (5Į will most 
likely alter the conformation of the LBD, an effect that was not modelled (Figure 1C), and more 
6detailed studies would be necessary to obtain a high resolution VWUXFWXUHRI(5Į-36 LBD in complex 
with E2. We next generated point mutations on these residues, replacing them with an A residue, and 
conducted in cellulo assays by transfecting HeLa cells with wild type (WT) or mutated ERĮ-36. We
found that overexpression of the WT protein triggered activation of ERK upon E2 treatment while the 
E180A and R221A mutants lost this capacity (Figure 1D).
E2 triggers the interaction of (5Į-36 with Src and PI3K kinases
In order to conduct experiments on cells endogenously expressing ERĮ-36, we produced an antibody 
specifically recognizing ERĮ-36, using a peptide containing the 27 amino-acids of the CTD of the 
protein. The antibody was validated by Western blot analyses using (i) GST-ERĮ-36, (Figure S2A), 
(ii) ERĮ-36 transfected into HeLa cells (Figure S2B), and (iii) in CAMA-1 cells, where ERĮ-36 was 
knocked down by a siRNA approach (Figure S2C). Next, we used the antibody to evaluate the level
of ERĮ-36 expression in a panel of human breast cancer cell lines as well as in different PDX models 
of breast cancers (Marangoni et al., 2007). We initially confirmed, as noted previously (Gu et al., 
2014; Lee et al., 2008; Shi et al., 2009; Wang et al., 2006), that ERĮ-36 is expressed both in ERD-
positive and in ERD-negative breast tumors (Figures S2D and S2E). One triple negative PDX, 
namely HBCx-12A, clearly expressed higher level of ERD-36, both in Western blots and in 
immunohistochemically stained tissues (Figures S2E and S2F). Furthermore, a cell line (named 
HBCc-12A), conserving a strong expression of the protein (Figure S2G), was previously established 
from this PDX; both PDX and cell line were thus selected for future experiments to distinguish ERD-
36-VSHFLILF VLJQDOLQJ LQGHSHQGHQWO\ RI(5Į Since ERD-36 was previously shown to trigger ERK 
and Akt activation (Lin et al., 2010; Wang et al., 2006), we studied these pathways in the HBCc-12A
cells, and found that E2 triggers a rapid and transient phosphorylation of ERK1/2 (Figure S2H), 
through no change in the phosphorylation of Akt was observed. Furthermore, the addition of E2 led 
to an increase in cell proliferation in vitro (Figure S2I) and in vivo, since estradiol supplementation 
also stimulated the growth of the HBCx-12A PDX (Figure S2J).
7To identify potential ERD-36 partners, we first targeted known ERD partners participating in non-
genomic signaling, such as Src and the PI3K kinases (Cabodi et al., 2004; Castoria et al., 2001; Le 
Romancer M. et al., 2008). We initially demonstrated a direct interaction between ERD-36 and both
Src and PI3K, by conducting GST pull-down experiments (Figures S3A and S3B). We next 
performed PLAs according to the method described by Soderberg et al. This assay enables a clear 
detection of protein-protein interactions in situ, with each red dot representing an interaction
(Soderberg et al., 2006). Upon estrogen treatment, we found an increase in the number of ERD-
36/Src and ERD-36/PI3K interactions in the cytoplasm of HBCc-12A cells (Figure 2A, panels a-f). 
These interactions were only detected when using a combination of both antibodies (Figures 2A, 
panels g-I and 2B). Interestingly, the number of red dots increased after 5 min of estrogen treatment, 
and then decreased after 15 min (Figures 2A and 2B). Since methylation of ERDon R260 was 
previously shown to trigger its association with Src and PI3K (Le Romancer M. et al., 2008), we 
attempted to detect methylation of ERD-36, but were unsuccessful (data not shown). Furthermore, 
since Src and PI3K kinase activities are required for their interaction with ERD (Poulard et al., 2012),
we investigated whether they are also required to interact with ERD-36. We observed that treatment 
of HBCc-12A cells with the Src inhibitor PP1 abolished ERD-36/Src interactions but had no effect on 
the ERD-36/PI3K interaction. In contrast, the PI3K inhibitor LY294002 inhibited RQO\(5Į-36/PI3K 
interaction (Figures S3C and S3D).
ERĮ-36 binds specifically to P-ERK2
To identify ERĮ-36-specific partners, we performed a bioinformatics search of the CTD to find 
known protein motifs using the Scansite software. We uncovered a putative D domain (docking 
domain) for ERK2 and verified the alignment of this D domain with known MAPK interactors
(Figure 2C). These D domains are characteristic of proteins involved in ERK signaling as they are
present in ERK’s substrates, phosphatases or adaptor proteins (Tanoue et al., 2000). We then verified
by GST pull-down experiment whether ERĮ-36 interacts with ERK2. The data obtained (Figure 2D)
8show that ERĮ-36 interacts specifically with ERK2, and that the deletion of the CTD of ERĮ-36
containing the putative D domain completely abolishes this interaction. These results were confirmed 
by immunoprecipitation in HeLa cells transfected with ERD-36 (Figure S4). Next, we studied 
HQGRJHQRXV(5Į-36/ERK2 interactions in HBCc-12A cells by PLA. E2 triggers a rapid interaction 
between both proteins with a peak at 5 min, and a decrease after 15 min (Figures 2E and 2F). Finally, 
in vitro phosphorylation assays revealed that ERD-36 is not a substrate for ERK2 (data not shown).
To decipher the functional interplay between ERD-36 and ERK2 in HBCc-12A cells, we first 
checked whether ERD-36 interacts with phosphorylated ERK2 (P-ERK2). The use of the MEK 
inhibitor U1026 abolished the interactions between ERD-36 and ERK2 following E2 treatment 
(Figures 2G and 2H), and concomitantly inhibited ERK phosphorylation (Figure 2I). These results 
suggest that ERD-36 interacts specifically with P-ERK2.
ERD-36 protects ERK dephosphorylation by the dual phosphatase MKP3
Next, we examined which amino-acid residues RI (5Į-36 were involved in its interaction with 
ERK2. An analysis of the 3D structure of ERK2-peptide complexes (Supplemental Table 3 for the 
list of the complexes) consistently pointed to R and L residues as playing an essential role in 
stabilizing the complexes (Table S1). Comparison of these data ZLWK WKH (5Į-36 CTD sequence 
pointed to leucine (L297) residue as implicated in this interaction, and indicated that the CTD of 
(5Į-36 could adopt a conformation similar to that seen in existing complexes (Figure 3A for a 3D in
silico PRGHO UHSUHVHQWLQJDSXWDWLYH LQWHUDFWLRQEHWZHHQ WKH&7'RI(5Į-36 and ERK2 and Table 
S1). The point mutation of this residue with an alanine residue resulted in an impairment in the 
binding of the ERĮ-36 L297A mutant to ERK2 (Figure 3B). Furthermore, we disrupted ERĮ-36/ERK
interaction by transfecting HBCc-12A cells with a Flag-CTD of WT ERD36 or RI(5Į-36 mutated 
on L297A. We found that the Flag-CTD strongly impaired the E2-induced ERD-36/ERK2 interaction
(Figure 3C, panels d-f and 3D) compared to the empty vector (Figure 3C, panels a-c). Interestingly,
the Flag-CTD peptide also completely impaired ERK phosphorylation (Figure 3E). These effects
9were not observed in cells transfected with the CTD mutant, which is unable to bind to ERK (Figures
3C, panels g-I and 3E). Control immunofluorescence (IF) experiments show that Flag-CTD peptides 
were equally expressed (Figure 3F). These findings show that L297 residue of ERĮ-36 is essential for 
the interaction between this receptor and ERK2.
Next, we overexpressed ERD-36 in HBCc-12A cells and found a sustained ERK phosphorylation 
(beyond 15 min) upon E2 activation (Figure 4A). Concomitantly, a sustained ERD-36/ERK2 
interaction was also observed by PLA in these cells (Figures 4B and 4C, panels e-h), compared to 
cells transfected with an empty vector (Figure 4C, panels a-d). We hypothesized that ERD-36 could 
regulate ERK phosphorylation by modulating its dephosphorylation. Since the dual phosphatase 
MKP3 has previously been implicated in ERK dephosphorylation (Roskoski, Jr., 2012), we knocked 
down MKP3 with 2 different siRNAs in HBCc-12A cells. This silencing approach resulted in 
sustained ERK phosphorylation upon E2 treatment showing that MKP3 depletion is sufficient to 
inhibit ERK dephosphorylation (Figure 4D). This event occurred concomitantly with a sustained 
ERD-36/ERK2 interaction (Figures 4E and 4F). We then hypothesized that the binding of ERK2 to
ERD-36 could impede its binding to MKP3 and therefore prevent ERK2 dephosphorylation. In order 
to verify this hypothesis, we studied the interaction between ERK2 and MKP3 by PLA in HBCc-12A 
cells transfected with the different Flag-CTD constructs as described above. Interestingly, we found 
that upon E2 treatment, ERD-36 binds to ERK2 after 5 min while MKP3 binds to ERK2 after 15 min. 
However, when we disrupted ERD-36/ERK2 interaction with the ERD-36 Flag-CTD, MKP3 bound
to ERK2 within 5 min of treatment (Figures 5A and 5B). Interestingly, the Flag-CTD L297A mutant,
which does not impair the binding of ERK2 to ERĮ-36, displayed results similar to those obtained 
when transfecting with the empty vector. Finally, ZKHQZH RYHUH[SUHVVHG(5Į-36 in HBCc-12A 
cells (as in Figure 4A), we observed that the ERK2/MKP3 interaction occurred later than in the 
control cells (Figures 5C and 5D). Overall, these findings confirm our initial hypotheVLVWKDW(5Į-36
prevents and delays the ERK2/MKP3 interaction, thus leading to a sustained ERK2 phosphorylation.
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The activation and regulation of the E2/ERD-36 pathway downstream of P-ERK 
To investigate the signaling pathway LQGXFHG E\ (5Į-36, downstream of ERK, we initially 
demonstrated by IF that P-ERK remains exclusively localized in the cytoplasm of the cells (Figure 
6A). From the literature, we identified a potential candidate, namely the adaptor paxillin (PXN),
which is a cytoplasmic substrate for ERK, and which undergoes phosphorylation on its serine (S126) 
residue (Cai et al., 2006). We found that upon E2 treatment of HBCc-12A cells, PXN 
phosphorylation increased in a rapid and transient manner following the same time course as ERK 
activation (Figure 6B). Since PXN has been described at the plasma membrane, as well as in the 
nucleus (Cai et al., 2006; Sen et al., 2012), we looked for the subcellular localization of P-PXN upon 
E2 treatment. IF experiments showed that E2 induced a rapid phosphorylation of PXN exclusively 
within the nucleus of HBCc-12A cells (Figure 6C). It was previously reported that P-S126-PXN can 
participate in the transcriptional regulation of cyclin D1 (Sen et al., 2012). We studied the expression 
of cyclin D1 following E2 treatment and observed an increase in the level of Cyclin D1 expression 
after 12hr (Figure 6D). Interestingly, when the pathway was blocked with the MEK inhibitor or when 
the ERD-36/ERK2 interaction was disrupted, E2 failed to induce PXN phosphorylation and cyclin D1 
expression (Figure 6E and 6F). Furthermore, the longer time course of these experiments revealed a 
second activation wave of ERK after 1hr of induction, corroborating similar observations described 
previously in MDA-MB-231 cells (Zhang et al., 2011).
Having deciphered this new pathway in the HBCc-12A cell line, we investigated whether the 
pathway occurred in the corresponding PDX (HBCx-12A) grown in the presence of E2. As described 
above, E2 supplementation stimulated tumor growth in vivo (Figure S2J). The analysis of these 
xenografts tumors at the end of the 51-day experimental time course, showed an increase in ERD-36 
interaction with Src (Figures 6G and 6H) and higher levels of P-ERK (Figure 6I), and, P-PXN 
expression (Figure 6J). ,QDGGLWLRQWKLVQRYHO(5Į-36-mediated signaling pathway was investigated 
LQ WKH(5Į-negative HBL100 cell line H[SUHVVLQJ(5Į-36 (Figure S2D). This cell line responded 
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similarly to the HBCc-12A cell line, since incubation of E2 also triggered ERD-36/ERK2 interaction, 
ERK activation, PXN phosphorylation, as well as cell proliferation (Figures S5A-S5D). 
In order to establish the sequential events of the pathway, we investigated whether Src and PI3K 
activities occur upstream of the ERK pathway. To do so, we treated the HBCc-12A cells with PP1 
and LY294002 and found that PP1 treatment completely abolished E2-induced ERK and PXN 
phosphorylation (Figure 7A). ERĮ-36/ERK2 interaction (Figures 7B and 7C, compare panels d-f to 
control experiments panels a-c), as well as cyclin D1 expression (Figure 7D). LY294002 had no 
effect on these activities (Figures 7A; 7B, panels g-i; 7C and 7D). Finally, the kinetic of the various 
events of this signaling pathway was determined by treating the HBCc-12A cells with E2 for a very 
short period of time. We found that (i) ERD-36 associates with Src within 3 min of E2 treatment then 
dissociates after 5 min (Figures 7F and S6), (ii) ERD-36 binds to ERK2 with a peak occurring after 5
min of treatment, concomitantly with ERK and PXN phosphorylation (Figures 7E), (iii) after 11 min,
MKP3 starts binding to ERK2 and the interaction lasts at 15 min after E2 treatment (Figures 7F and
S6).
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DISCUSSION
In this study, we unveil the precise molecular events underlying ERD-36-mediated signaling pathway 
in triple negative breast cancers. These findings introduce a new paradigm in which ERD-36 activates 
ERK signaling at two levels, (i) firstly at the plasma membrane by binding to Src and, thereby, 
activating MEK-induced ERK phosphorylation and (ii) second in the cytoplasm by directly binding 
to P-ERK, and thus sustaining the ERK-mediated signals by preventing its dephosphorylation by the 
phosphatase MKP3.
,Q FRQWUDVW WR (5Į (5D-36 isoform has mainly been reported outside the nucleus (Wang et al., 
2006). We uncovered a functional NES in ERD-36 CTD (Figures 1A; 1B; S1A and S1B), suggesting 
that ERD-36 normally enters the nucleus via its nuclear localization signal, and is then efficiently 
exported into the cytoplasm through its NES. These findings are similar to those observed for the
PRMT1 isoform v2, which contains a similar NES responsible for its cytoplasmic localization, in 
contrast to other PRMT1 isoforms localized exclusively in the nucleus (Goulet et al., 2007).
The aim of the present investigation was to focus on triple negative breast cancers, since they are 
very aggressive, and no current targeted therapies. Using our antibody, we screened for a triple 
negative cell line endogenously expressing high levels of the protein, namely the HBCc-12A cell 
line, derived from the HBCx-12A PDX (Figure S2G). Next, while screening for cytoplasmic partners 
of (5Į-36, we observed specific binding of the receptor with Src and with PI3K, which were also 
described to mediate ERD non-genomic signaling in breast cancer, by forming a trimeric complex
(Cabodi et al., 2004; Castoria et al., 2001; Le Romancer M. et al., 2008; Poulard et al., 2012).
However, the mechanisms underlying the formation of the complex seem to be different in the case 
of ERD-36. Indeed, the ERD/Src interaction was dependent on ERD methylation at the level of its 
R260 residue (corresponding to R184 in ERD-36) (Le Romancer M. et al., 2008) as well as on its 
phosphorylation at the level of the Y537 residue, a docking site for the SH2 domain of Src 
(Varricchio et al., 2007). Here, we were unable to detect any ERD-36 methylation on R184, and, in 
addition Y537 is not present in the ERĮ-36 sequence. We can speculate, seeing that the Src kinase 
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activity is required for its binding to ERD-36 (Figures 2A and 2B), that a yet unidentified tyrosine 
residue could be involved in their interaction. Moreover, the binding of ERD-36 with Src depends 
only on Src activity, as well as only PI3K activity is required for ERD-36/PI3K interaction. However, 
further investigations are required to ascertain which residues are involved in this interaction.
The functional activation of ERK by ERD-36 was shown by various research groups (Tong et al., 
2010; Wang et al., 2006; Wang and Yin, 2015). In the present study, we mechanistically demonstrate 
that two routes tightly regulate ERK2 activation by acting both on its phosphorylation (i) and 
dephosphorylation (ii). We describe for the first time a direct binding of ERD-36 with ERK2 via a
newly identified D domain located in the CTD of ERD-36. The D domain is a conserved docking 
motif in MAPKs used in the recognition of their activators, substrates and regulators, such as in
MAKK kinases and phosphatases (Tanoue et al., 2000). The D-site contains both hydrophobic and 
positively charged basic residues with the following canonical sequence: (R/K) 2-3X2-6-IA-X-IB,
conserved in ERD-36 as the CTD contains KKRILNL (Figure 2C). A combined in silico 3D model 
and in vitro approach, enabled us to identify the crucial role of L297 in the binding interaction 
between ERD-36 and ERK2, which was confirmed as the mutation of L to A disrupted completely 
the interaction with ERK2 (Figure 3B). Deactivation of ERK1/2 is carried out by several serine 
threonine or tyrosine phosphatases. Among them MKP3 is a dual phosphatase with the capacity to 
dephosphorylate both threonine and tyrosine residues (Muda et al., 1996; Muda et al., 1998).
Knowing that ERD-36 specifically binds to the phosphorylated form of ERK, we hypothesized that 
ERD-36 could regulate ERK dephosphorylation. Interestingly, ERD-36 was capable of preventing 
MKP3 binding to ERK presumably through stearic competition, maintaining ERK activation. This 
was confirmed by the disruption of ERĮ-36/ERK2 interaction, allowing a more rapid binding of 
MPK3, and resulting in the constant dephosphorylation of ERK. Inversely, overexpression of ERĮ-36
delayed the binding of MKP3 to ERK. Such a regulation of P-ERK has already been described for 
the adaptor molecule MyD88 and the Rab2A GTPase. Indeed, MyD88 and Rab2A GTPase have been 
14
shown to prevent ERK inactivation by MKP3, leading to cell transformation (Coste et al., 2010) and 
to promoting breast cancer stem cells respectively (Luo et al., 2015).
Although many ERK’s substrates are localized in the nucleus and participate in the regulation of 
transcription, others are found in the cytosol and cellular organelles (Yoon and Seger, 2006). We 
found that P-ERK remained in the cytoplasm of HBCc-12A cells (Figure 6A), which directed our 
investigation to one of its cytoplasmic substrates. Recently, the hepatocyte growth factor (HGF) was
shown to induce the phosphorylation of PXN, an important mediator downstream of ERK2 in HGF-
induced motility, on its S126 residue (Radtke et al., 2013). PXN is a 68-kDa focal adhesion-
associated protein that functions as a scaffolding protein assembling signaling molecules into
complex downstream of integrin and growth factors. PXN regulates a variety of physiological 
functions, including matrix organization, cell motility, metastases and proliferation. PXN is 
comprised of multiple structural domains and several phosphorylation targets that act as docking sites 
for various signaling proteins (Brown and Turner, 2004; Schaller, 2001). Initially, ERK was 
identified as a priming kinase for the GSK3-mediated PXN phosphorylation on residue S126 (Cai et 
al., 2006). Furthermore, PXN was shown to function as an upstream mediator of ERK activation and 
a downstream regulator of ERK signaling via different phosphorylation. Epidermal growth factor and 
Dihydrotestosterone (a ligand to Androgen receptor) induces Src-mediated phosphorylation of PXN
on residue Y118 to activate ERK phosphorylation but triggers also ERK-mediated phosphorylation 
of PXN on residue S126 (Sen et al., 2010). Since we found that P-PXN translocates to the nucleus 
following E2 treatment (Figure 6C), and that ERĮ-36 triggers cyclin D1 transcription (Zhang et al., 
2011), we speculate that PXN activates cyclin D1, thus triggering cell proliferation (Figure 6D). Of 
note, we proved that this (5Į-36/Src/ERK2/PXN pathway is also activated in patient-derived breast 
tumors by showing that a treatment of the HBCx-12A PDX with E2 induces tumor growth and an 
increase in ERD-36/Src interaction, P-ERK and P-PXN (Figure 6). Unfortunately, we were unable to 
detect ERĮ-36/ERK2 interaction in formalin-fixed tissues possibly due to the fact that ERK2
antibodies may not work in the PLAs conducted in formalin-fixed tissues.
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Overall our work identified 2 complexes formed with ERD-36, namely: ERD-36/Src and ERD-
36/ERK2 and we wanted to establish whether the ERD-36/Src interaction occurred upstream of ERK 
signaling. The use of kinase inhibitors clearly showed that Src activity not only triggers ERD-36/Src 
interaction but also ERK phosphorylation (Figure 7A). Several experiments were conducted to unveil 
the kinetics of this pathway, and based on these results we obtained; we propose the following 
preliminary model of regulation of the E2/ERD-36 signaling pathway (Figure 7G). When E2 enters 
within the cells, it FDXVHV (5Į-36 interaction with Src, inducing MEK activation, which in turn 
phosphorylates ERK. Activated ERK phosphorylates its substrate PXN on residue S126, triggering 
its translocation to the nucleus where it acts as a coactivator to induce cyclin D1 transcription, and 
leading to an increase in cell proliferation. Interestingly, (5Į-36 reinforces the signal induced by the 
P-ERK phosphorylation by preventing the rapid dephosphorylation of by MKP3. Given that the PI3K 
activity doesn’t affect this pathway, we hypothesize that ERD-36/PI3K interaction may regulate other 
pathways.
The identification of this new signaling pathway could have significant implications in breast cancer
treatment. Indeed, a retrospective study of 896 cases of breast cancer patients revealed that 40% cases 
of ERD-SRVLWLYHEUHDVWFDQFHUVH[SUHVVHG(5Į-36, and those patients benefited less from tamoxifen 
therapy (Shi et al., 2009). Moreover, this study revealed that 40% of ERD-negative breast cancers, 
while lacking (5ĮH[SUHVVLRQH[SUHVVHG(5Į-36. Its prognosis value in this breast cancer subtype is  
less clear, since contradictories results have been published (for a review see: (Gu et al., 2014).
Future studies could, based on our approach, determine whether this novel pathway is conserved 
between (5Į-positive and -negative subtypes; investigating whether it could impede the beneficial 
effect of tamoxifen or whether it is also active, in vivo, in triple negative breast cancers, respectively.
For these (5Į-36-positive tumors, combining Src or MEK inhibitors with hormonotherapy may 
improve the response to conventional treatment.
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EXPERIMENTAL PROCEDURES
Antibodies
A polyclonal antibody against ERĮ-36 specifically generated for this study by Covalab (Lyon, 
France), and commercially-available antibodies are listed in the Supplemental Experimental 
Procedures.
Cell Culture
MCF-7 and HeLa cells were obtained from ATCC. The HBCc-12A cell line was established from the 
HBCx-12A xenograft, a PDX model of primary triple-negative breast cancer (Marangoni et al., 
2007). Additional information can be found in the Supplemental Experimental Procedures.
Plasmids and mutagenesis
The pCDNA3-ERĮ-36 plasmid  was a gift from Dr Wang (Wang et al., 2005). The mutations were 
obtained using the Quickchange XL Site-Directed Mutagenesis Kit according to the manufacturer’s 
instructions (Agilent Technologies, USA). Additional information can be found in the Supplemental 
Experimental Procedures.
Proximity ligation assay (PLA)
This technology developed by Olink Bioscience (Sweden) enables the visualization of protein/protein 
interactions in situ and was firstly published in 2006 (Soderberg et al., 2006). Additional information 
can be found in the Supplemental Experimental Procedures.
Molecular modeling
Homology models of (5Į-36 ligand binding domain (118-310) were obtained using the structure 
prediction server ROBETTA (http://robetta.bakerlab.org/). The amino-acid sequence of ERĮ-36 was 
retrieved from NCBI (GenBank: BX640939.1). 3D Models were compared to the crystal structures of 
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(5Į-E2 (PDB ID: 1A52). Analysis of the complexes between ERK2 and D motif peptides was 
performed as described in the Supplemental Experimental Procedures. Figures were realized with the 
PyMOL molecular graphics software.
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LEGENDS TO FIGURES
Figure 1: ERĮ-36 molecular properties.
(A) Schematic representation of ERĮ-36 mutants. ERD-36'C has been generated by deleting the 
CTD. The mutant ERĮ-36V288A/L297A was obtained by mutating essential hydrophobic residues
of the NES.
(B) MCF-7 cells were transfected with pSG5Flag vector (panels a–c), pSG5Flag-ERD-36 (panels d-
f), pSG5Flag-ERD-36'C (panels g-i), or pSG5FlagERD-36 V288A/L295A (panels j-l) for 36 hr,
then fixed and stained with DAPI and anti-Flag antibody.
(C) (Left) Modelled structure of the LBD of ERĮ-36 showing E2 docked in the ligand binding 
pocket. The proteins homology model is not refined and lacks the C-WHUPLQDOSDUWRI(5Į+WR
+7KHVSHFLILFVHTXHQFHRI(5Į-36 is colored in blue and the ligand in red. The docked E2 is
forming electrostatic interactions with residues E180 and R221. (Right) The experimental crystal 
WUXFWXUHRI(5Į/%'3'%,'$(Tanenbaum et al., 1998)) in complex with E2 is shown for 
comparison. The C-Terminal part which differs frRP(5Į-36 is highlighted in red and the position 
of the helices 9, 10 and 12 are indicated.
(D) HeLa cells were transfected with the pSG5Flag vector, with the pSG5Flag-ERD-36 plasmid, or 
the point mutated pSG5Flag-ERD-36-E180/A and pSG5Flag-ERD-36-E180/A-R221/A constructs,
before being treated with E2. A Western blot analysis was performed to detect P-ERK, ERK and 
ERD-36 expression.
Figure 2: ERD ligands trigger ERĮ-36 interaction with Src, PI3K and P-ERK2
(A) HBCc-12A cells were treated with E2 for the indicated times. After fixation, in situ PLA for 
(5Į-36/Src (panels a-c) DQG(5Į-36/PI3K dimers (panels d-f) were SHUIRUPHGZLWK(5Į-36-, Src-,
and PI3K-specific antibodies. The detected dimers are represented by red dots. The nuclei were 
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counterstained with DAPI (blue) (Obj: X63). Control PLA experiments were performed using
single antibodies (panels g-i).
B) Quantification of the Figure 2A was performed by counting the number of signals per cell as 
reported in the Supplemental Experimental Procedures. The experiment was performed three 
times, and this graph is representative of one of the experiment. The P-value was determined by 
the Student’s t-test.
C) Sequence alignment of known D domains in selected MAPK substrates aligned with the putative 
docking site. Basic residues are highlighted in boldface type, and the hydrophobic motif IA-X-IB
is underlined (modified from (Martin et al., 2008)).
(D) Direct interaction between ERD-36 and ERK2 was analyzed by GST-pull-down experiments. 
35S-labeled in vitro translated ERĮ-36 or ERD-36'C was incubated with GST or GST-ERK2-
glutathione-Sepharose beads. The eluted proteins and 1/50 of input radiolabeled proteins were 
analyzed by SDS-PAGE and visualized by autoradiography. The right panel shows the 
corresponding gel stained with Coomassie. 
(E) HBCc-12A cells were treated for the indicated times with E2. After fixation, in situ PLA for 
ERD-36/ERK2 interaction was performed. The nuclei were counterstained with DAPI (x63
magnification).
(F) The quantification of cells highlighted in Figure 2E was performed as described in Figure 2B.
(G) HBCc-12A cells were treated or not with the MEK inhibitor, U1026 (10μM) for 15 min prior to 
E2 treatment. In situ PLA for ERD-36/ERK2 interaction was performed. The nuclei were
counterstained with DAPI (x63 magnification).
(H) The quantification of cells highlighted in Figure 2G was performed as described in Figure 2B.
(I) Cell extracts from the experiment depicted in Figure 2G were analyzed by Western blot for P-
ERK and ERK expression.
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Figure 3: Disruption of ERD-36/ERK2 interaction abolishes E2-induced ERK activation
(A) Modelled structure of ERK2 complex with the CTD of (5Į-36. The structure of ERK2 is 
displayed as ribbons, and based the PDB ID 2FYS.  The modelled CTD of ERĮ-36 is represented in 
red.
(B) GST pull down experiment was performed by incubating the GST-ERK2 fusion protein in the 
presence of in vitro translated 35S-labeled ERĮ-36 or ERĮ-36-L297A mutant (*). 1/50 of input 
radiolabeled proteins were analyzed by SDS-PAGE and visualized by autoradiography. The 
corresponding Coomassie-stained gel is shown in the right panel. 
(C) HBCc-12A cells were transfected with pSG5-Flag vector, pSG5-Flag-ERĮ-36-CTD or pSG5-
Flag- ERĮ-36-CTD-L297A for 36 hr. The cells were treated with E2 and fixed in methanol. ERD-
36/ERK2 interactions were analyzed by PLA. The nuclei were counterstained with DAPI (blue) 
(x63 magnification).
(D) Quantification of the cells detected in Figure 3C was performed as described in Figure 2B. The 
experiment was performed in triplicate, and this graph is representative of one of the experiments
The P-value was determined by the Student’s test. *** P<0.001.
(E) P-ERK and ERK, in cells from Figure 3C, were analyzed by Western blot.
(F) The cells from the experiment in Figure 3C were fixed and stained with DAPI and anti-Flag 
antibody.
Figure 4: Crosstalk between ERĮ-36 and MKP3 to regulate ERK phosphorylation
(A) The pSG5-Flag or pSG5-Flag-ERD-36 vectors were transfected into HBCc-12A cells for 36 hr
prior to their treatment with E2. The cell extracts were analyzed for the expression of P-ERK, ERK 
and ERD-36.
(B) Following the PLA conducted in Figure 4C, ERĮ-36/ERK2 interactions were quantified as 
described in Figure 2C. The experiment was performed in triplicate, and this graph is 
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representative of one of the experiments. The P-value was determined by the Student’s test. *** 
P<0.001.
(C) Cells from the experiment conducted in Figure 4A were used to perform in situ PLA to detect, 
ERĮ-36/ERK2 interactions. (x63 magnification).
(D) Lysates of MCF-7 cells transfected with control siRNA duplexes or with specific MKP3 siRNA 
duplexes were analyzed for P-ERK, ERK and MKP3 expression.
(E) Quantification of the interactions detected in Figure 4F was done as described in Figure 4B.
(F) Cells from the experiment in Figure 4D were used to perform an in situ PLA, as described in 
Figure 4C, in order to detect (5Į-36/ERK2 interactions following MKP3 silencing.
Figure 5: ERD-36 impedes MKP3 interaction with ERK2
(A) HBCc-12A cells were transfected with pSG5-Flag vector, pSG5-Flag-ERĮ-36-CTD or pSG5-
Flag- ERĮ-36-CTD-L297A prior to E2 treatment. A PLA was then conducted to analyze 
ERK2/MKP3 interactions. (x63 magnification).
(B) Quantification of the interactions detected in Figure 5A was performed as described in Figure 
2B. The experiment was performed in triplicate, and this graph is representative of one of the 
experiments. The P-value was determined by the Student’s test. *** P<0.001.
(C) The pSG5-Flag and pSG5-Flag-ERD-36 vectors were transfected into HBCc-12A cells for 
36hr prior E2 treatment. We then analyzed ERK2/MKP3 interactions by PLA as described in 
Figure 5A.
(D) Quantification of the interactions revealed experiment in Figure 5C was performed as 
described in Figure 5B.
Figure 6: The study of estrogen signaling pathway downstream of ERK
(A) HBCc-12A cells were treated with E2. The cells were then fixed and immunostained with the 
anti-PERK antibody by immunofluorescence (IF).(x63 magnification).
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(B) HBCc-12A cells were treated with E2. The cell extracts were subsequently analyzed by Western 
blot for the expression of P-ERK, ERK, P-PXN and PXN.
(C) HBCc-12A cells were treated with E2. The cells were then fixed and immunostained to study 
the localization of P-PXN by IF as described in Figure 6A.
(D) HBCc-12A cells were treated with E2. The cell extracts were analyzed by Western blot for the 
expression of Cyclin D1 and tubulin.
(E) HBCc-12A cells were treated or not with the MEK inhibitor, U1026 (10μM) for 15 min prior to 
their treatment with E2 for 5 min. Expression of cyclin D1 and tubulin were assessed by Western 
blot.
(F) HBCc-12A cells were transfected with pSG5-Flag vector, pSG5-Flag-(5Į-36-CTD or pSG5-
Flag- (5Į-36-CTD-L297A for 36 hr. The cell extracts were analyzed by Western blot for P-ERK, 
ERK, P-PXN, PXN and cyclin D1 expression.
(G) HBCx-12A PDX was grown with and without the supplementation of E2 in the drinking water
of mice (See Figure S2I). Mice were sacrificed at the end of the experiment (day 51) and tumours
were embedded in paraffin. A bright field PLA was performed to study ERĮ-36/Src interactions in
each group. The brown dots represent protein-protein interactions (x40 magnification).
(H) The interactions detected in Figure 6G were quantified as reported in the Supplemental 
Experimental Procedures. The experiment was performed in triplicate, and this graph is 
representative of one of the experiments. The P-value was determined by the Student’s test. *** 
P<0.001.
(I) From the paraffin-embedded tumors obtained from Figure 6G, P-ERK was assessed by IHC 
staining.
(J) From the paraffin-embedded tumors obtained from Figure 6G, P-PXN was assessed by IHC 
staining.
Figure 7: Src activity regulates E2-induced ERK signaling
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(A) HBCc-12A cells were treated or not with PP1 (5 μM) or LY294002 (20 μM) 15 min before E2 
treatment. Cell lysates were analyzed by Western blot for the expression of P-ERK, ERK, P-
PXN.and PXN.
(B) Cells from the experiment conducted in Figure 7A were used to perform in situ PLA to detect
ERĮ-36/ERK2 interactions. (x63 magnification).
(C) Quantification of the interactions detected in Figure 7B was performed as described in Figure 
2B. The experiment was performed in triplicate, and this graph is representative of one of the 
experiments. The P-value was determined by the Student’s test. *** P<0.001.
(D) HBCc-12A cells were treated or not with PP1 (5 μM) or LY294002 (20 μM), as described in 
Figure 7A, were lysed and the expression of Cyclin D1 and tubulin were analysed by Western blot.
(E) HBCc-12A cells were treated with E2. Cell lysates were analyzed by Western blot for the 
expression of P-ERK, ERK, P-PXN and PXN 
(F) From the experiment performed in Figure 7E, ERĮ-36/Src, ERĮ-36/ERK2 and ERK2/MKP3 
interactions were studied by PLA (pictures are shown in Figure S6) and the quantification was 
performed as already described.
(G) Model of theE2/ERĮ-36 signaling pathway. Upon E2 stimulation, ERĮ-36 binds to Src, 
activating MEK that phosphorylates ERK, which phosphorylates PXN on residue S126. P-PXN 
translocates to the nucleus to activate the transcription of cyclin D1, thus regulating cell 
proliferation. ERĮ-36 binds directly to P-ERK2 and prevents the dephosphorylation of ERK2 by
MKP3, thereby sustaining the downstream signalling pathway.
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Figure S1, Related to Figure 1. Identification of a nuclear export signal in ERα-36 sequence 
 (A) The NetNES algorithm predicts a putative leucine-rich NES encoded by exon 9 in ERα-36. Scores obtained from 
the neural network (NN) and hidden Markov model (HMM) calculations are plotted in green and blue, respectively. 
The combined score obtained from the NetNES algorithm is plotted in orange, and the cut-off threshold is shown as a 
pink line. Only the portion of the sequence with scores above this threshold is shown.  
(B) The putative ERα-36 NES sequence shows a high level of conservation with other known CRM1-dependent NES, 
following their alignment (modified from Goulet et al., 2007). The conserved hydrophobic residues are shown in red.  
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Figure S2, Related to Figure 2. Characterization of the in-house anti-ERα-36 antibody and of the HBCx-12A 
tumor 
(A) GST-ERα-36 and GST-ERα-36'C were analyzed by SDS-PAGE followed by Western blot with our in-house anti-
ERα-36 antibody (left panel), with the corresponding Coomassie-stained gel (right panel). * indicates the full length 
fusion proteins. 
(B) HeLa cells transfected with the empty vector, pSG5Flag-ERα-36 or pSG5Flag-ERα-36'C were analyzed by 
Western blot using the anti-Flag (left panel) or the anti-ERα-36 antibodies (right panel).  
(C) Cama-1 cells were transfected with control siRNA duplexes or with 2 specific ERα-36 siRNA duplexes. On day 3, 
cells were re-transfected with the corresponding siRNAs. Cells were then lysed on the indicated dates and the lysates 
were tested for ERα-36 expression. Tubulin was used as a loading control. 
(D) ERα-36 expression was evaluated in a wide range of human breast cell lines by Western blot using the anti-ERα-36 
antibody. ERα and tubulin expression were also assessed using the corresponding antibodies. 
(E) ERα-36 expression was evaluated in human patient derived xenografts (PDXs) as indicated in Figure S2D. 
(F) ERα-36 expression was analyzed by immunohistochemical (IHC) staining on formalin-fixed human tumors from 2 
PDXs: namely the HBCx-12A, expressing high level of ERα-36 and the HBCx-8, which do not express ERα-36. (x40 
magnification).  
(G) HBCc-12A cell lysate was assessed for ERα-36, ERα, PR and HER2 expression. 
(H) HBCc-12A cells were treated for the indicated times with E2 (10-8 M). The cell lysates were analyzed by Western 
blot for ERK and Akt activation by measuring their phosphorylated state using specific antibodies. The abundance in 
ERK and Akt proteins were measured using specific antibodies.  
(I) HBCc-12A cells growth rate was monitored by the Incucyte real-time imaging system, under control conditions 
(vehicle) or after treatment with E2 (10-8M). The P-value was determined by the Student’s test. *P<0.05. 
(J) Tumor growth of HBCx-12A PDX was analyzed with or without estrogen for 51 days. For each group the relative 
tumor volume was measured. Each treatment group included 10 mice. Statistical significances of TGI were calculated 
using an unpaired Student’s test. **P<0.01 
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Figure S3, Related to Figure2. Study of ERα-36/Src and ERα-36/PI3K interaction. 
(A) GST pull down Assay was performed by incubating in vitro-translated 35S-labeled Src (*) with GST, GST-
ERα-36 and GST-ERα-36'C. The corresponding Coomassie-stained gel is shown in the lower panel. * indicates 
the full length fusion proteins. 
(B) GST and GST-P85 of PI3K fusion proteins were incubated with in vitro-translated 35S-labeled ERα-36 (*). 
The corresponding Coomassie-stained gel is shown in right panel. * indicates the full length fusion protein. 
(C) HBCc-12A cells were treated in the presence or in the absence of the Src inhibitor PP1 (5μM) or the PI3K 
inhibitor LY294002 (20μM) for prior to the addition of E2. After fixation, in situ PLA was performed with ERα-
36-, Src-, and PI3K-specific antibodies. The detected dimers are represented by red dots. The nuclei were 
counterstained with DAPI (blue) (x63 magnification).  
(D) Quantification of the number of signals per cell in Figure S3C was performed using computer-assisted 
analyses as reported in the Supplemental Experimental Procedures. The experiment was performed in triplicate, 
and this graph is representative of one of the experiments. The P-value was determined using the Student’s test. ** 
P<0.01; *** P<0.001. NS: non significant. 
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Figure S4, Related to Figure 2. ERD-36/ERK2 interaction in HeLa cells. 
(A) pSG5Flag-ERα-36, pSG5Flag-ERα-36'C and pCDNA3HA-ERK2 were overexpressed in HeLa cells. Cell 
lysates were immunoprecipitated with the anti-Flag antibody and the presence of ERα-36 and ERK2 were 
revealed by Western blot using the anti-Flag and anti-HA antibodies, respectively. The lower panel shows the 
expression of the different proteins in the input. 
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Figure S5, Related to Figure 6.  ERα-36 signaling in HBL100 cells 
(A) The growth rate of HBL100 cells was monitored using the Incucyte real-time imaging system in the absence or in the 
presence of E2 (10-8M). The experiment was performed in triplicate, and this graph is representative of one of the 
experiments.  
(B) Steroid-depleted HBL100 cells were treated with E2 (10-8M) for the indicated times. Cell lysates were analyzed by 
Western blot for expression of P-ERK and P-PXN. ERK and PXN expression was also assessed.  
(C) From the same experiment as depicted in Figure S5B, in situ PLA was performed to detect ERα-36/ERK2 
interactions. The detected dimers are represented by red dots. The nuclei were counterstained with DAPI (blue) (x63 
magnification).  
(D) The quantification of the interactions detected in the PLA in Figure S5C was performed by counting the number of 
signals per cell using computer-assisted analyses, as reported in the Supplemental Experimental Procedures. The 
experiment was performed in triplicate, and this graph is representative of one of the experiments. The P-value was 
determined using the Student’s test. *** P<0.001. 
 
 
  
Figure S6 
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  Figure S6, Related to Figure 7. Precise time course of the E2/ERα-36-mediated signaling pathway. 
HBCc-12A cells were treated with E2 (10-8 M) for the indicated times. Then, ERα-36/Src, ERα-36/ERK2 and 
ERK2/MKP3 interactions were studied by PLA using the different couples of antibodies, as previously described. 
The detected dimers are represented by red dots. The nuclei were counterstained with DAPI (blue) (x63 
magnification).  
 
Table S1 Related to Figure 3: Residues in the D motif peptides which contribute for 4 kcal/mol and more to the 
binding free energy. For each structure listed in Table S3, we identified the residues of the bound peptide that 
contribute (in absolute value) for 4 kcal/mol or more to the binding free energy.  For each complex, the number of 
the amino-acids, as given in Table S2, and the energetic contribution (in kcal/mol) are indicated.  The known 
peptide binders differ in sequence, and do generally not conform exactly to the consensus (R/K)2-3X2-6-)A-X-)B  D 
motif.  However, basic and hydrophobic residues consistently emerge in all structures as making important 
stabilizing interactions, with the important hydrophobic interactions situated in either N-terminal or C-terminal (or 
sometimes on both side) of the important basic arginine (R).  From this energetic analysis, and consideration of the 
structure of peptide bound ERK2, we identified L297 in ERα-36 (in the sequence: K293KRIL297NL299) as a likely 
candidate for making essential interactions.. 
 
 
 
2GPH 4FMQ 
L17 -5.9 L436 -4 
R21 -6.3 L439 -4.9 
L27 -5.4 L444 -5.8 
L29 -6.2 R448 -7.3 
3TEI 2Y9Q  
L714 -6.7 M434 -4.7 
I717 -5.2 L436 -6.8 
L722 -5.4 P439 -4.9 
R726 -4.4 L444 -5.6 
  R448 -6.9 
3O71 4H3P 
R1148 -5.5 L714 -7.3 
P1149 -5 I717 -5.3 
L1152 -6.4 L722 -5.8 
I1154 -4.2 R725 -4 
4H3Q 2FYS  
R5 -4.4 R65 -4.9 
L9 -4 L71 -7.1 
L12 -5.8 R74 -5.6 
I14 -4.9   
 
  
Supplemental Experimental Procedures 
 
Cell Culture 
We used a panel of human tumoral mammary cells, a gift from Jessie Auclair (CLB, Lyon). (Cama-1, T47D, ZR75.1, 
MDAMB361, BT20, Cal51, HCC38, HBL100, SKBR3, MDAMB157, MDAMB231, MDAMB436, MDAMB453 
cells). 
We also used frozen tumors from human breast patient’s derived xenograft (PDX) from Dr Marangoni of Curie 
Institute, Paris. These PDX have already been characterized: HBCx-14, HBCx-10, HBCx-15, HBCx-17, HBCx-3, 
HBCx-8, HBCx-13A, HBCx-5, HBCx-12A, HBCx-29, HBCx-1, HBCx-1 (Marangoni et al, 2007). 
The HBCx-12A was established by engrafting a triple negative tumor, and its molecular characterization has been 
previously published (Marangoni et al., 2007). The HBCc-12A cell line was established from the HBCx-12A PDX. 
This cell line was grown at 37°C in DMEM Glutamax medium supplemented with 10% Fetal Bovine Serum, 1% 
Penicillin Streptomycine, 1% Hepes Buffer, 1% Sodium Pyruvate and 10 μg/ml Insulin (Novorapid).  
Prior to performing treatment with estrogen ligands, cells were grown for 48 hr in phenol red-free medium 
supplemented with 10% charcoal-stripped serum (Biowest), in order to remove steroid hormones (steroid-depletion). 
The cells were then treated for different times with E2 (Sigma) 10-8 M. When stated, cells were treated with the Src 
inhibitor PP1, the PI3K inhibitor LY294002, or with the MEK inhibitor U1026 (Calbiochem). 
 
Plasmids 
ERα-36 cDNA was cloned into the pSG5Flag and the pGEX-4T1 plasmids. The ERα36 CTD was cloned into a pSG5-
Flag vector (pSG5Flag-ERα-36-CTD). The pSG5Flag-ERα-36 was used for mutagenesis to generate the following 
mutants: V288A/L295A, E180A, E180A/R221A, and L297A. The pCDNA3 ERK2-HA and pCDNA3-Src plasmids 
were purchased from Addgene. ERK2 cDNA was subsequently cloned into a pGEX-4T1 vector for recombinant 
protein production. pGEX-4T1-P85 (PI3K) plasmids are gifts from Dr G. Castoria. 
 
 
Antibodies  
Antibody Company Species Dilution for 
WB 
Dilution 
for PLA 
Dilution for 
IF 
Dilution for 
IHC 
Flag (E1B11) Euromedex Mouse 1:1000  1 :250  
Tubulin (T6074) Sigma Mouse 1:10000    
Src, B12 (sc-8056) Santa Cruz Mouse  1:200   
ERα-36 In-house 
(Covalab, Lyon) 
Rabbit 1:1000 1:100  1:50 
PI3K (ab86714) Abcam Mouse  1:300   
p42/44 MAPK 
(4376) 
CST Rabbit 1:1000    
p-P42/44Thr 
202/Tyr204 MAPK 
(4370) 
CST Rabbit 1:1000  1 :100 1 :400 
ERK2 D2 (1647) Santa Cruz Mouse 1:1000 1:100   
MKP3 (ab76310) Abcam Rabbit 1:1000 1:100   
PXN (5574) Santa Cruz Rabbit 1:1000    
P-PXN Ser126 (44-
1022G) 
Invitrogen Rabbit 1:1000  1 :100 1 :300 
Cyclin D1 
(ab16663) 
Abcam Rabbit 1:200    
AKT (9272S) CST Rabbit 1 :1000    
P-AKT Ser473 
(9271L) 
CST Rabbit 1 :1000    
HA (H6908) Sigma Rabbit 1:1000    
HER2 (ab16901) Abcam  Mouse 1:500    
PR (C1A2) CST Rabbit 1:1000    
ERα (60C) Millipore Rabbit 1 :1000    
 
Table S2: List of the antibodies used in the current work 
 
 
Modelling data: Analysis of ERK2/peptide structures and identification of important amino acids. 
We analyzed 8 crystal structures of ERK2 bound to peptide that contain D motifs (see list in Table S1). Hydrogen 
atoms were added using the HBUILD facility (Brunger and Karplus, 1988) in the CHARMM program (Brooks et al., 
2009). The structures were energy minimized and free energy decomposition (Lafont et al., 2007) of the minimized 
structure was used to estimate the contribution of each amino acid to the binding free energy.  Free energy 
decomposition allows a semi-quantitative estimate of the contribution of amino acids to the stability of a complex, and 
is well suited to identify amino acids essential for complex formation (Lafont et al., 2007). Amino acids detailed in 
Table S1 are in bold red. 
 
 
PDBid Peptide sequence Reference 
2GPH R16LQERRGSNVALMLDC31 (Zhou et al., 2006) 
4FMQ L436SSLAASSLAKRRQQ450 (Garai et al., 2012) 
3TEI P712QLKPIESSILAQRRVR728 (Garai et al., 2012) 
2Y9Q M434KLSPPSKSRLARRRAL450 (Garai et al., 2012) 
3O71 R1148PPDLWIH1155 (Ma et al., 2010) 
2FYS R64RLQKGNLPVR74 (Liu et al., 2006) 
4H3P P712QLKPIEASILAARRV727 (Gogl et al., 2013) 
 
Table S3: Structures used for the interaction between ERK2 and D motif peptides. Amino acids detailed in Table S1 
are in bold red. 
 
Patient-derived xenografts (PDXs) 
The HBCx-12A PDX was established from a primary triple-negative breast cancer (ERα-, PR-, HER2-) with the 
patient’s informed consent, as described previously (Marangoni et al., 2007). The PDXs were engrafted in 10-week old 
female Swiss nude mice, purchased from Charles River (L’Arbresle, France) and maintained under specific pathogen-
free conditions. Their care and housing were done in accordance with institutional guidelines approved by the French 
Ethical Committee, (Marangoni et al., 2007). The ER+, HER2+ and triple-negative status were confirmed in the PDX 
models by immunohistochemistry (IHC) (Marangoni et al., 2007; Reyal et al., 2012). For in vivo studies, 10 mice 
received estradiol (E2, Sigma-Aldrich, Saint-Quentin-Fallavier, France) diluted in their drinking water (8 μg/ml). A 
two-tailed student t-test was used for the statistical analysis of tumor growth in treated E2 versus control mice. 
 
Glutathione transferase (GST) pull-down assay 
ERα-36 and ERα-36'C expression plasmids were transcribed and translated in vitro using T7-coupled reticulocyte 
lysate in the presence of [35S] methionine. Labeled proteins were incubated with 10 μg of purified recombinant GST-
fusion proteins in 200 μl of binding Buffer (Tris 20 mM pH7.4, NaCl 0.1 M, EDTA 1 mM, Glycerol 10%, Igepal 
0,25%) with 1 mM DTT and 1% milk) for 2 hr at room temperature. After washing, bound proteins were resolved on 
SDS-polyacrylamide gel electrophoresis (PAGE), and visualized by autoradiography.  
 
Transfections  
The siRNA sequences targeting ERα-36 correspond either ERα-36 to the 3’UTR 
(GGUCAAAGAUCAAGAUCAAdTdT) (Nucleotides 1631 – 1643) or to the ERα-36 and ERα conserved sequence 
(GAAUGUGCCUGGCUAGAGAdTdT) (Nucleotides 852 – 870). 
SiRNA directed against MKP3 (DUSP6) were purchased from Qiagen GeneSolution (Cat No. GS1848). 50 nM of 
specific siRNAs or the scrambled siRNA (Eurogentec) were transfected into HBCc-12A cells (1 x 106) using 
lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s guidelines. The proteins were analyzed 72 
hr after transfection. 
Plasmids transfection was performed using the Xtreme gene agent following the manufacturer’s instructions 
(Roche). Proteins were analyzed 48 hr after transfection. 
HBCc-12A cells were infected with Histone H2B fused to GFP (gift from Dr Y. Mikaelia, CRCL, Lyon, France). 
 
Proliferation assay 
Cells were plated in quadruplicate in 96-well plates at a density of 2000 cells per well. After 6h, the ligands were 
added into the medium, and subsequently every two days. Growth curves were constructed by imaging plates using 
the Incucyte Zoom (Essen BioScience, Ann Arbor, USA). The growth curves were built from confluence 
measurements for HBL100 cells, and from counting fluorescent nuclei for HBCc-12A cells, acquired during round-
the-clock kinetic imaging. Each experiment was performed in quadriplicate. 
 
Immunoprecipitation and Western blot 
To study the effect of ERα ligands on ERα-36 signaling, the cells were treated for different periods of time with E2. 
After treatment, cells were lysed using RIPA buffer (50 mM Tris HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 1% NP-
40, 0.25% deoxycholate) supplemented with protease inhibitor tablets (Roche Molecular Biochemicals) and 
phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4, 1 mM E-glycerophosphate). Protein extracts were incubated 
with primary antibodies overnight at 4°C with in a shaking incubator. Protein A-Agarose beads were added and the 
solution was incubated 1 hr at 4°C. The immunoprecipitates were separated on SDS-PAGE. The proteins were 
visualized by enhanced chemiluminescence (ECL) (Roche Molecular Biochemicals). 
 
Immunofluorescence 
HBCc-12A cells (9 x 104) were grown on coverslips in 12-well plates. Cells were fixed in methanol for 2 min, 
washed twice in PBS and incubated with primary antibodies for 1 hr at 37°C. After PBS washes, the cells were 
incubated for 30 min at 37°C with the secondary antibody Alexa Fluor 468 from Molecular Probes (1:3000) in Dako 
diluent, then washed in PBS and mounted on glass slides in mounting solution (Dako), and visualized using a 
fluorescent microscope. 
 
Immunohistochemical (IHC) staining 
Paraffin embedded tumour tissues fixed in formalin were used for analysis. After deparaffinization and 
rehydratation, tissue sections were boiled in 10 mM citrate buffer pH 6 at 97°C for 40 min. The slides were then 
incubated in 5% hydrogen peroxide in sterile water to block the activity of endogenous peroxidases. The slides were 
then incubated at room temperature for 1 hr with the primary antibodies. The slides were subsequently incubated 
with a biotinylated secondary antibody bound to a streptavidin peroxidase conjugate (Envision Flex kit Ref: 
K800021-2, Dako). Bound antibodies were revealed by adding the substrate 3, 3-diamino benzidine. Sections were 
counterstained with haematoxylin. 
 
Proximity ligation assay (PLA) 
PLAs performed on fixed cells were revealed by adding fluorescent probes, while PLAs performed on fixed tissues 
were revealed by adding peroxidase-labeled probes. 
 
Fluorescence detection 
Cells were grown on coverslips in 12-well plates, and then fixed in methanol for 2 min, before being washed twice 
in PBS. The cells were initially saturated using the blocking solution, then different couples of primary antibodies 
(rabbit and mouse in our case) were added and incubated 1 hr at 37°C. After washes, the PLA minus and plus probes 
(containing the secondary antibodies conjugated with complementary oligonucleotides) were added and incubated 1 
hr at 37°C. Following the ligation of the oligonucleotides, nucleotides and a polymerase were added to the solution 
to initiate, a rolling-circle amplification (RCA) reaction, using the ligated circle as a template for 100 min at 37°C. 
The amplification solution contained fluorescent-labeled oligonucleotides, which hybridized to the RCA product. 
Following hybridization, the samples were mounted with Duolink II Mounting Medium containing 4',6-diamidino-
2-phenylindole (DAPI), and then visualized under fluorescent microscopy. 
 
Bright-field detection 
Fixed tumor tissues were initially incubated in a hydrogen peroxide solution, for 5 min at room temperature, to 
avoid peroxidase quenching. The following steps were to those described above. For the detection, the probes were 
labeled with horseradish peroxidase after two washes in high purity water. A nuclear staining solution was added 
onto the slides and incubated 2 min at room temperature. After washing the slides 10 min under running tap water, 
the samples were dehydrated in ethanol and in xylene. Samples were mounted in non-aqueous mounting medium 
and then analyzed using a bright-field microscope. 
 
Image acquisition and analysis 
The hybridized fluorescent slides were viewed under a Nikon Eclipse Ni microscope. Images were acquired under 
identical conditions at x63 magnification. Image acquisition was performed by imaging DAPI staining at a fixed Z 
Position while a Z stack of +/- 5μm at 1 μm intervals was carried out. The final image was stacked to a single plane 
before further quantification. On each sample, at least one hundred cells were counted. Analyses and quantifications 
of these samples were performed using Image J software (free access). PLA dots were quantified on 8-bit images 
using the ‘Analyse Particles’command, while cell numbers were numerated using the cell counter plugin. 
IHC images were acquired using a Leica DMRB microscope at x40 magnification and PLA dots were quantified as 
described above. 
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COMPLEMENTARY RESULTS TO ARTICLE 1 
 
1. Tamoxifen mediates ERα-36 non-genomic signaling. 
ERα-36 has been reported to mediate not only estrogen, but also anti-estrogen 
mitogenic signaling. For this purpose we wished to investigate whether the clinically 
used anti-estrogen (tamoxifen) could mediate similar signaling mechanisms as 
described in Article 1. 
 
a. ERα-36 conserves tamoxifen binding properties 
Bioinformatic analysis of ERα-36 structure revealed that, similarly to estrogen, it 
had two amino acids, E180 and R221, which constituted its affinity binding sites 
(Figure 26A). Upon mutagenesis of these two amino acids into alanines, we 
observed a loss of the ERα-36 mediated MAPK activation in HeLa cells transfected 
with either WT ERα-36 or the two mutant constructs (Figure 26B).  
 
A                                              B 
 
 
Figure 26: Tamoxifen binding sites on ERα-36. A: Modelization of the 
tamoxifen binding sites in ERα-36 ligand binding pocket. B: HeLa cells 
transfected with either WT of the indicated mutant versions of ERα-36 were 
treated with tamoxifen for the indicated times and western blot was carried out to 
detect P-ERK, ERK and ERα-36. 
 
These results indicate that tamoxifen is a ligand for ERα-36 for MAPK pathway 
activation. 
 
b. Tamoxifen treatment mediates ERα-36 binding with Src and PI3K 
We wanted to investigate whether tamoxifen could mediate ERα-36 association 
with Src and PI3K in a similar action mechanism of estrogen. For this purpose, 
HBCc-12A cells were treated with tamoxifen and ERα-36/Src and ERα-36/PI3K 
interactions were analyzed by PLA (Figure 27).  
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A                                                                     B 
 
Figure 27: Tamoxifen mediates the formation of the ERα-36/Src and PI3K 
complex. A: PLA images of HBCc-12A cells treated with tamoxifen for the 
indicated times and the mentioned interactions have been analyzed. B: 
Quantification of the number of interaction dots/cell for both couples. 
 
Our data revealed that, similarly to estrogens, tamoxifen mediated the formation 
of the ERα-36/Src and ERα-36/PI3K complexes in cells. 
 
c. Tamoxifen induces ERK phosphorylation and the formation of the 
ERα-36/ERK2 complex 
Similarly to what was observed in Article 1 for estrogen, tamoxifen mediated 
subsequent phosphorylation of ERK but not AKT in HBCc-12A cells. We also 
analyzed ERα-36/ERK2 interaction and found that tamoxifen treatment 
significantly increases it (Figure 28).  
       A 
 
 
 B                         C 
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Figure 28: Tamoxifen induces ERK2/ERα-36 interaction and ERK 
phosphorylation. A: PLA images of HBC12c cells treated with tamoxifen for the 
indicated times and analyzed for ERα-36/ERK2 interaction. B: Quantification of the 
data collected from PLA in A, C: Western blot analysis on protein extracts from the 
same experiment as in A and analyzed for the indicated proteins. 
 
Furthermore we analyzed downstream ERα-36 signaling on these cells and found 
that tamoxifen mediated MAPK activation, without inducing any change in AKT 
phosphorylation (Figure 28C). Even if the whole pathway till the induction of Cyclin 
D1 has not been analyzed, these data seem to show that tamoxifen mediates ERα-
36 non-genomic signaling in an estrogen-like manner as described in Article 1. 
 
 
d. Tamoxifen regulates growth of triple negative HBCc-12A cells 
According to what we have described in Article 1, we wanted to investigate whether 
tamoxifen could impact on the growth of HBCc-12A triple-negative cells. Cells were 
treated with tamoxifen or estrogen over 7 days and analyzed for proliferation (Figure 
29) as described for estrogen in Article 1. 
 
Figure 29: Growth of HBCc-12A cells under vehicle, estrogen (E2) or tamoxifen 
treatment (Tam). 
 
Similarly to what has been observed with estrogen, tamoxifen also mediated cell 
proliferation. This is in accordance with what has been previously described for ERα-
36 in MDA-MB-231 cells (Wang and Yin, 2015). 
 
2. ERα-36 interacts specifically with ERK2 and not ERK1. 
Following the bioinformatics detection of the specific ERK2 D-Domain in ERα-36 C-
Terminal domain, we wanted to experimentally verify that ERα-36 binding was 
specific to ERK2. For this purpose, we used an in-vitro GST Pulldown approach 
(Figure 30A) followed by the study of ERα-36 and ERK1 interaction in HBCc-12A 
cells using an antibody specifically directed against ERK1 (Figure 30B). Cells were 
treated with tamoxifen and analyzed for both ERα-36/ERK2 and ERα-36/ERK1 
interactions. 
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A           B 
 
 
Figure 30: ERα-36 interacts specifically with ERK2 and not with ERK1. A: GST-
Pulldown using recombinant GST or GST-ERα-36 and radioactive in-vitro translated 
ERK1 or ERK2. B: PLA images of HBCc-12A cells treated with tamoxifen for the 
indicated times and analyzed for ERα-36/ERK1 and ERα-36/ERK2 interaction. 
 
Our data gathered using both approaches definitely demonstrate that ERα-36 binds 
specifically to ERK2 and not with ERK1. While 5min tamoxifen treatment dramatically 
increases ERα-36/ERK2 interaction, there is no change in ERα-36/ERK1 binding in 
HBCc-12A cells. 
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DISCUSSION TO ARTICLE 1 
 
Since its discovery in 2005, enough evidence has been gathered to certify 
that ERα-36 is a functional estrogen receptor with distinct ligand binding properties 
and a main involvement in estrogen non-genomic signaling through initiation of 
signaling cascades at the level of the plasma membrane. One of the objectives of our 
team at the beginning of the project was to generate an animal model KO for the 
expression of ERα-36 to analyze its role in physiology and breast tumorigenesis. 
However we were confronted with a major obstacle. In fact, screening for ERα-36 
revealed that its expression was limited to humans and higher mammals like 
chimpanzees (pan troglodytes). These findings were confirmed by an external group 
of bioinformaticians specialized in mice KO (Genoway, Lyon). Indeed, the unique 27 
amino-acid C-Terminal domain of ERα-36 was not found in any genomic sequences 
except Homo sapiens and Pan troglodytes. The most controversial observations 
arose when three separate research groups used an anti-ERα-36 antibody designed 
to recognize the C-Terminal domain of ERα-36 (Wang et al., 2006) in IHC analyses 
on mice and rat tissues and promoting the discovery of a role for ERα-36 in mice 
meiotic oocytes (Xu et al., 2009) or rat hippocampal neurons (Liu et al., 2013). 
 
Upon the start of our project on ERα-36, we wished to understand the specific 
cytoplasmic and membrane localization of ERα-36. First studies on ERα-36 
suggested that putative palmitoylation sites in the protein were revealed and could be 
functional due to the alternative splicing of the first introns (Wang et al., 2005). These 
putative sites would then be localized in the N-Terminal part of the protein which 
could account for their functionality. While palmitoylation sites can actually have an 
effect on cytoplasmic localization (Marino et al., 2006), we proposed that the 
previously unidentified C-terminal domain could be responsible for the export of ERα-
36. Indeed we found a functional nuclear export sequence in the C-terminal region of 
the protein. It is worthy to note that despite having a nuclear export sequence, ERα-
36 retains three nuclear localization signals in its hinge domain (common to ERα). 
This suggests that the protein can be imported into the nucleus but our observations 
suggest that the latter is actively exported to the cytoplasm. The three putative 
palmitoylation sites identified could be responsible for the membrane anchoring of 
ERα-36 for non-genomic signaling, but this has not been clearly demonstrated. 
 
The alternative splicing of the C-terminal domain of ERα-36 results in a 
protein lacking the AF-2 transcription transactivation domain and part of the ligand 
binding domain. One could argue whether missing α-helixes in the LBD could still 
trigger a response to ligand. By collaborating with bioinformaticians from IGBMC 
(Strasbourg), we modelized ERα-36 structure and found that it had altered ligand 
binding properties, where estrogen would no longer bind in the ligand binding pocket 
but kept two amino acids, responsible for ligand anchorage, in the modified ligand 
binding pocket through electrostatic interactions. The bioinformaticians predicted that 
ERα-36, as a result, could have less affinity for estrogen, but we found no such 
change in affinity in terms of response to the hormone in practical. Furthermore 
alternative splicing in ERα-36 conferred it with a more open ligand binding pocket 
that enables it to bind not only estrogens, but a series of other molecules discusses 
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in the introduction (Chapter 3: ERα-36) which can have agonist effects on the 
receptor. Furthermore the lack of helix 12 in the ligand binding domains makes the 
receptor resistant to fulvestrant mediated proteasomal degradation, and many 
studies have depicted the importance of Helix 12 of the ERα ligand binding domain 
as an essential actor in fulvestrant-mediated degradation. 
 
Our team was interested in understanding the non-genomic signaling 
pathway mediated by ERα-36, and at the beginning of the project, we turned to the 
known non-genomic actors of ERα, Src and PI3K. Surprisingly, we found through 
several approaches that ERα-36 has the ability to bind both Src and p85 of PI3K in 
vitro, and these interactions are modulated in cells following estrogen treatment. This 
result was quite surprising since, in the estrogen non-genomic pathway, P-Y537 has 
been shown to be essential for Src binding (Varricchio et al., 2007). Due to 
alternative splicing of the C-terminal domain, this tyrosine is absent from ERα-36 
sequence. At first, we thought the binding could be mediated by the unique C-
Terminal domain of ERα-36 but our experiments demonstrated that Src could bind to 
ERα-36 irrespective of its presence. We are currently investigating potential binding 
sites of Src with ERα-36 and we have identified a tyrosine, which, according to the 
bioinformaticians, could be a substrate and docking site for Src. We hypothesize that 
the new conformation of ERα-36 allows Src binding through unmasking of previously 
inaccessible phosphorylation sites in ERα. The binding of PI3K regulatory sub-unit 
p85 to ERα-36 was not characterized and remains to be done. Our team previously 
identified the methylation of arginine 260 on ERα to be an essential pre-requisite for 
the initiation of the non-genomic pathway. Despite having this arginine conserved in 
its sequence, we found no evidence of ERα-36 methylation. This suggests that 
methylation is not a crucial step in ERα-36-mediated non-genomic signaling and not 
necessary for conformational recruitment of molecular actors.  
 
 
Our team investigated the expression of ERα-36 in breast cancer cell lines 
and breast tumor xenografts and we found it could be expressed in both ERα positive 
and ERα negative cells, confirming what has been observed in previous studies (Lee 
et al. 2010). Arguments also point toward the use of mice bearing patient derived 
xenografts for the study of breast tumors in terms of physiology and micro-
environment, but solid transcriptomic studies have demonstrated that patient derived 
xenografts conserve the characteristics of the parental tumors, making them a model 
of choice to study breast cancer pathology (Marangoni et al., 2007). 
 
Several studies reported Akt phosphorylation as being evidence for estrogen 
induced ERα non-genomic pathway. Our team previous showed that Akt is activated 
during the ERα mediated non genomic-pathway (Le Romancer et al., 2008). Other 
studies have demonstrated that Akt activation resulted from ERα-36 non-genomic 
pathway as well (Fu et al., 2014). In our study, we could not demonstrate any Akt 
phosphorylation mediated by ERα-36 through estrogen treatment. We suppose that 
Akt phosphorylation mediated by ERα-36 could be a separate event resulting from 
the formation of different molecular complexes that would be dependent on cell type 
and tissular context. To strengthen these observations, we found no clinical 
correlation between ERα-36 expression and Akt phosphorylation. Furthermore we 
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found that only Src activity was required for the mediation of downstream ERK 
signaling through ERα-36. We think this divergence in ERα and ERα-36 non-
genomic pathways could imply that the role of PI3K in the complex is different for 
ERα-36. We hypothesize that ERα-36 and PI3K can form a different complex 
independently of Src with different regulatory elements that definitely need further 
investigation. Although these data clearly show that common actors are involved in 
both the ERα and ERα-36 non-genomic pathways, the regulation mechanisms 
involved are different. 
 
For the first time, we describe a steroid receptor with a D-domain, conferring 
it the ability to directly bind to MAPK proteins. Although ERα can be phosphorylated 
by ERK, we found no D-Domain on the latter. This mechanism seems to be exclusive 
on ERα-36 and we are currently working on the docking site on the ERK2 protein. 
We are currently focusing on ERK2’s CD-Domain, which has been confirmed by the 
bioinformatitians as the potential docking site for ERα-36. Furthermore, it is 
interesting to note that ERα-36 and the dual phosphatase MKP3 share the same 
docking site on ERK2, which makes sense according to our observations. We also 
found that ERα-36 can only bind to the phosphorylated form of ERK2 which allows us 
to suppose that a phosphorylation mediated conformational change of ERK2 is 
requires for ERα-36 interaction. 
 
We used a peptidic approach mimicking the C-Terminal domain of ERα-36 to 
break up its interaction with ERK2. Our peptide functioned successfully as the 
previously described peptide used to break up Src/ERα interaction (Varricchio et al., 
2007). We found that we lost downstream activation of the ERα-36 pathway upon 
peptide use, which suggest that the whole ERα-36 protein is required to mediate its 
protective effect on ERK2, probably through stearic hindrance of the binding of 
MKP3. 
 
Our whole characterization of the ERα-36/ERK pathway has been done in 
triple negative HBCc-12A cells. We also wished to see if this pathway could exist in 
other cells lines and in ERα positive cell lines to determine whether ERα expression 
could impact on ERα-36 non-genomic signaling. We began enquiring this aspect and 
we found that the pathway is conserved in other ERα negative cells namely HBL100 
cells as well as in ERα positive cells like MCF-7 (data not shown), suggesting that 
ERα expression has no influence in the non genomic pathway mediated by ERα-36. 
This pathway may be extended to several types of breast cancers. 
 
Using several approaches, we have shown that ERα-36 will bind specifically 
to ERK2 and not to ERK1. A poorly understood aspect of our work in the binding 
process of ERα-36 with ERK2, is that we find similar effects on downstream ERK1 
and ERK2 signaling. Indeed the use of our inhibitory CTD peptide abrogates not only 
ERK2 but ERK1 phosphorylation as well. We suppose that in this context, ERK1 
phosphorylation is dependent on ERK2 state of activation. Furthermore we found 
using in-vitro GST pulldown experiments that the C-Terminal domain of ERα-36 
could bind to ERK2 as well as ERK1. In cells, this may translate as the C-terminal 
domain having an involvement in ERK1 dephosphorylation but more experiments are 
necessary to understand this process.  
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Our studies revealed the involvement of paxillin in the downstream ERα-36 
signaling. Paxillin had been demonstrated to be a very important actor in the 
regulation of cell adhesion and migration in association with FAK at the plasma 
membrane (Sen et al., 2012). However, recent studies uncovered a nuclear role for 
paxillin as part of transcription factor complexes (Sen et al., 2012). In line with these 
observations, we also found a strong accumulation of phosphorylated paxillin in the 
nucleus and we hypothesize it is involved in the ERα-36 mediated Cyclin D1 
transcription. We also found strong nuclear accumulation of active paxillin in nuclei of 
PDX IHC sections in ERα-36 positive PDX, comforting our results. 
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INTRODUCTION TO CLINICAL STUDY 
Growing evidence showed that ERα-36 expression is linked to hormonotherapy 
resistance in patients expressing both ERα and ERα-36. Our team found that none of 
the commercially available antibodies directed against ERα could recognize ERα-36. 
For these reasons we produced a rabbit polyclonal antibody targeting the unique C-
Terminal Domain of ERα-36. We used this antibody to assess ERα-36 expression in 
a cohort of 175 breast tumors from the Centre Leon Berard. In this study, we present 
the correlation between ERα-36 expression and clinic-pathological characteristics as 
well as its association to other well defined bio-markers. 
 
 
METHODS 
 
Patients 
We screened 200 consecutive female patients with operable breast cancers who 
underwent radical surgery and received adjuvant/neoadjuvant therapy in Centre 
Leon Berard between January 1999 and December 2001. Paraffin blocks of tumor 
tissue were available for 182 patients. Among these, we failed to assess ERα-36 in 
22 tumor specimens as a result of insufficient tumor or tissue loss during TMA 
preparation. Therefore, specimens from 160 patients with operable primary breast 
cancer were analyzed in this study.  
 
Patients underwent either modified radical mastectomy, or breast-conserving 
surgery. Axillary lymph node invasion was assessed by sentinel node and/or level I 
and II axillary dissection and the number of lymph nodes harboring metastasis was 
determined based on histologic examination. Tumor size was defined as the 
maximum tumor diameter measured on the tumor specimens at the time of surgery. 
ERα and PR were detected by immunohistochemistry and tumors were considered 
positive if they have nuclear staining in 10% or more of the tumor cells. HER2 
expression was determined using immunohistochemistry and tumors were 
considered positive if they have 3+ staining by immunohistochemistry or 2+ staining 
with HER2 amplification detected by FISH. 
 
The data exported from the patients' files for analysis included: age, histologic 
subtype, maximum tumor size, number of LNs involved, SBR grade, date of 
diagnosis, date of relapse, and date of death or last clinic visit. Tumor samples and 
clinical data were obtained under Institutional Review Board approval. 
 
Cutoff Definition 
Biomarker expression was evaluated by 2 observers who assessed both the 
percentage and the intensity of the membranous staining for ERα-36 in the infiltrative 
carcinomatous cells only (Faint cytoplasmic staining which was found in almost all 
the malignant cells was not considered). For scoring purposes, the highest intensity 
of staining in malignant cells was classified into 3 levels (0: no staining, 1: weak 
staining, 2: moderate to strong staining) and the percentage of the stained cells was 
also classified into 3 levels (0: no stained cells, 1: staining in less than one half of the 
2. ERα-36 expression in breast tumors 
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malignant cells, 2: staining in one half or more of the malignant cells). Then both 
intensity and the percentage scores were added to conclude a single score (from 0 to 
4) in a manner similar to the Allred score of ER and PR staining. For the purpose of 
correlation and survival analysis, tumours were considered to have low expression 
for ERα-36 if they had a score of 0-2 and were considered to have high expression if 
more than 2.  
 
 
Immunohistochemistry 
The breast tumour samples were inserted as triplicates using a 600μm needle in 4 
Tissue Micro Array (TMA) blocks. The blocks containing invasive carcinoma were 
sectioned at a thickness of 4 μm. After deparaffinization and rehydration, 
endogenous peroxidases were blocked by incubating the slides in 5% hydrogen 
peroxide in sterile water. For heat induced antigen retrieval, tissue sections were 
boiled in 10 mM Citrate Buffer pH6 (Dako, Trappes, France) using a water bath at 
98°C for 50 minutes. 
The slides were then incubated at room temperature for 60 minutes with the home 
made antibody against ERα-36 (rabbit polyclonal antibody) (Covalab, Lyon). 
These antibodies were diluted using an antibody diluent solution (Chemmate, Dako, 
Trappes, France) at 1/50. After rinsing in Phosphate Buffer Saline, the slides were 
incubated with a biotinylated secondary antibody bound to a streptavidin peroxidase 
conjugate (LSAB+ Kit, Dako, Trappes, France). Bound antibody was revealed by 
adding the substrate 3, 3-diamino-benzidine. Sections were counterstained with 
hematoxylin. 
 
 
Statistical analysis 
The correlation between ERα-36 expression and clinico-pathologic characteristics 
was determined using Pearson’s chi square test (or Fisher’s exact test) for 
categorical variables and Student's T test for numerical variables. Distant metastasis 
free survival (DMFS) was defined as the time from the date of histological diagnosis 
of breast cancer to the date of distant metastasis or death. Disease free survival 
(DFS) was defined as the time from the date of histological diagnosis of breast 
cancer to the date of any cancer recurrence (local, distant or contralateral) or death.  
Overall survival (OS) was defined as the time from the date of histological diagnosis 
of breast cancer to the date of death. The database was locked at 12 years of follow 
up and patients who were event-free at the last follow up visit (or at 12 years) were 
censored.  
 
Survival curves, median DMFS, DFS and OS (if reached) in addition to 8 year DMFS, 
DFS and OS (with 95% CIs) were derived from Kaplan-Meier estimates and the 
curves were compared using log-rank test (3). Hazard ratios and 95% CIs were 
calculated using Cox regression model (4). Cox multivariate analysis was performed 
to determine whether a factor is an independent predictor of DMFS, DFS or OS after 
adjusting for other significant factors at the univariate level. All statistical tests were 
two-sided, and the p value was considered statistically significant if less than 5%. 
The statistical analyses were performed using SPSS 17.0 statistics package (SPSS 
Inc, Chicago, IL). 
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RESULTS 
Clinico-Pathological Characteristics 
For the 160 assessable patients the median follow up interval was 10 years (range: 
0.2 to 12y). Median age at diagnosis was 56.9 years (range: 30.4 to 87.4 years). 
57.5% of the patients had tumors more than 20mm and 52.5% of had axillary LN 
metastasis. 18.8% of the patients had SBR grade I tumors, 56.3% grade II tumors 
and 25.0% grade III tumors. 63.1% of the patients received adjuvant chemotherapy 
while 83.1% received adjuvant hormonal therapy. Table 6 shows the clinico-
pathological characteristics of the tested patient cohort (160 patients). 
 
 
Characteristic Number Percent 
Age group < 50 years 
>50 years 
51 
109 
31.9% 
68.1% 
Menopausal status Pre 
Post 
57 
103 
35.6% 
74.4% 
Tumor size <2cm 
>2cm 
68 
92 
42.5% 
57.5% 
Axillary LN 
metastasis 
No 
Yes 
76 
84 
47.5% 
52.5% 
    
SBR grade I 
II 
III 
26 
71 
63 
16.3% 
44.4% 
39.4% 
ERα status Negative 
Positive 
Missing 
14 
145 
1 
8.8% 
90.6% 
PR status Negative 
Positive 
Missing 
40 
118 
2 
25.3% 
74.7% 
HER2 status Negative 
Overexpressed 
Missing 
129 
23 
8 
84.9% 
15.1% 
 
    
Breast cancer 
subtype 
Luminal 
Basal 
HER2 driven 
Missing 
142 
10 
3 
5 
91.6% 
6.5% 
1.9% 
Adjuvant Hormonal 
treatment 
No 
Yes 
27 
133 
16.9% 
83.1% 
Adjuvant (or neoadj) 
chemotherapy 
No 
Yes 
59 
101 
36.9% 
63.1% 
ERα-36 Low 
High 
95 
65 
59.4% 
40.6% 
Table 6: Clinico-Pathological Caracteristics of the 160 patient  
cohort. 
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Pattern of ERα-36 Expression 
Representative images of microscopic pictures showing tumor cells with high and low 
expression of ERα-36 are shown in figure 1. ERα-36 was high in 65 (40.6%) cases 
(Figure 26 A), while 95 (59.4%) cases showed low expression (Figure 26 B). We 
observed no correlation between high expression of ERα-36 with any of the 
traditional prognostic markers as age, menopausal status, tumor size, ERα status, 
PR status or axillary lymph node metastasis. There was a tendency towards 
correlation between ERα-36 and high SBR grade (G3) but that was not statistically 
significant. The correlation between ERα-36 and different clinico-pathological 
parameters is shown in table 7 
 
 
Table 7: Correlation between ERα-36 expression and clinico-pathological 
features. *Correlations tested by Pearson's Chi square test (2sided), † 
Difference between means by Student's T test. 
 
Variable ERα-36 low 
No.   (%) 
95   (59.4%) 
ERα-36 high 
No.   (%) 
65   (40.6%) 
P* 
Age (Yr) Mean (+ SD) 57.9    (±11) 61.3    (±11) 0.20† 
Breast side -Right 
-Left 
42       (44.2%) 
53       (55.8%) 
30       (46.2%) 
35       (53.8%) 
0.81 
Age groups - <50y 
- >50y 
32        (33.7%) 
63        (66.3%) 
19       (29.2%) 
46       (70.8%) 
0.55 
T. size - <2cm 
- >2cm 
41        (43.2%) 
54        (56.8%) 
27       (41.5%) 
38       (58.5%) 
0.84 
LN met -Negative  
-Positive 
45        (47.4%) 
50        (52.6%) 
31       (47.7%) 
34       (52.3%) 
0.97 
SBR grade -Gr 1 
-Gr 2 
-Gr 3 
13        (13.7%) 
50        (52.6%) 
32        (33.7%) 
13       (20.0%) 
21       (32.3%) 
31       (47.7%) 
0.04 
SBR grade 
grouped 
-Gr 1 & 2 
-Gr 3 
63        (66.3%) 
32        (33.7%) 
34       (52.3%) 
31       (47.7%) 
0.08 
ERα-66 status -Negative 
-Positive 
9         (9.6%) 
85       (90.4%) 
5         (7.7%) 
60       (92.3%) 
0.68 
PR status -Negative 
-Positive 
23       (24.5%) 
71       (75.5%) 
17       (26.6%) 
47       (73.4%) 
0.77 
HER2 status -Negative 
-Positive 
78       (85.7%) 
13       (14.3%) 
51       (83.6%) 
10       (16.4%) 
0.72 
(Neo)/Adjuvant 
Hormonal ttt 
-Tam.  
-Tam.+AI 
-AI 
64       (85.3%) 
4         (5.3%) 
7         (9.3%) 
43       (75.4%) 
4         (7.0%) 
10       (17.5%) 
0.33 
     
(Neo)/ Adjuvant 
chemotherapy 
-Anthra. only 
-Anthra & 
Taxane 
43       (79.6%) 
11       (20.4%) 
29       (80.5%) 
7         (19.5%) 
0.30 
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Figure 26: Representative microscopy images of ERα-36 IHC on breast tumors. 
A: Example of a high ERα-36 expression. B: ERα-36 negative tumor. 
 
ERα-36 predicts poorer outcome in breast cancer 
High expression of ERα-36 was a marker of poor prognosis. Patients with high ERα-
36 expressing tumors had more distant metastasis than those with low expression 
(38.5% versus 23.2%, p=0.037). There was also a tendency towards more deaths in 
the ERα-36 high patients (36.9% versus 23.2, p=0.059). Death and relapse events in 
correlation with ERα-36 expression are shown in table 8. 
 
By Kaplan Meier estimates, DMFS in patients with high ERα-36 expression was 
shorter than those with low expression with an 8y DMFS rate of 59.0% (95%CI: 43.9-
74.1%) in patients with high expression versus 76.6% (95% CI: 65.3-89.9%) in the 
ERα-36 low expression group (p=0.007). DFS was similarly shorter with 8year DFS 
rate of 54.7% (95% CI: 37.8-71.6%) versus 70.9% (95%CI: 59.4-82.4%) respectively 
(p=0.029). OS was worse in cases with high ERα-36 expression with 8year OS of 
68.6% (95%CI: 54.1-83.1%) versus 79.6% (95%CI: 69.8-89.4%) respectively 
(p=0.040). Figure 27 shows the Kaplan Meier's curves for DMFS, DFS and OS for 
patients with high versus low expression of ERα-36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Death, relapse and metastatic events associated with ERα-36 
expression 
 
 
 
 
Events ERα-36 low 
No.    (%) 
95   (59.4%) 
ERα-36 high 
No.   (%) 
65    (40.6%) 
P* 
Death Alive 
Dead 
73     (76.8%) 
22     (23.2%) 
41    (63.1%) 
24    (36.9%) 
0.059 
Any 
Recurrence 
-No 
-Yes 
65     (68.4%) 
30     (31.6%) 
35    (53.8%) 
30    (46.2%) 
0.061 
Distant 
metastasis 
-No  
-Yes 
73     (76.8%) 
22     (23.2%) 
40    (61.5%) 
25    (38.5%) 
0.037 
Negative 
Tumor 
Highly Positive 
Tumor 
 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Kaplan Meier's curves 
for patients with high (green) 
versus low (blue) expression of 
ERα-36.A: Overall Survival, B: 
Disease Free Survival, C: Distant 
Metastasis Free Survival.  
A 
B 
C 
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Cox Proportional Hazards Model 
In the cox proportional hazard model high ERα-36 expression doubled the risk of 
developing distant metastasis (HR=2.02, 95%CI: 1.2-3.4, p=0.008). ERα-36 
expression also increased the risk of any cancer recurrence (HR=1.69, 95%CI: 1.1-
2.7, p=0.031) and the risk of death from any cause (HR=1.82, 95%CI: 1.02-3.2, 
p=0.043). 
 
Regarding the effect of the classical prognostic factors, DMFS was also shorter with 
tumors larger than 2 cm (HR=2.17, 95%CI: 1.2-3.8, p=0.007), axillary LN metastasis 
(HR=2.04, 95%CI: 1.2-3.5, p=0.009) and high SBR grade (HR=2.64, 95%CI: 1.6-4.4, 
p=0.0002).  
 
 
Multivariate Analysis 
In the multivariate analysis, when adjusted to tumor size, LN metastasis and SBR 
grade, high ERα-36 expression was still an independent predictor for DMFS 
(HR=1.93, 95%CI: 1.1-3.3, p=0.016) with a tendency towards poorer OS (HR=1.65; 
95%CI: 0.9-3.0, p=0.09).  
 
In addition to ERα-36, large tumor size (HR=1.84; 95%CI: 1.04-3.28, p=0.04) and 
high SBR grade (HR=2.04; 95%CI: 1.2-3.5, p=0.008) were also independent 
predictors of poor DMFS. 
 
 
CONCLUSION 
In all our study reveals that ERα-36 has a main membrane localization in breast 
tumors. Its expression is not linked to the classical clinic-pathological characteristics 
such as age, or tumor size. There is a potential correlation between membrane ERα-
36 expression and SBR grade. We did not find any correlation between anti-estrogen 
treatment and ERα-36 expression, nor ER, PR and HER2 expression. ERα-36 
membrane expression is associated with more deaths, tumor recurrence and 
distance metastasis according to the cox proportional hazards model. Furthermore 
when adjusted to other parameters in a multivariate analysis, ERα-36 expression 
was shown to be an independent predictor of distant metastasis free survival and has 
a tendency to indicate poorer overall survival. Our study reveals that 
immunohistochemically detected membranous ERα-36 is a marker of poor prognosis 
in breast tumors. 
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DISCUSSION TO ARTICLE 2 
 
To evaluate a role for ERα-36 in breast carcinomas, we analyzed its expression in a 
cohort of 160 breast tumors. As previous groups have reported we confirmed that 
ERα-36 is expressed in both ERα positive and negative tumors (Wang and Yin, 
2015).  
 
ERα-36 staining in the tumors present with a characteristic membrane expression as 
confirmed by the pathologist and a diffuse cytoplasmic marking was observed in 
most of the tumors suggesting a ubiquitous role for cytoplasmic ERα-36 in breast 
cancer biology.  Our findings revealed that its expression was associated with poorer 
prognosis in terms of disease free survival and distant metastasis free survival. 
However, we did not find any association between ERα-36 expression and HER2 
which has been previously reported(Shi et al., 2009). We believe this might be due to 
the relatively low number of HER2-positive tumors in our study (23). 
 
 Several studies have been done on ERα-36 expression in breast tumors, and till 
date, controversial association has been made for ERα-36 in triple negative breast 
tumors, which still remain the most aggressive tumor type these days, probably due 
to the use of different antibodies and low tumor numbers (Pelekanou et al., 2012). 
The data available on ERα-36 in breast tumors suggest that is might not be involved 
with the onset, but rather with the progression of breast tumors (Chaudhri et al., 
2012).  
 
Studies have shown that tamoxifen can induce ERα-36 expression and that patients 
with ERα-36 are less likely to benefit from tamoxifen treatment (Shi et al., 2009) 
suggesting a step forward in tumor resistance to hormonotherapy. In our study, we 
did not find any kind on association between tamoxifen treatment and ERα-36 
expression. Multivariate analysis did not reveal any correlation between tamoxifen 
treatment and survival data in our cohort. This is probably due to the fact that most of 
these patients were treated with tamoxifen, and we do not have a group of patients 
who underwent solely tamoxifen treatment, therefore biasing the results. 
Furthermore, chemotherapeutic drugs of the family of Topoisomerase-1 inhibitors 
have been shown to deeply affect alternative splicing events and could be 
responsible for the appearance of ERα-36 in breast cancers (Dutertre et al., 2010). 
 
At the time being, only ERα expression is taken into account at the moment of 
diagnosis but our study comforts what has been previously data showing that ERα-
36 expression constitutes a marker of poor outcome and poor prognosis in breast 
cancer. Other studies demonstrate that patients with high ERα-36 expression are 
less likely to benefit from tamoxifen treatment. We think that given the data on ERα-
36, there should be a modulation of clinical practices in order to take into account the 
expression of this variant. In this line anti-aromatase therapy, currently used in 
postmenopausal women with metastatic breast cancer, could have an effect in 
tumors expressing high levels of ERα-36. Studies have revealed that some ERα 
negative breast tumors respond positively to anti-aromatase therapy and this could 
be due in part to the deprivation of estrogen to ERα-36 expressing cancer cells. In 
parallel, there is an actual phase 1 clinical trial using the flavonoid Icaritin on patients 
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with high ERα-36 expression in China (Chapter 3). This substance has been shown 
to downregulate ERα-36 expression and results of this study are not yet available. 
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In summary, our identified mechanism of ERα-36 signaling seems to rest on a 
previously undescribed mechanism in steroid receptor signaling where ERα-36 will 
act on a first level through Src/MAPK activation and then act on a second level by 
regulating the dephosphorylation of ERK by inhibiting MKP3 binding, revealing a new 
paradigm in ERα-36 non genomic signaling. 
 
Our results demonstrate that ERα-36 can mediate the non-genomic pathway in an 
estrogen and tamoxifen dependent manner. We found that its cytoplasmic 
localization was mainly due to the presence of a functional nuclear export sequence 
in its C-Terminal domain thereby allowing it to translocate to the cytoplasm. 
 
Similarly to ERα non-genomic signaling, we found the involvement of protein 
complexes including Src and PI3K. Our study mainly describes the involvement of 
the Src pathway in the activation of ERα-36 non-genomic signaling. In this aspect we 
wish to elucidate the binding sites of ERα-36 to Src. As previously discussed, the 
only interacting tyrosine described for Src in ERα is absent from the structure of ERα-
36, and the interaction is also independent of ERα-36 unique C-Terminal domain. 
Our bioinformatics collaborators helped us identify a new potential phosphorylation 
site for Src on ERα-36 and this is currently under investigation.  
 
Regarding PI3K, we found that it can form a rapid and transient complex with ERα-36 
under both estrogen and tamoxifen treatment. However we have not been able to 
demonstrate its involvement in the downstream signaling pathway in terms of ERK2 
binding and CyclinD1 induction. We are planning to understand which signaling 
pathways are regulated by this interaction through the use of phospho-antibody 
arrays regrouping various signaling pathways, coupled with the PI3K inhibitor 
LY294002.  
 
Following activation of the MAPK pathway by ERα-36 our team discovered that the 
latter will act on a second level by directly binding to ERK2, thereby protecting it from 
dephosphorylation by MKP3.  However many molecular mechanisms in this 
protection are still unclear. We have found that despite the specific interaction 
between ERα-36 and ERK2, both ERK1 and ERK2 undergo dephosphorylation upon 
abrogation of the ERα-36/ERK2 interaction. This data needs to be further studied 
using siRNA directed specifically at ERK1 or 2 and verifying if the use of our 
inhibitory peptide could also direct MKP3 to dephosphorylate ERK1 through an 
indirect mechanism. Collaborating bio-informaticians are currently helping us to 
identify other potential sites that could explain the specific interaction between ERK2 
and ERα-36, as well as the understanding of molecular dynamics between ERK1/ 
ERK2 and MKP3. 
 
Our team has identified estrogen induced paxillin phosphorylation on Serine 126 as a 
molecular signature event of ERα-36 non-genomic pathway in HBCc-12A cells. This 
target has been identified through a screen for ERK substrates, but we have no idea 
whether it has a main involvement in Cyclin D1 regulation. First of all we wish to 
verify these results by making use of siRNAs to downregulate paxillin and observe 
whether we still have similar effects on cyclin D1 induction. Furthermore we have 
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performed a phospho-Antibody array chip focused on the MAPK pathway in order to 
identify new actors in the ERα-36 non-genomic signaling. 
 
Our findings revealed that ERα-36 its expression was associated with poorer 
prognosis in terms of disease free survival and distant metastasis free survival. We 
are currently investigating ERα-36 expression in la larger cohort of 450 tumors and in 
another 150 breast tumors (Thierry Dubois, Curie Institute) in order to verify our 
previous findings and to assess the association between ERα-36 and to check 
whether its expression is associated with patient outcome in TNBC patients. We also 
wish to analyze the role of ERα-36 in tumors treated with tamoxifen or anti-
aromatase to find if there are correlations in between these conditions and ERα-36 
expression in terms of patient prognosis. Our ongoing work includes analysis of 
Src/ERα-36 interactions in breast cancer TMA, and we are currently awaiting 
statistical analyses on these experiments. Our data has helped us uncover new 
mechanistic insights into ERα-36 signaling and had also promoted the identification 
of new targets in breast cancer. We could imagine for instance that patients 
expressing high levels of ERα-36 could benefic from anti-aromatase therapy or 
current MEK inhibitors that are used in patients with metastatic melanoma. 
 
Altogether our work has shed some light on the mechanistic of ERα-36 
signaling, with the identification of novel signaling partners, which could be effectively 
targeted in breast cancer therapies. 
 
 
Following my thesis defense, I will be staying as a post-doc in the lab for a 
couple of months and we wish to initiate the following projects in order to help us 
better understand the involvement of ERα-36 in breast tumorigenesis: 
For the time being, our collaborating bioinformaticains have been working on 
predicted models of ERα-36, since there is no crystal structure of ERα-36 currently 
available. To go further we wish to initiate crystallization of the ERα-36 variant which 
will help us better understand its ligand binding properties and provide high 
resolution mapping for the study of ERα-36 docking with other proteins such as 
ERK2 and ERK1. This might help us find subtle differences explaining the binding of 
ERα-36 to one form and not the other despite the high degree of homology between 
these two proteins. 
 
In the imparted time, I also wish to study the role of tamoxifen in the whole 
pathway mediated by ERα-36. Indeed preliminary results suggest that tamoxifen 
could be involved in the same pathway as mediated by estrogen and I wish to carry 
out an in depth investigation on the whole pathway till the study of cyclinD1 induction. 
 
We have currently initiated a CRISPR-Cas9 approach to try and abrogate 
ERα-36 expression and I wish to develop this project to firstly establish ERα-36 KO 
HBCc-12A cells, which could be extended to other ERα-36 expressing cell lines. We 
wish to study the pathway in these cells and perform xenografts in mice mammary fat 
pads to investigate the role of ERα-36 in breast tumorigenesis. 
 
A recent collaboration with S. Wittman (CLB) and Said El Elaoui (Covalab, 
Lyon) has revealed that a fraction of HBCc-12A cells express membranous ERα-36 
detectable with our antibody in non-permeabilzed cells through FACS analysis. I wish 
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to develop this project to investigate distinct properties of membrane ERα-36 
expressing cells which would be more relevant to what is observed in breast tumors. 
 
 
We also wish to perform a massive screening of all available anti-estrogens 
to see whether some of them could actually have an effect in downregulating ERα-36 
or abrogating its signaling pathways. In parallel we also wish to investigate molecules 
having inhibitory properties on the ERα-36/ERk2 and ERα-36/Src interaction through 
the Centre for Drug Design and Discovery platform (Collab S.Giraud, CLB). 
 
Altogether our project has led to understand the mechanistic insights of ERα-
36 signaling and might open the way to novel therapeutic targets in breast cancer. 
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